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The cost of drug development is high with many drugs failing during toxicity testing.  
This is a particular problem in veterinary medicine where the pharmaceutical market 
size is so small that it may not be economically viable to develop drugs. The liver 
and specifically hepatocytes have a crucial role in drug metabolism via oxidation by 
cytochrome enzymes (CYP), conjugation and excretion into the biliary system. This 
drug metabolism is unpredictable between species as each has unique CYP profiles. 
Furthermore there is breed variation of CYP profiles within the canine species. The 
ability to produce an in vitro source of canine hepatocytes to model drug metabolism 
in this species and in different breeds would greatly reduce the expense of candidate 
drug testing.  If an unlimited supply could be produced in vitro this would reduce the 
number of animals required in pre-clinical testing. The aim of this thesis was to 
produce an in vitro supply of canine hepatocyte-like cells from stem cell sources, 
namely hepatic progenitor cells (HPC), mesenchymal stem cells (MSC) or induced 
pluripotent stem cells (iPSC). Cultures of canine primary hepatocytes were produced 
to use as a gold standard, but also to develop and refine tests of hepatocyte 
characterisation and function. A panel of primers was developed for use in real time 
polymerase chain reaction (PCR) as well as optimising tests for low density 
lipoprotein (LDL) and indocyanine green uptake, albumin production, periodic acid-
Schiff staining for glycogen and CYP activity using a luciferase-based system.  As 
primary hepatocytes rapidly lost their defining characteristics and function in vitro, 
methods of maintaining function using CYP inducers and culture substrates were 
assessed.  
Isodensity centrifugation and magnetic-activated cell sorting was employed to isolate 
HPCs. Selection of cells from the non-parenchymal cell fraction with stem cell 
marker Prominin 1 demonstrated that these were keratin 7 positive, a HPC marker.  
Cells morphologically consistent with HPC appeared and expanded in culture after 2 
weeks.  On passaging, these cells failed to continue expanding, despite plating onto 
collagen, laminin, SNL feeder cells or using Kubota’s medium (known to allow rapid 
expansion of rodent and human HPCs). 
xi 
 
Canine adipose (Ad-MSC) and bone marrow-derived mesenchymal stromal cells 
(BM-MSC) were isolated post mortem.  These were characterised as CD45, 105 and 
STRO-1 positive, CD11b, 19 and 45 negative cells which could be differentiated into 
adipocytes, chondrocytes and osteocytes based on staining characteristics and 
relative gene expression.  Protocols published for other species were used to 
differentiate both Ad-MSC and BM-MSC towards a hepatocyte phenotype.  
Although a dramatic change in morphology and a reduction in vimentin gene 
expression were noted, suggesting a loss of mesenchymal phenotype, these protocols 
did not induce a hepatocyte phenotype. Pre-treatment with 5-Aza-2′-deoxycytidine  
to cause DNA demethylation and valproic acid to inhibit histone deacetylation  also 
failed to allow transdifferentiation.  
A polycistronic vector containing Oct-4, c-Myc, Sox2 and Klf4 was successfully 
transfected into canine epidermal keratinocyte progenitor cells which became 
alkaline phosphatase positive and assumed a morphology consistent with iPSC. After 
colony selection and expansion, PCR evidence of plasmid presence was lost, colony 
morphology changed, and alkaline phosphatase activity reduced, consistent with 
vector expression factor and pluripotency loss.  
Canine iPSCs produced by lentiviral method were then differentiated towards 
hepatocyte phenotype using a published protocol for mouse and human iPSC.  These 
cells were then assessed for hepatocyte characteristics using the developed reagents 
and primers. These cells demonstrated increased gene expression and morphology 
consistent with differentiation towards a hepatocyte-like phenotype. 
This thesis demonstrates successful culture of canine primary hepatocytes and 
validation of tests of hepatocyte phenotype.  This provides a basis for optimising 
primary hepatocyte function in vitro and assessment of the success of differentiation 
protocols on stem cell sources.  Canine mesenchymal stromal cells do not appear to 
transdifferentiate towards a hepatocyte-like phenotype using published protocols for 
other species.   Canine iPSC are a promising candidate for an in-vitro source of 
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Chapter 1: Introduction 
1.1 The liver  
The liver is the largest internal organ in the body and contains an extensive network 
of afferent and efferent vessels transporting blood, bile and lymph that interdigitate.  
The vasculature, and its surrounding connective tissue, which make up 
approximately 22% of the organ’s weight, provides structural support in the liver.  
Resting blood flow is approximately 25% of cardiac output, reflecting its high 
metabolic activity.  Only 25% of this blood flow is fully oxygenated and supplied by 
the hepatic artery. The remainder is partially oxygen depleted, supplied by the portal 
vein draining the splanchnic viscera including the gastrointestinal tract (Arias et al., 
2011).    
 
1.1.1 Structure of the liver 
The liver is composed of lobules which can be seen histologically as hexagonally 
shaped and consist of cords of hepatocytes radiating from a central vein.  Located at 
each corner of the hexagon are three vessels, artery, vein and bile duct, known as the 
portal triad.  Functionally, the liver acinus, defined by hepatocytes supplied by one 
triad, is the most useful method of demarcation.  The hepatocytes in the acinus are 
subjected to an oxygen and biochemical gradient with a drop in oxygen 
concentration from the peri-portal to peri-venous zone.   
The liver contains an array of cell types; hepatocytes, cholangiocytes, endothelial 
cells, macrophages (known as Kupffer cells in location), lymphocytes and stellate 
cells are all intimately involved in contributing to the liver’s function.   
 




Figure 1.1 Organisation of the liver lobule and acinus  
Although histologically the triad is easily defined, the acinus, demarcated by the 
yellow line, is the most applicable.  The acinus can be sub-divided into three zones; 
1- periportal, 2- transitional, and 3 – perivenous.  
 
The liver has a diverse array of functions and as a result has a heterogeneous mix of 
cells.   As the liver receives all venous blood from the gastrointestinal system, many 
of the functions involve processing products in this blood supply.   
 
1.1.2 Main cells of the liver and function 
 
1.1.2.1 Endothelial cells 
These differ from endothelial cells elsewhere in the body as they lack a basement 
membrane, are fenestrated and intimately attached to stellate cells. They separate 
hepatocytes from sinusoidal blood and act as a selective filter for substances.  As 
well as simple filtration they also have the ability to endocytose, and phagocytose 
substances (Kmiec, 2001).  
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1.1.2.2 Kupffer cells  
These are resident macrophages in the liver and as stated above are intimately linked 
with the endothelial cells with the cell membrane reaching through the fenestrations 
of the endothelial cells into the space of Disse to contact stellate cells and 
hepatocytes.   They are located in the greatest density peri-centrally and as a result 
are exposed to and clear lipopolysaccharides, bacterial toxins and translocated 
bacteria from the gastrointestinal tract (Kmiec, 2001).  They make up 80-90% of the 
total tissue macrophage population in the body, highlighting their importance as an 
initial defence against gastrointestinal bacteria and toxins (Bilzer et al., 2006).     
 
1.1.2.3 Stellate cells 
These are situated between hepatocytes and endothelial cells, interdigitating with 
both, and contribute up to 15% of cell number in the normal liver (Hellerbrand, 
2013).  These cells store vitamin A and also regulate the extracellular matrix by 
production of matrix and also secretion of matrix metalloproteinases (MMP) as well 
as inhibitors of MMPs (TIMPS).  
 
1.1.2.4 Cholangiocytes 
These are epithelial cells that line the biliary tree. Their function is to modify bile 
which is produced by hepatocytes. These differ in morphology and derivation in 
different parts of the biliary tree. The intra-hepatic component of the biliary tree 
contains cells derived from hepatic progenitor cells whilst the extra-hepatic 
component has the same origin as the pancreas and duodenum. Cholangiocytes 
secrete chloride, bicarbonate and water and reabsorb bile acids, amino acids and 
glucose (Tabibian et al., 2013). 
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1.1.2.5 The Hepatocyte 
Hepatocytes make up approximately 80% of the liver by weight and are also known 
as hepatic parenchymal cells (Si-Tayeb et al., 2010).  They are large, polygonal, 
functionally complex cells with endocrine and exocrine functions (Arias et al., 2011). 
In vivo hepatocytes have several functionally distinct   surfaces.  Approximately 50% 
is adjacent to surrounding hepatocytes with areas containing microvilli which form 
bile caniliculi   making up 13%.  A further   35% face towards sinusoids with 
microvilli extending into the space of Disse (Arias et al., 2011) (Figure 1.2).   
 
Figure 1.2 Hepatocyte structure and surrounding architecture 
Between the layers of hepatocytes are fenestrated endothelial cells separated by the 
space of Disse.  Macrophages (Kupffer cells) are present within the sinusoids.   H – 
Hepatocyte, SC – Stellate cell, KC – Kupffer cell, D – Space of Disse, S – Sinusoid. 
Figure adapted from Frevert et al., 2005.  
 
Hepatocytes are responsible for production of many proteins including albumin and 
the majority of clotting factors.  Hepatocytes are the major centre for 
gluconeogenesis as well as providing a store of glucose in the form of glycogen. The 
hepatocyte is also a key player in lipid metabolism, producing bile acids, which 
emulsify ingested fat allowing efficient absorption, as well as synthesising 
apoproteins which facilitate lipid distribution throughout the body via lymphatics and 
blood vessels (Fraczek et al., 2013).    
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Another crucial hepatocyte function is the transformation and detoxification of 
endogenous substances.  Endogenous compounds include hormones, for example 
steroid hormones, but also ammonia which is produced in the gastro-intestinal tract 
from protein metabolism and delivered via the portal vein directly to hepatocytes 
Ammonia is then efficiently converted to the much less toxic compound urea, before 
the blood enters the systemic circulation (Kaneko et al., 2008). Compounds may also 
be removed from the systemic circulation by hepatocytes secreting the substance 
through their bile canalicular membrane, ultimately causing the substance to be 
excreted in faeces (Tomlin, 2010). There appears to be remarkable zonation of 
hepatocyte function   which is related to haemodynamics and which hepatocytes are 
exposed to the highest concentrations of substances. For example, peri-portal 
hepatocytes are exposed to the highest ammonia concentrations and have the greatest 
activity of carbamoyl phosphate synthetase I which is the first enzyme used in the 
urea cycle for ammonia detoxification (Arias et al., 2011).   
 
1.1.3 Liver development 
The liver forms from endoderm and mesoderm. Hepatocytes and cholangiocytes are 
formed from endoderm whilst other non-parenchymal cells have a mesodermal 
origin. The primitive gut tube endoderm forms fore, mid and hindgut regions, with 
the liver arising from the foregut (Figure 1.3).  The endodermal portion then joins 
with the septum transversum mesenchyme to form a liver bud.   
 
 




Figure 1.3 Origin of liver lineage 
Both hepatocytes and cholangiocytes arise from foregut endoderm whilst the non-
parenchymal cell compartment is mesenchymal in origin.  
 
1.1.3.1 Signalling in liver development 
Formation of both endoderm and mesoderm is controlled by Nodal with high 
concentrations forming endoderm and lower concentrations mesoderm (Zorn, 2008). 
Thereafter, fibroblast growth factor (FGF), Wnt, bone morphogenic protein (BMP) 
and retinoic acid combinations produced by the mesoderm stimulate specific 
endodermal zonation.  For liver development, FGF from cardiac tissue along with 
BMP from the septum transversum cause hepatic development from the foregut 
endoderm (Figure 1.4). Wnt is also produced from the adjacent mesoderm; the 
function of this in hepatic development has not been elucidated (Zorn, 2008).  





Figure 1.4 Liver bud development 
Transverse section schematic demonstrating hepatic endoderm invaginating and 
subsequent migration into septum transversum mesenchyme. STM – septum 
transversum mesenchyme From Zorn (2008). 
 
 
1.2 In vivo liver regeneration 
The liver, as an organ, has very low cell turnover in health with approximately 1 year 
taken for complete cell turnover (Dolle et al., 2010). Despite this, mature hepatocytes 
have tremendous hyperplastic capacity.  The original experiments by Higgins and 
Anderson in 1931 demonstrated that rats undergoing 2/3 hepatectomy regained their 
original liver weight within 7 days of the procedure (Higgins and Anderson, 1931). 
Although often termed “liver regeneration” in the literature, technically regeneration 
is defined by replacement of like with like e.g. limb replacement in many 
amphibians.  The resultant replaced liver tissue is due to hypertrophy of the 
remaining lobes therefore the term “compensatory hypertrophy” is more accurate 
(Miyaoka and Miyajima, 2013). This response is thought to be due to cytokine 
queues of TNFα and IL-6. Further growth factors including hepatocyte growth factor 
(HGF), epidermal growth factor (EGF) and transforming growth factor (TGFα) then 
cause progression through the cell cycle. It has classically  been thought that almost 
all quiescent mature hepatocytes enter the S phase of the cell division cycle and  that 
the number of cell divisions per hepatocyte is low, between 1 and 2 (Fausto et al., 
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2006). This was based on studies examining incorporation of radioactive nucleotides 
into hepatocytes (Bucher and Oakman, 1969).   
Recently, this view has been questioned.  Mature hepatocytes are often binucleate 
and it has been recognised for almost 70 years that the number of binucleate cells 
decreases after compensatory hypertrophy (St Aubin and Bucher, 1952). Genetic 
tracing of labelled hepatocytes indicates that after 70% partial hepatectomy, 40% of 
hepatocytes do not undergo division and that after 30% hepatectomy, only a small 
fraction entered the S phase and no hepatocytes divided, despite rapid restoration of 
liver mass. It appears that cellular hypertrophy i.e. increase in hepatocyte cell size 
accounts for a significant part of liver weight restoration and that this occurs as an 
early response.  Hepatocytes will then only enter the cell cycle if cellular 
hypertrophy is insufficient to restore mass (Miyaoka et al., 2012). Furthermore the 
mature binucleate cells undergo cell division where one binucleate cell produces two 
mononuclear daughter cells which are more polyploid than the mother (Miyaoka and 
Miyajima, 2013). The factors that govern liver mass are still being investigated but 
blood flow, blood bile acid and glucose concentration have been shown to be 
important (Meng et al., 2011; Schoen et al., 2001; Simek et al., 1965). Additionally, 
hepatocyte paracrine signalling with TGFβ has been suggested as a mechanism to 
terminate proliferation (Carr et al., 1986).  
 
1.3 Hepatic progenitor cells 
If mature hepatocytes are unable to multiply, for example due to chronic hepatitis 
causing hepatocyte loss and fibrosis, then there are adult stem cells within the liver 
termed hepatic progenitor cells (HPC) or oval cells in rodents (Dolle et al., 2010). 
HPC are thought to be present in the Canals of Hering (Figure 1.2), anatomically 
located between hepatocytes and the biliary tree by the portal triads of zone 1 (Figure 
1.5) (Roskams, 2006).  These are present in very low numbers in healthy adult livers, 
approximately 0.5-2% of the parenchyma (Turner et al., 2011). It is thought that 
these HPC sequentially mature as they pass from periportal to pericentral in zone 3. 
HPCs have been sub-divided into hepatic stem cells (HpSCs) and hepatoblasts (HBs) 
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although this subdivision is not used universally (Schmelzer et al., 2007).  HpSCs are 
bi-potential, in that they can differentiate into cholangiocytes or hepatocytes 
depending on need. As they differentiate towards hepatocytes, 8 distinct stages are 
recognised with cells increasing in size as they progress towards mature hepatocytes. 
Hepatoblasts are the second stage when differentiation towards cholangiocytes is still 
possible before the cells become committed progenitors. There is debate as to the 
phenotypic markers present on HPC as there has been no specific marker identified 
at present (Darwiche and Petersen, 2010). This presents a difficulty in research into 
HPC as different groups use different selection panels and markers may not apply 
across different species. Among the markers identified in human and rodent HPCs 
are CD133, epithelial cell adhesion molecule (EpCAM),  neural cell adhesion 
molecule (NCAM), SOX9, keratins 7,8,18,19 (Figure 1.6) (Darwiche and Petersen, 
2010; Roskams, 2006).  Some authors state that αfoetal protein (AFP) is present on 
HPC, whilst others state this is not expressed until the hepatoblast has been reached 
(Darwiche and Petersen, 2010; Roskams, 2006). As with all tissue stem cells, they 
are protected within a “niche” of surrounding cell types and extracellular matrix that 
is required for their maintenance and self-renewal (Kordes and Haussinger, 2013). 
Among the cell types thought to be important in HPC maintenance are periportal 
fibroblasts, stellate cells, endothelial cells, hepatocytes, cholangiocytes, and immune 
cells (Darwiche and Petersen, 2010). It is thought   angioblasts, associated 
mesenchymal cells, mature in concert with NPC and as a result provides sequential 
soluble factors and matrices to direct differentiation (Turner et al., 2011; Wang et al., 
2010). In chronic liver disease a “ductular reaction” occurs where intermediate 
hepatocytes arise, surrounding fine biliary ducts (Schotanus et al., 2009; Yoshioka et 
al., 2004).    Activation of these HPCs appears to be stimulated by release of 
Hedgehog ligand from damaged hepatocytes (Jung et al., 2010). 




Figure 1.5 Schematic diagram demonstrating location of hepatic stem cells in the 
liver and sequential lineage between canal of Hering and central vein.  
Image from Turner et al,. 2011. 
 
 
Figure 1.6 Keratin 7 staining of canine hepatic parenchyma. 
Staining with monoclonal mouse antibody (OV-TL 12/30, Dako) 1:500 with 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT).  Black arrowhead 
indicated staining of cholangiocytes in bile duct.  Black arrow indicates hepatic 
progenitor cells.  Staining performed by Neil MacKintyre, R(D)SVS Pathology 
Laboratory. 
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1.4 Hepatic metabolism of xenobiotics 
The liver also has the remarkable ability to metabolise a wide variety of synthetic 
drugs.  This is performed by hepatocytes. To allow this, hepatocytes contain a large 
group of oxidative enzymes which are membrane bound haemoproteins, known as 
the cytochrome (CYP) P450 superfamily (Sevior et al., 2012).  At present 1056 
distinct forms have been  identified in mammals with 116 in humans and 35 in the 
dog (Nelson, 2009).  These individual enzymes are identified by the abbreviation 
CYP followed by a number for the gene family, a letter for the subfamily and finally 
a number for the individual gene e.g. CYP2D15.  There is marked species variation 
in the cytochrome P450 profile with many species having unique enzymes and also 
response to induction by drugs (Graham and Lake, 2008; Martignoni et al., 2006).  
Comparable enzymes or orthologues to these unique enzymes can be identified in 
other species; however there can be marked differences in substrate specificity 
between orthologues, making extrapolation of drug pharmacokinetics between 
species unpredictable (Martignoni et al., 2006).   
In the dog, the CYP family has not been fully characterised, however unique canine 
orthologues have been identified (Trepanier, 2006). Table 1.1 demonstrates known 
canine CYP orthologues, comparable human enzymes and known metabolic 
differences. In addition, there are polymorphisms within species which can cause 
increased or reduced drug metabolism depending on whether the variation increases 
or reduces function (Martignoni et al., 2006). Human directed breeding of dogs into 
specific morphologies (designated pedigree breeds), and subsequent genetic 
restriction within some breeds due to high levels of inbreeding has meant that some 
breeds have low genetic diversity with the consequence that different dog breeds 
may have specific CYP profiles (Fleischer et al., 2008; Rimbault and Ostrander, 
2012).  This has not been thoroughly investigated at present, although breed 
differences in CYP profiles and drug metabolising ability have been recognised 
(Table 1.2) (Fleischer et al., 2008).  The implications of this are that 
pharmacokinetics, pharmacodynamics and effects of drugs may vary widely between 
different breeds and that drug testing using the laboratory Beagle, for example, may 
not ensure the drug is safe to use in the Greyhound or Labrador Retriever. To add to 
Chapter 1: Introduction 
12 
 
the difficulty of assessing drug metabolism and hepatotoxicity within the canine 
population, there have been five CYP enzymes identified at present in the dog that 
are polymorphic (CYP1A2, CYP2C41, CYP2D15, CYP2E1 and CYP3A12), 
therefore testing drugs with a range of breeds may not be enough to predict toxicity 



















Human substrates Cytochrome P450 canine Known canine substrates 
CYP1A Dioxin, other 
environmental chemicals 
CYP1A Induced by environmental 
toxins (e.g., polychlorinated biphenyls) 





theophylline (?), Induced by omeprazole  
CYP2B6 Propofol CYP2B11 
Possible second 
gene? 




Induced by phenobarbital 
CYP2E1 Ethanol, chlorzoxazone, 




CYP2C9 Phenytoin, fluconazole, warfarin, glipizide, 
flurbiprofen, piroxicam, ibuprofen, 
celecoxib, naproxen, meloxicam 
CYP2C21 Testosterone (16-α-hydroxylation), 
diclofenac 
Modest induction by phenobarbital  
CYP2D6 Codeine, tramadol, propranolol and other 
beta-blockers, phenothiazines, quinidine, 
dextromethorphan, chlorpheniramine, 






CYP3A4 Ketoconazole, itraconazole, ciclosporin, 
tacrolimus, lincosamides, cisapride, 
diazepam, midazolam, diltiazem, digoxin, 
quinidine, verapamil, aflatoxin, budesonide 
Induced by rifampicin  
CYP3A12 
CYP3A26 




Induced by phenobarbital, rifampicin  
Table 1.1 Canine and human cytochrome P450 enzyme orthologues and known substrates  
Modified from Trepanier, 2006 and Martinez et al., 2013  








Beagle CYP1A Polymorphism/genotypic variation in CYP1A2 activity (due to differences in enzyme 
expression). Poor metabolizers and extensive metabolizers result in significant 
polymorphic hydroxylation of a novel benzodiazepine  




CYP2B11 14-fold variance in CYP2B11 activity in mixed breed dogs. Mixed breed dogs tended to 
span range of Vmax seen in Beagles (high) and Greyhounds (low) 
Beagle CYP2D15 Significant pharmacogenetic variation in gene encoding CYP2D15 (counterpart to human 
CYP2D6). Other undefined CYPs may also be involved. Significant pharmacogenetic 
variation in celecoxib metabolism in purebred Beagles. Celecoxib is primarily a 
CYP2D15 substrate in dogs. Extensive metabolizers (about 50% of those tested) have an 
elimination half-life of 1.5–2 h. Poor metabolizers have an elimination half-life of 
approximately 5 h. 
Table 1.2 Known CYP variations in canine breeds 
Adapted from Fleischer 2008 
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1.5 Liver disease in the dog  
The most common type of liver disease in dog and man is inflammatory .i.e. 
hepatitis.  Whereas in man, the cause of hepatitis is often recognised e.g. viral, 
alcohol-induced or due to fat accumulation, in the dog despite searching, no specific 
underlying cause has been identified in the vast majority of cases (Boomkens et al., 
2004; Boomkens et al., 2005; Van den Ingh et al., 2006).  A recently discovered 
hepacivirus in dogs, which is the closest genetic relative of hepatitis C virus, was not 
found to be associated with chronic liver disease in the dog (Bexfield et al., 2014).  
This is not to say that all cases of hepatitis in the dog are idiopathic. Copper 
associated hepatitis is well recognised in the dog and is similar to Wilson’s disease in 
humans (Favier et al., 2012).   
Chronic hepatitis (CH) is thought to be the most common liver disease in the dog 
although prevalence rates vary.  Poldervaart et al. (2009) reported a prevalence of 
0.5% in a referral population, whilst Watson et al. (2010) found evidence of CH in 
12% of post-mortem examination of 200 unselected dogs.  As the cause is unknown, 
treatment is symptomatic and the prognosis for dogs with chronic hepatitis is poor. A 
median survival time of 18.3 months is reported (Poldervaart et al., 2009; Watson, 
2004). 
Chronic hepatitis is characterised by hepatocyte apoptosis and necrosis with an 
inflammatory infiltrate which is mononuclear or mixed (Watson, 2004).  Fibrosis 
occurs and is progressive in the majority of cases to the point of cirrhosis.  
Regenerative nodules are often present within the liver (Van den Ingh et al., 2006).  
Fibrosis results from increased extracellular matrix (ECM) deposition, particularly 
type I and III collagen (Mallat and Lotersztajn, 2013).  This increase in ECM is due 
to activation of hepatic stellate cells to a myofibroblast morphology which upregulate 
ECM production and TIMPS, which inhibit degradation of ECM (Hellerbrand, 
2013).  This transformation is induced by TGFβ.  It is thought that myofibroblasts 
further contribute to inflammation by cytokine production which attracts further 
leucocytes.  Portal fibroblasts have also been shown to transform to myofibroblasts 
and there is evidence that bone marrow fibrocytes may localise within the liver 
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(Forbes et al., 2004; Mallat and Lotersztajn, 2013).  In vitro studies have 
demonstrated that TGFβ can induce epithelial to mesenchymal transition of 
hepatocytes and cholangiocytes; however, evidence of this has not been found in vivo 
(Mallat and Lotersztajn, 2013).  As suggested by their name, myofibroblasts are 
contractile cells. This contractility along with deposition of ECM disrupts the normal 
hepatic architecture causing portal hypertension by altering sinusoidal tone and blood 
flow as well as intrahepatic cholestasis.  Continued portal hypertension causes the 
recruitment of collateral porto-systemic shunting vessels allowing portal blood direct 
access to the systemic circulation (Szatmari and Rothuizen, 2009; Watson, 2004).  
Intrahepatic cholestasis causes the development of jaundice, portal hypertension may 
result in ascites, particularly if combined with hypoalbuminaemia as a result of 
reduced hepatocyte number.  Porto-systemic shunting results in the development of 
hepatic encephalopathy (HE) which is a clinical syndrome of neurological 
dysfunction.  A key player in HE is high systemic ammonia concentrations ,which 
are neurotoxic (Shawcross et al., 2005). This thought not to be the only factor in HE 
development and there is evidence for a role of inflammation and manganese (Mn) 
(Ahboucha, 2011; Shawcross and Jalan, 2005). Increased systemic delivery of these 
factors results from the failure of portal blood to pass through the liver.  Ammonia is 
converted to the less toxic compound urea by hepatocytes.  Similarly manganese is 
efficiently extracted by hepatocytes and secreted in bile such that only approximately 
2% of portal Mn normally reaches the systemic circulation (Davis et al., 1993).  As 
stated above, the liver has a large population of tissue macrophages which act to 
remove potential inflammatory mediators from portal blood before it reaches the 
systemic circulation.   
As the liver has a huge reserve capacity of hepatocytes, a large proportion must be 
lost before there is a noticeable reduction in hepatocyte function.  Once this occurs, 
reduced serum albumin can further contribute to the development of ascites.  
Inability to maintain adequate concentrations of clotting factors may cause 
coagulopathy; however, this is further compounded by pre-disposition to 
disseminated intravascular coagulation and potentially vitamin K deficiency 
(Szatmari and Rothuizen, 2009). 




1.6 Human in vitro hepatocyte production 
In human medicine, the increase in prevalence of chronic liver disease, coupled with 
a shortage of healthy livers for transplantation, has stimulated much research to 
produce and expand hepatocytes in vitro (Palakkan et al., 2013). In human medicine 
it is anticipated that these would be used in a variety of ways, for transplantation; in 
bio-artificial liver devices to support patients as a bridge until a transplant was 
available, or allow sufficient regeneration in cases of acute hepatic failure; as an in 
vitro model of liver disease; or as an in vitro system for modelling hepatic 
metabolism of candidate drugs (Dalgetty et al., 2009).   The source of these 
hepatocytes may be derived from primary hepatic tissue, cell lines or stem cell 
sources (Donato et al., 2013; Fraczek et al., 2013; Greenhough et al., 2010). 
 
1.7 Rational for in vitro canine hepatocyte production 
In dogs, chronic hepatitis is common. A small percentage of chronic hepatitis cases 
are caused by infectious agents (e.g. leptospirosis), toxins (e.g. aflatoxicosis) or 
associated with abnormal hepatic copper accumulation, however to date, in contrast 
to human medicine, the initiating cause is unknown in the vast majority of canine 
cases (Boomkens et al., 2004; Boomkens et al., 2005; Van den Ingh et al., 2006; 
Watson, 2004). As a result, therefore, potentially these patients would benefit from 
liver transplant in a similar manner to human patients with liver disease.  Although 
liver transplant is frequently performed experimentally in the dog as a model for the 
human procedure, the ethics, logistics and financial cost makes clinical liver 
transplantation for dogs with liver disease  unlikely (Liu et al., 2013; Pan et al., 
2013).   Hepatocyte transplantation/transfusion is used clinically in humans as a 
“bridge” to transplantation (Pareja et al., 2013). There is concern that the pre-existing 
disruption in architecture with fibrosis and conditions causing hepatocyte death 
would be too harsh for transfused cells; the “rocky ground” (Forbes, 2008).   
Therefore this may also be the case in dogs with chronic hepatitis.  There may 
however still be utility in veterinary medicine; dogs with acute hepatic failure may 
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benefit where a transient improvement in hepatic function via hepatocyte transfusion 
or stem cell derived hepatocytes may act as a “bridge” until sufficient endogenous 
hepatic regeneration has occurred.  
The ability to provide liver support via an extracorporeal device populated with 
hepatocytes (Bioartifical liver device, BAL) is also another potential use for in-vitro 
canine hepatocytes (Leckie et al., 2012).  The number of cells required for these 
devices is a potential stumbling-block (Chan et al., 2004). Again this is envisaged to 
be used as a bridge to transplantation in human medicine. In veterinary medicine, this 
could be used as a bridge in acute hepatic failure until sufficient hepatic regeneration 
has taken place, although again the expense and logistics of this producing the 
required cell numbers may be prohibitive.  
 
There has also been much interest in the ability to correct hepatic metabolism 
disorders in man by transfusion of autologous stem cell derived hepatocytes which 
have undergone genetic correction e.g. α1-antitrypsin deficiency (Yusa et al., 2011). 
Many dog breeds have hepatic metabolic defects e.g. the Dalmatian  and Cavalier 
King Charles Spaniel’s defects in hepatic purine metabolism and the Bedlington 
Terrier’s hepatic defect in copper transport (Forman et al., 2005; Gow et al., 2011; 
Safra et al., 2006).  Hepatocyte transfusions have been used the Dalmatian as a 
human model for treatment of hepatic metabolic defects. Technically, this procedure 
is straightforward with the cells delivered intra-splenically although 
immunosuppression was required as these were allotransplants (Benedetti et al., 
1997; Dunn et al., 2000). If autologous stem cells were utilised, immunosuppression 
would not be required. The expense and effort involved in correction of these genetic 
defects in individual dogs would be ethically difficult to defend as veterinary 
medicine has the luxury of genetic manipulation via breeding selection to which 
effort and money would be better put, for example testing of Bedlington Terriers for 
a mutation in the COMMD1 gene which causes copper accumulation within 
hepatocytes and subsequent genetic selection of the future generation (Mellersh, 
2012).  




The most immediate reason for producing an in vitro source of canine hepatocytes is 
the ability to model hepatocyte functions in vitro, particularly with regard to drug 
metabolism.  Drug development is expensive and many candidate drugs fail during 
toxicity testing (Kola, 2008). Preclinical studies on candidate drugs are usually 
performed on laboratory animals to assess pharmacodynamics, pharmacokinetics as 
well as possible toxicities.  The hepatocyte plays a crucial role in metabolism of 
many drugs via three main phases: Phase I -  oxidation via the cytochrome P450 
monooxygenases, Phase II – conjugation of  phase I products, Phase III – transport 
ofthe product out of the hepatocyte (Sevior et al., 2012).   Pre-clinical testing may 
initially be in non-target species e.g. rodents to reduce cost.   As different species 
have different CYP profiles, these studies may not always predict potential toxicities 
in the target species (Graham and Lake, 2008). The ability to utilise species specific 
in vitro hepatocytes to monitor candidate drug metabolic products and assess 
hepatotoxicity would have the potential to greatly reduce the expense of drug 
development and also the number of animals used in pre-clinical drug testing. 
Furthermore, if these cells were derived from an unlimited stem cell source then this 
would further reduce the number of animals required for testing.   The most 
commonly used laboratory dog breed is the Beagle (Home Office, 2012). As stated 
earlier, many breeds have different CYP profiles therefore proof of safety in a 
limited number of breeds will not predict safety in all pedigrees.   Some drugs fail at 
phase III clinical trials when they are used in a large group of individuals and drug 
induced liver injury is the most common reason that drugs are withdrawn from 
market (after phase III trials) (Kaplowitz 2007, Suzuki 2010).  As an example of this, 
in the human medical field, between 1995-2005 13 drugs were withdrawn due to 
hepatotoxic effects which were not evident in phase I,II or III trials (Need et al., 
2005). This has not only economic consequences of the costs of development to that 
point but also ethical consequences in that individuals receiving that drug may have 
been harmed (Dieppe et al., 2004; Kola, 2008). In veterinary medicine, canine pre-
clinical data such as pharmacokinetics, pharmacodynamics and toxicology on new 
drugs which have been developed for human medicine but are being considered for 
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the canine veterinary market can be available as dogs are occasionally used as a 
human model in pre-clinical testing (Peters, 2005).  Ironically, if better in-vitro 
human models are developed then this resource would reduce. 
 
The ability to produce in vitro canine hepatocytes with species specific CYP profiles 
would allow rapid screening of candidate drugs for potential hepatotoxicity not only 
of the parent drug but also the hepatic metabolic products.  This would greatly reduce 
the cost of drug development for the veterinary market but also contribute to 
reducing the number of animals required in pre-clinical testing in line with the aims 
of the National Centre for the Replacement, Refinement and Reduction of Animals in 
Research (http://www.nc3rs.org.uk/).  Furthermore, the ability to screen different 
breed phenotypes in vitro would hopefully avoid idiosyncratic breed reactions once 
the drug has been licensed, reducing the number of drugs withdrawn from the market 
and also reducing canine patients harmed.  
 
To be a useful model of drug metabolism in vitro, the cells should be able to perform 
fully as hepatocytes with functional and inducible drug metabolising pathways 
including CYP activity (Hengstler et al., 2005).  Practically, one metabolic function 
and one synthetic function are commonly accepted as demonstrating a hepatocyte-
like cell in vitro (Meier et al., 2013). 
 
1.8 Sources of in-vitro hepatocytes 
 
1.8.1 Primary liver tissue as a source of in vitro hepatocytes 
As primary hepatocytes have tremendous capacity for replication in vivo, this would 
seem the obvious choice (Higgins and Anderson, 1931).  Primary hepatocyte cultures 
can be readily derived from hepatic tissue via collagenase digestion (Berry and 
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Friend, 1969). In human medicine there is the same problem as for liver 
transplantation i.e. shortage of supply of healthy hepatic tissue.  Disappointingly, 
despite primary hepatocyte isolation being described for over 40 years in many 
species, culture conditions that allow mature hepatocyte division in vitro have not 
been achieved and hepatocytes in culture do not multiply to any appreciable extent.  
Furthermore, the majority of functions that would be desired of a hepatocyte e.g. 
protein production, CYP activity are lost rapidly in vitro (Elaut et al., 2006). A final 
problem with primary hepatocyte cultures is batch variability depending on donor 
source and time between death and processing (Donato et al., 2013).  Although 
production of in vitro canine primary hepatocytes would be less limited than in 
human medicine in the sense that dogs may be specifically bred for this purpose, the 
continual sacrifice of these animals would not be the ideal solution especially at a 
time when much effort is being directed towards the mantra of the 3 R’s (replace, 
reduce, refine) in animal research. 
 
1.8.2 Stem Cells as a source of hepatocytes 
Stem cells may be broadly divided into two main types– adult determined stem cells 
and pluripotent stem cells. Adult determined stem cells may be further sub-divided 
into organ specific stem cells and mesenchymal stem cells.  
 
1.8.3 Hepatic progenitor cells 
 Many organs of the body have multipotent rather than pluripotent stem cells i.e. can 
differentiate into all the cells of the organ from which they have been derived, for 
example, as stated above, HPC in the liver are bipotent, producing both hepatocytes 
and cholangiocytes. At present, no unique HPC marker has been identified, which 
hampers isolation and enrichment.  HPC have been isolated from many species 
including humans, rodents and dogs (Arends et al., 2009b; Gerbal-Chaloin et al., 
2010; Yovchev et al., 2008).  It has been demonstrated that human and rodent HPC 
can be expanded in vitro with specialized media and differentiated into hepatocytes 
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(Li et al., 2013b; McClelland et al., 2008; Wauthier et al., 2008). Hepatic progenitor 
cells have been identified in normal and diseased canine liver and also cultured in 
vitro (Arends et al., 2009a; Schotanus et al., 2009). If these cells could be expanded 
sufficiently and differentiation directed to hepatocyte lineage, as has been done for 
rodents, these could be a useful source of canine hepatocytes in vitro (Chen et al., 
2010). 
 
1.8.4 Pluripotent stem cells 
The first pluripotent stem cells identified were embryonic stem cells (ESC) and 
derived from the inner cell mass of mouse embryos (Evans and Kaufman, 1981).  
These cells are naturally pluripotent i.e. have the ability to differentiate into many 
cells types. ESC have now been described in the human, cat and dog (Gomez et al., 
2010; Hatoya et al., 2006; Thomson et al., 1998).  Since the first description of 
canine ESC by Hatoya et al.(2006), there have been three other reports (Hayes et al., 
2008; Schneider et al., 2007; Vaags et al., 2009).  There has at present been little 
further work detailing directed differentiation of these cells, suggesting that culture 
conditions allowing self-renewal may require optimization. 
 
In 2006, differentiated cells which were induced to become pluripotent (induced 
pluripotent stem cells, iPSC) by the addition of four transcription factors (Oct3/4, 
Sox2, cMyc & Klf4) were described (Yamanaka 2006). These behaved in a similar 
manner to ESC in that that they appear to have limitless expansion potential.  iPSC 
have now been described in a range of species, including human, pig, rat, dog and cat 
(Esteban et al., 2009; Shimada et al., 2010; Takahashi et al., 2007; Verma et al., 
2012). 
Both stem cell types are an attractive potential source of hepatocytes as their 
pluripotency and expansion ability offer the potential for a limitless supply of 
hepatocytes (Palakkan et al., 2013).   There are concerns with using both ESC and 
iPSCs in vivo as teratoma formation is common with ESC implantation, and the 
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majority of iPSC have been produced using retroviral vectors and oncogenic 
transgenes which are integrated into the host cell’s genome (Palakkan et al., 2013).  
This raises issues of mutations and tumour formation with this cell type also.  Much 
progress has been made in production of iPSC’s without genomic abnormalities or 
oncogenes and will be further discussed in Chapter 6.  iPSC’s have the advantage in 
that if they are derived from the patient requiring treatment, autologous therapy 
would not require immunosuppression although some studies have demonstrated an 
immune rejection response (Guha et al., 2013; Zhao et al., 2011).  If these stem cell 
types are used as an in vitro source then this avoids the problem for tumour 
formation, although mutations may cause the resultant hepatocytes to behave 
differently to primary cells.    
 
 
1.8.5 Mesenchymal stem cells 
Cells termed mesenchymal stem cells (MSC) were first isolated more than 50 years 
ago from bone marrow (Friedenstein et al., 1966). These cells arise from the neural 
crest and mesoderm and have been shown to have the capacity to differentiate into 
any mesodermal lineage (e.g. bone, cartilage, fat and tendon) (Pittenger et al., 1999).  
Since then, it has been realized that these cells can be isolated from any vascularized 
tissue and that they are derived from pericytes (Crisan et al., 2011; Crisan et al., 
2008), however the differentiation capacity does appear to vary dependent on source 
(Innes et al., 2013; Kern et al., 2006; Ock et al., 2012). There has been huge interest 
in MSC in regenerative medicine, due to their ease of isolation, simple 
cryopreservation and also the ability to differentiate into bone, cartilage and tendon.  
As a result, they have been used clinically to effect enhanced repair to these tissue 
(Steinert et al., 2012).  Furthermore, MSC appear to have beneficial effects on tissues 
not of mesodermal origin including liver, kidney and lung (Tanimoto et al., 2013; 
Wang et al., 2013b; Xu et al., 2013). In-vitro, it has been shown that MSC can trans-
differentiate into ectodermal and endodermal cell fates, albeit at low efficiencies e.g. 
hepatocytes and are a potential in vitro source of these cells (Dezawa et al., 2004; 
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Lee et al., 2004).  There has been much debate as to the action and fate of MSC once 
transfused into non-mesenchymal organs.  It appears that  many of their apparent in 
vivo therapeutic effects are not due to their differentiation capacity but due to a 
paracrine effect and as a result their name has been modified to mesenchymal 
stromal cell and then medicinal signalling cells (Caplan, 2009; Horwitz et al., 2005; 
Parekkadan and Milwid, 2010; Parekkadan et al., 2007). The two most common 
tissues from which MSC’s are isolated are the bone marrow and adipose tissue, 
although as stated above any tissue may potentially yield MSC’s (Caplan and Bruder, 
2001). 
  MSC do not appear to have the same expansion abilities as ESC and iPSC with 
many reporting senescence and reduced differentiation capacity at varying passage 
numbers which also appears species, site and donor dependent (Bernardo et al., 2007; 
Izadpanah et al., 2006; Kern et al., 2006). The advantage that MSC have is the ability 
to rapidly expand an individual’s MSC from adipose or bone marrow for use 
therapeutically either as MSC’s or after terminal differentiation, thus avoiding the 
need for immunosuppression.   
 
1.9 Use of undifferentiated stem cells in liver disease  
 
1.9.1 Bone marrow cells 
There has been interest in the potential of bone marrow cells (BMCs) to promote 
hepatic regeneration since bone marrow cells were identified in human livers after 
both bone marrow transplantation and after partial hepatectomy or full 
transplantation (De Silvestro et al., 2004).   In experimental rodent models of 
fibrosis, autologous BMCs injected into the tail vein improved fibrosis and 
stimulated regeneration (Sakaida et al., 2004). BMCs are an unselected population 
which contains both haematopoietic stem cells (HSC) and MSC. A further study 
showed that mice with fumarylacetoacetate hydrolase deficiency, a model of 
tyrosinemia type I a hepatocyte metabolic defect in humans, had restored hepatic 
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metabolic function after transfusion of haematopoietic stem cells (Lagasse et al., 
2000).  Subsequent work showed that this was due to fusion of monocytes with 
hepatocytes and that the high selection pressure of the experimental model meant 
that this was unlikely to be clinically useful (Willenbring et al., 2004).  Clinical trials 
in human have been performed with autologous mononuclear bone marrow cells.  
Improved serum albumin concentrations, and clinical scoring was noted; however the 
number of subjects was small and no control groups were used (Terai et al., 2006).  
A further study involving 15 treated and 15 control patients demonstrated an 
improvement in liver function in the treated group that was maintained for 90 days 
(Lyra et al., 2010).   HSC have been shown to differentiate into hepatocyte like cells 
in vitro and that as small percentage of these were found integrated into liver in vivo 
after transfusion (Khurana and Mukhopadhyay, 2008) 
 
1.9.2 Mesenchymal stem cells 
There is debate as to whether BM-MSC’s promote liver repair by differentiation to 
hepatocytes, producing growth factors or via an immune-modulatory route to reduce 
immune-mediated damage (Zhang et al., 2012). Recent work has shown that BM-
MSC’s appear to possess potent anti-inflammatory properties, exhibiting an 
inhibitory effect  on T and B cell, dendritic and natural killer cell proliferation (Asari 
et al., 2009; Sato et al., 2007; Spaggiari et al., 2009; Spaggiari et al., 2006). 
Experimentally, BM-MSC have been shown to reduce hepatic fibrosis in NOD-SCID 
mice, however other studies have shown that MSC can potentiate fibrosis by 
becoming myofibroblasts (Baertschiger et al., 2009; Forbes et al., 2004; Tanimoto et 
al., 2013). In human clinical studies, MSC have been shown to improve patients with 
steroid resistant graft versus host and also decreased rejection rate, risk of 
postoperative infection and increased renal function of transplanted kidneys (Le 
Blanc et al., 2008; Le Blanc et al., 2004; Tan et al., 2012). Experimental studies have 
demonstrated that both BM and adipose-derived mesenchymal stem cells (AD-MSC) 
rescued immunodeficient mice with acute liver failure (Banas et al., 2008; Kuo et al., 
2008).  As of November 2014, 362 human clinical trials using MSC’s are registered 
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with the National Institute of Health’s www.clinicaltrials.gov website, treating 
diverse diseases including multiple sclerosis, dilated cardiomyopathy, ulcerative 
colitis and chronic renal failure. Twenty-nine  studies are listed for liver disease, 23 
for cirrhosis. Seven of these trials have completed and been published (Meier et al., 
2013). Six of these used autologous BM-MSC and one allogeneic umbilical cord 
derived MSC’s. In two studies hepatocyte differentiation in vitro was performed. The 
majority of the studies involved small numbers of patients (5 studies involved <20 
patients).  Although the studies differed in patient selection and route of delivery, the 
majority of patients exhibited no negative effects and only minor side-effects were 
noted.   The results of these studies have been summarised as suggesting “that 
autologous MSC infusion allows mild biological improvements in patients with liver 
diseases, but clear and significant clinical benefit was not yet reported” (Meier et al., 
2013).  Interestingly the one study which used both undifferentiated and hepatocyte 
differentiated MSC noted no difference in efficacy between the two (El-Ansary et al., 
2012). Criticisms include: no investigation of histological improvements, poor 
characterisation of the MSC, poor experiment power and lack of control groups 
(Meier et al., 2013).    One small study (of 11 humans) has since been published 
which assessed histology after MSC transfusion and noted improvement, however 
this study lacked a control group (Jang et al., 2013).  Potential risks of MSC 
treatment that have been raised are genetic mutations during in vitro expansion and 
spontaneous malignant transformation (Miura et al., 2006; Zhou et al., 2006). 
Finally, there is evidence that MSC can stimulate tumour growth of occult tumours 
or pre-cancerous lesions (Bian et al., 2010; Karnoub et al., 2007; Kucerova et al., 
2010).   This is of concern in human medicine where chronic hepatitis predisposes to 
hepatocellular carcinoma (HCC) development therefore the very patients that would 
be receiving MSC treatment would have high risk of  pre-cancerous or cancerous 
lesions (Moradpour and Blum, 2005).  Despite chronic hepatitis being common in 
the dog, HCC occurrence is infrequent therefore this risk may be of lesser 
consequence in the dog (Charles et al., 2006). 
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As stated earlier in the chapter, chronic hepatitis is common idiopathic inflammatory 
in the dog resulting in fibrosis and cirrhosis, the mainstay of treatment consists of 
immunosuppression with prednisolone.  Despite treatment, prognosis is poor.  With 
the increasing evidence of an immune-modulatory effect of MSC there is the 
potential to study the effect of MSC transfusion on the course of disease in the dog.  
It has been stated that there is a lack of large animal models of fibrosis for 
translational research to human medicine.  The dog with naturally occurring hepatic 
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1.10  Aims of Thesis 
The aim of this project was to produce an in vitro source of canine hepatocytes from 
stem cell sources.  To facilitate this, primary canine hepatocytes were cultured and 
used as a gold-standard to allow development and optimisation of methods to assess 
hepatocyte characteristics and function.  As many of the function of canine primary 
hepatocytes were lost rapidly in vitro, methods of maintaining function by utilising 
CYP inducers and culture substrates were also assessed. 
The project isolated adult hepatic stem cells, also known as hepatic progenitor cells 
as well as canine AD-MSC and BM-MSC. The MSC’s were characterised using 
criteria developed by the International Society for Cellular Therapy (Dominici et al., 
2006). A number of methods shown to be effective in other species were used to 
differentiate canine MSC’s towards hepatocyte-like cells.  
Finally, primary hepatocytes and canine keratinocytes were transfected with a 
plasmid containing the Yamanaka factors (Oct3/4, Sox2, cMyc & Klf4) to induce 
pluripotency. Canine iPSC’s were differentiated according to published protocols in 
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Chapter 2: Materials and Methods 
2.1 Tissue culture plastic coating 
Tissue culture plates were coated with agents to improve cell attachment when 
required. 
2.1.1 Collagen type I 
Tissue culture plates were coated with 0.05mg/ml collagen type I.  This solution was 
made by addition of 1 part 5mg/ml bovine collagen type I (Gibco) to 99 parts 
phosphate buffered saline (PBS).  Sufficient was added to completely cover the base 
of the vessel and the plates incubated at 37
o
C overnight. The solution was then 
aspirated and plates rinsed with PBS before drying and storing at 4
o
C for up to 1 
week.  
2.1.2 Laminin 
Laminin (Sigma-Aldrich) was thawed on ice slowly and diluted to 50µg/ml with 
Hank’s balanced salt solution (HBSS, Invitrogen). A volume of 2.4mls was added to 
each well of a 6 well plate and incubated at 37
o
C for 2 hours.  The remaining 
solution was aspirated and the plate washed with HBSS. 
 
2.1.3 Gelatin 
A 0.1%w/v gelatine solution was prepared by dissolving 0.5g of Gelatine type A 
(Sigma-Aldrich) in 500mls of distilled water. This was then autoclaved and cooled. 
Sufficient solution was added to plates to cover the base.  Plates were then incubated 
at room temperature for 10 minutes before the solution aspirated and plates washed 
with PBS. 
2.2 Cell counting  
Cells were suspended in a known volume of medium and 20µl of suspension added 
to an equal volume of Trypan blue (Sigma-Aldrich). The solution was loaded onto a 
haemocytometer (Menzel-Glaser, Germany) and cells counted.  The result was 
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multiplied by two to give a starting cell concentration. Positively stained Trypan blue 
cells were non-viable. 
2.3 RNA extraction and quantification 
The RNeasy mini kit (Qiagen, UK) was used according to the manufacturer’s 
instructions. Cell pellets were disrupted in 350µl of lysis buffer using a Qiashredder 
(Qiagen, UK). DNA digestion was performed using DNase I (Qiagen, UK) at the 
recommended point in the RNA extraction protocol.  Total RNA was quantified and 
purity checked using absorbance spectrophotometry at 260 and 289nm (Nanodrop 
1000, Thermo, UK).   
2.4 Reverse transcription 
RNA was converted to cDNA using the Omniscript reverse transcription kit (Qiagen, 
UK) according to the manufacturer’s instructions using random nanomers (Sigma-
Aldrich, UK) and RNase inhibitor (Promega, UK). One µg of RNA was added per 
reaction. 
2.5 Primer design and preparation 
Where available, previously published primers were checked using NCBI Primer-
blast.  For primer design, the NCBI nucleotide database was used. Primers spanning 
an intron were designed if possible.   All primers were ordered from MWG Eurofins, 
diluted to 100 pmol/μL with nuclease-free water and stored at -20 °C. 
2.6 Real-time polymerase chain reaction (qPCR) 
The Platinum Sybr Green Qpcr Kit (Invitrogen, UK) was used in all qPCR reactions. 
The master mix is outlined in Table 2.1. Reactions were performed on the Stratagene 
MX3000P (Agilent, UK).  For primer optimisation, cDNA from freshly isolated 
canine hepatocytes was diluted in ten-fold steps to 100,000 and 9.5µl of this added to 
each well. Primer efficiency, and dissociation curve calculated using MXPro 
software (Agilent, UK), specificity was assessed by agarose gel electrophoresis.  
Relative gene expression was performed using cDNA, diluted 1:20 and 9.5µl of this 
added to each well. Each reaction was performed in triplicate and three no template 
controls were also included for each primer using 9.5 µl of nuclease-free water.  
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Reference genes are specified in the specific chapters.  Data were analysed using 
Microsoft Office Excel 2003 program using the method described by Pfaffl (2001) to 
calculate relative gene expression. 
 
Component Volume 
(µl per reaction) 
SYBR Green mix 12.5 
Forward primers 1.25 
Reverse primers 1.25 
Rox 0.5 
TOTAL 15.5 
Table 2.1 qPCR master mix  
Reaction conditions are were 2 minutes at 50
o
C, 2 minutes at 95
o
C, then 40 cycles of 
95
o
C x 15secs and 60
o
C x 30secs.  The final cycle was 95
o
C for 1 minute then 
cooling to 60
o
C before monitoring for dissociation to 95
o
C.  The dissociation curve 
produced and lack of amplification of the no template controls were checked using 
MXPro Software (Agilent, UK). 
 
2.7 Agarose gel and product analysis 
PCR products were run on a 2% agarose gel. This was prepared by melting 2g of 
agarose (Sigma, UK) in100 mL of 1 x Tris Acetate EDTA (TAE, Gibco, UK). A 
volume of 10 μL Gel Red 10,000X (Biotium) was added to the 100 mL melted 
agarose and the agarose was poured into a setting tray with inserted comb and 
allowed to set at room temperature. A volume of 12 μL of PCR product was added to 
4 μL of 6 X Blue/Orange Loading Dye (Promega, UK). This was loaded into the cell. 
A 100 base pair ladder (Promega, UK) was used to assess product size.  A Bio-Rad 
transformer was used to create 80V differential. Gels were run for approximately 2 
hours and then visualized using a BioRad Molecular Imager GelDoc. 
 








DiI-LDL and acetylated DiI-LDL (both Invitrogen, UK) were diluted to 20µg/ml in 
appropriate culture medium and added to cell culture wells for 3 hours.  Wells were 
then washed with phosphate-buffered saline (PBS) three times and fixed with 4% 
paraformaldehyde for 30 minutes.  The cells were washed with PBS three times and 
4',6-diamidino-2-phenylindole (DAPI) at a concentration of 200ng/ml for 30 minutes 
added.  The slides were then washed with phosphate buffered saline with 0.1% 
Tween (Sigma) (PBST) and examined using fluorescent microscopy.  No LDL 
controls were also performed. 
2.9 Immunofluorescence assay for LDL receptor 
Mesenchymal cells were cultured in four chambered slides (BD Biosciences) until 
they were approximately 50% confluent.  Canine primary hepatocytes were cultured 




.  Medium was 
removed, the cells washed with PBS and then fixed with 4% paraformaldehyde for 
30 minutes.  The cells were washed with PBS three times, permeabilised with 100% 
ethanol for 5 minutes before repeating the wash step. Blocking buffer (PBS 
containing 10% goat serum (Invitrogen) and 0.1% Tween 20 (Sigma) was added for 
1 hour at room temperature.  This was then aspirated and rabbit anti-human LDL 
receptor antibody with known cross-reactivity with the dog (ABIN672111, 
antibodies-online) was diluted to 1:500 with PBS containing 1% goat serum, 0.1% 
Tween added. This was then incubated at 4
o
C overnight and then washed three times 
in PBST. Fluorescently tagged goat anti-rabbit secondary antibody (Alexa Fluor 594 
goat anti-rabbit IgG, Life Technologies), diluted 1:1000 in PBS containing 1% goat 
serum and 0.1% Tween was added and incubated at room temperature in the dark for 
1 hour.  Slides were then rinsed three times with PBST and the 4', 6-diamidino-2-
phenylindole (DAPI) added at a concentration of 200ng/ml for 30 minutes.  The 
slides were then washed with PBST and examined using fluorescent microscopy 
Chapter 2: Materials and methods 
33 
 
(Zeiss, Aviovert 40) and Zeiss Aviovision 4.7 software. Secondary only and no 
antibody controls were also indluded for each cell type and antibody. 
2.10  Cytochrome P45 activity and Cyp induction 
The Promega PFBE-Luciferase assay was used to assess Cyp activity.  Cells cultured 
in a 96 well plate were used.  Experiments were performed in triplicate and no cell 
control wells were measured and this value subtracted from the sample wells.  For 
Cyp induction, phenobarbital and rifampicin (both Sigma-Aldrich, UK) were used. 
Phenobarbital was diluted in medium to a stock 200mM solution and rifampicin to 
20mM.  Drugs were added to a final concentration of 250µM and 25µM respectively 
for 72 hours as well as a basal no drug control before the wells were rinsed with PBS 
and 60µl of PFBE-Luciferase added to the wells in appropriate medium at a 1:40 
dilution. Cells were then incubated at 37
o
C and 5% CO2 for 3 hours.  A volume of 
25µL of supernatant was added to a white 96 well plate in duplicate from each well.  
This was then mixed with 25µl of the detection buffer for 20 minutes before 
luminescence was read using a plate reader (Victor3, Perkin Elmer, USA). 
 
2.11  3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay 
5mg/ml) of MTT (Sigma Aldrich M5655) stock solution diluted in appropriate cell 
culture medium  well to achieve a final concentration of 1mg/ml and 50µl  incubated 
at 37
o
C for 3 hours. The MTT solution was removed and tetrazolium salt solubilised 
with 100μl of solubilisation agent (0.1M HCL, 10% Triton x -100 and isopropanol) 
added.  The plates were then placed on an orbital shaker at 100rpm for 10 minutes 
before being read at 570nm in a plate reader (Victor3, Perkin Elmer, USA). No cell 
control wells were used to measure background and this value was removed from the 
sample values.  
 
A chapter-specific materials and methods section is included in each chapter. 
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Chapter 3: Establishment and characterisation 
of primary canine hepatocyte cultures 
 
3.1 Abstract 
In preparation of experiments to differentiate canine stem cells to hepatocyte-like 
cells it was necessary to optimise and validate qualitative and quantitative tests that 
would be anticipated to be useful and also provide a positive control to which 
hepatocyte-like cells could be compared.  
In this chapter the tests that are often performed on stem cell-derived hepatocyte-like 
cells are discussed followed by the description of the isolation and culture of canine 
primary hepatocytes from ischaemic tissue as a positive control. Quantitative and 
qualitative tests were validated using these cells.  A panel of primers for genes 
expressed by hepatocytes was validated along with a canine-specific ELISA for 
albumin, DiI-LDL and DiI-Ac-LDL uptake, Luciferase-based cytochrome activity 
test and periodic acid-Schiff staining for glycogen. Indocyanine green uptake was 
found not to occur in viable canine primary hepatocyte cultures and appeared to stain 
only dead hepatocytes. 
The ability of rifampicin and phenobarbital to induce cytochrome activity was 
assessed along with changes in gene expression and albumin secretion in primary 
hepatocyte cultures over time.  The effect of Matrigel on in vitro function over time 
was examined.   Although a Matrigel overlay improved cell attachment, no 
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3.2 Introduction 
Primary hepatocyte cultures are still considered to be the gold standard for in vitro 
toxicological testing (Fraczek et al., 2013; Kia et al., 2013).  Isolation of primary 
hepatocytes was first described by Berry and Friend (1969) and subsequently 
modified by Selgen (1976).  These protocols involve a two-step collagenase 
digestion of the surrounding matrix to dissociate the hepatocytes, producing a cell 
suspension.  Hepatocytes are fragile cells and this process causes oxidation as well as 
loss of surrounding cells and extracellular matrix (Wang et al., 1998). The resultant 
isolated hepatocytes are plated onto a rigid substrate, commonly type I collagen 
(Pichard et al., 2006).  This results in a “2D” or monolayer culture system in which 
the cells undergo dramatic changes in morphology and polarity, becoming polygonal 
and similar to epithelial cells in culture (Dunn et al., 1989).  These factors all 
contribute to a reduction in gene expression and hepatocyte-specific functions which 
is termed de-differentiation.  This is reported to remain the greatest barrier to in vitro 
drug toxicity testing (Soldatow et al., 2013).  As stated in Chapter 1, hepatocytes can 
be defined by a range of functions and genes expressed.  One of the crucial functions 
for drug toxicity testing is maintenance of cytochrome P450 expression and activity, 
in primary hepatocytes these are lost rapidly in vitro, stated to be within the first 24-
48 hour of culture (Knobeloch et al., 2012; Soldatow et al., 2013).  There appear to 
be species differences in the rapidity of this de-differentiation process with Nelson et 
al. (2013) reporting that porcine hepatocytes retained function for longer than human 
hepatocytes.  In comparison of rat, human and canine hepatocytes in 2D culture, total 
cytochrome content declined most rapidly in the rat; 50% with the first 24-48 to 23% 
after 48 hours.  Canine P450 content was stable for 24 hours then reduced to 50% at 
48 hours whereas human were stable for 48 hours and reduced to 20% at 72 hours 
(Ubeaud et al., 2001). Ditewig et al. (2013) reported canine primary hepatocytes 
exhibited a 1000-fold decrease in CYP expression after 120 hours in culture. 
Maintenance of CYP function appears also highly culture condition dependent 
(Nelson et al., 2013). Utilising a sandwich method of culturing hepatocytes with a 
Matrigel overlay has been shown to improve constitutive and induced CYP gene 
expression in human and rodent primary hepatocytes (Gross-Steinmeyer et al., 2005; 
Sellaro et al., 2010; Sidhu et al., 1993). However, this has also been shown to be 
Chapter 3: Establishment & characterisation of primary canine hepatocyte cultures 
36 
species specific leading Olsavsky Goyak et al. (2010) to conclude that “considering 
species specific responses to in vitro conditions, a thorough evaluation of any 
primary hepatocyte culture system is warranted to secure confidence in its use.”  
 
3.2.1 Methods of assessing hepatocyte phenotype and 
function 
As hepatocytes are functionally highly complex cells, there are arrays of tests of 
phenotype and function that can be used to demonstrate differentiation to a 
hepatocyte-like cell. Figure 3.1 gives a summary of commonly used characteristics 
that have been used to demonstrate hepatocyte-like properties during directed stem 
cell differentiation.   
 
Figure 3.1 Summary of commonly used qualitative and functional characteristics 
that are used to define hepatocyte-like cells. 
LDL – Low-density lipoprotein, ICG – Indocyanine green.  Modified from Zhang et 
al. (2013c). 
 




Mature hepatocytes in 2D culture systems assume a polygonal shape, are often 
binucleate, with a large cytoplasm to nucleus ratio and intracytoplasmic granules 
which may be lipid or glycogen.  Refractive borders between cells in the form of bile 
caniliculi may be present (Figure 3.2) (Nelson et al., 2013; Sancho-Bru et al., 2009).  
 
Figure 3.2 Porcine primary hepatocyte morphology on collagen type I. 
Primary hepatocytes in 2D culture exhibiting high cytoplasm to nuclear ratio, sharp 
demarcation between borders and many binucleate cells. From Wang et al. (2004). 
 
3.2.3 Gene expression 
There are panels of genes that are generally accepted as representing stages of 
differentiation, although few genes are specific.  Table 3.1 lists genes expressed at 
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Table 3.1 Gene expression markers used to assess hepatocyte-like cells.  
Modified from Zhang et al. 2012 and Sancho-Bru et al. 2009. 
 
3.2.4 Indocyanine green uptake 
Indocyanine green (ICG) is a cyanine fluorescent dye which has been used 
intravenously as a test of liver function as it is extracted by hepatocytes and excreted 
in bile (Cherrick et al., 1960).  It is commonly used as a test of hepatocyte-like cells 
in vitro whereby a positive result is defined as uptake after incubation with ICG and 
subsequent secretion of the compound when cells are placed in fresh medium.  The 
first report of ICG use in vitro is by Watanabe et al. (1976) who stated that human 
oval cells vitally stained with ICG. For hepatocyte-like cell differentiation of stem 
cells, Yamada et al. (2002) described ICG positive cells in embroid bodies which 
expressed liver specific genes such as albumin and transthyretin.  The first 
description of ICG uptake and subsequent secretion was demonstrating hepatocyte-
like differentiation of human umbilical cord cells (Wang et al., 2005).  These two 
papers incubated cells at 1mg/ml for 15 minutes. Other authors have used the same 
concentrations for 60-90 minutes (Agarwal et al., 2008; Hay et al., 2007). 
Neutrophils and reticulocytes have been shown to take up ICG; it is therefore not 
hepatocyte-specific (Wei et al., 2003). 
 
 
Cell Type Markers 
Definitive 
endoderm 
Hex, Mixl1, Cxcr4, Tm4sf2, Gsc, Sox17, E-cadherin; not Sox7 
Hepatic stem 
cell 
OV6, Albumin, Keratin 8,18,7,19, c-kit, CD34 






α1-antitrypsin, Albumin, ApoAII, ApoF, CEBP, Keratin 8,18, 
Cytochrome P450 enzymes, Hepatocyte nuclear factor 3b, 4a,6 
Glucose 6-phosphate,  liver-specific organic anion transporter-1, 
phosphoenolpyruvate carboxykinase, Tyrosine aminotransferase, 
tryptophan-2,3-dioxygenase, Transferrin, Transthyretin 
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3.2.5 Albumin secretion 
Albumin is the main plasma protein in circulation and responsible for controlling 
blood volume by providing oncotic pressure as well as acting as a carrier for many 
hydrophobic compounds, such as steroid hormones.  Hepatocytes are the chief source 
of albumin and therefore gene expression and secretion is often used to demonstrate 
a hepatocyte-like state (Fanali et al., 2012; Hengstler et al., 2005). Albumin gene 
expression has however also been documented in adipose tissue, bone, kidney, 
mammary gland as well as T cells and pancreatic and hepatic stellate cells, 
suggesting that albumin gene expression is not specific for a hepatocyte-like state 
(Kim et al., 2009; Mor and Cohen, 2013; Nahon et al., 1988; Shamay et al., 2005; 
Sirico et al., 2012; Yamaguchi et al., 2003; Yoo et al., 2010).  It is unknown whether 
these extra-hepatic sources of gene expression can synthesise albumin.  
 
3.2.6 Low density lipoprotein (LDL) uptake 
LDL is a transport molecule for lipids, including cholesterol and triglycerides, in 
extracellular fluid.  Specific LDL receptors on the cells membrane bind LDL and 
allow endocytosis.  In vivo, most LDL receptors are present on hepatocytes to supply 
cholesterol for bile secretion, conversion to bile acids and production of de novo 
lipoproteins (Goldstein and Brown, 1987). Harada-Shiba et al. (2004) demonstrated 
that cultures of wild-type murine primary hepatocytes avidly took up fluorescently 
labelled LDL; however, hepatocytes from LDL receptor knock-out mice failed to do 
so. As a result, demonstration of LDL uptake is commonly used as a test of 
hepatocyte like cells.  Commercially, two types of fluorescently tagged LDL are 
available, native LDL and acetylated LDL (AcLDL), a synthetic analogue of 
naturally occurring oxidised LDL. Acetylated LDL (and oxidised LDL) is not 
recognised by the LDL receptor but is taken up by scavenging receptors, present 
chiefly on macrophages and endothelial cells (Horiuchi et al., 2003). Oxidised LDL 
is responsible for endothelial dysfunction leading to atherosclerosis (Li and Mehta, 
2005). Nahhmias et al. (2006) showed that human and rat primary hepatocytes took 
up LDL but not AcLDL and as stated above, Harada-Shiba et al. (2004) 
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demonstrated that LDL uptake is receptor-dependent on hepatocytes. Despite this 
apparent clear-cut division, in the field of stem cell differentiation to hepatocyte-like 
cells there appears to be confusion.  There is variation in whether LDL or AcLDL is 
used, with many papers describing LDL use in the abstract yet stating use of AcLDL 
in the materials.  Table 3.2 documents recent papers using a form of LDL as a test of 
hepatocyte-like cells and which compound is listed in the abstract and in materials 
and methods. 
Study Abstract Materials & 
Methods 
Prasajak and Leeanansaksiri, 2013 LDL AcLDL 
Vosough et al., 2013  Ac-LDL Ac-LDL 
Asgari et al., 2013 LDL Ac-LDL 
Cao et al., 2012 Not Stated LDL 
Takayama et al., 2012 LDL LDL 
Pournasr et al., 2011 LDL Ac-LDL 
Huang et al., 2011 Not stated  Ac-LDL 
Ouyang et al., 2010 LDL Ac-LDL 
Si-Tayeb et al., 2010 LDL LDL 
Table 3.2 Papers detailing stem cell to hepatocyte differentiation and type of LDL 
used.   
Detailing type of LDL documented in abstract and materials and methods in paper.  
LDL- low-density lipoprotein, Ac-LDL – acetylated low-density lipoprotein. 
 
3.2.7 Urea production 
Hepatocytes are responsible for the detoxification of ammonia.  In peri-portal 
hepatocytes this occurs via the urea cycle whereby the net effect is that one molecule 
of urea and water is produced from two of ammonia and one carbon dioxide.  In peri-
venous hepatocytes, ammonia is utilised in the reaction of glutamate to glutamine 
(Kuntz and Kuntz, 2009).  The synthesis and increase in supernatant urea 
concentration in vitro is commonly used to demonstrate hepatocyte-like activity 
(Zhang et al., 2013c). 
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3.2.8 Cytochrome P450 activity 
One of the main advantages of developing canine in vitro hepatocytes would be the 
ability to model drug metabolism. The CypP450 enzyme system is the most 
important component of hepatocyte drug metabolism and, as a result, demonstration 
of CYP is an important characteristic. As genes may be expressed but non-
functional, gene expression of CYP is insufficient (Sancho-Bru et al., 2009). 
Demonstration of CYP activity may be either by the use of commercially available 
kits which a results in colour change, fluorescence or luminescence (such as 
pentoxyresorufin dealkylation to resorufin by CYP2 subfamily), or by measurement 
of the products of drug metabolism such as hydroxylation of testosterone via 
testosterone 6β-hydroxylase activity of CYP3A12 (Abass et al., 2012; Graham et al., 
2006; Lubet et al., 1985).  One testing method commonly used during stem cell 
differentiation to hepatocyte-like cells adds luciferin-pentafluorobenzylether 
(Luciferin-PFBE) from which luciferin (a fluorescent compound) is dissociated  by 
CYP3A4 and subsequently measured using luminometry (Cao et al., 2012; Shiraki et 
al., 2011; Sullivan et al., 2010). CYP activity can be induced in vivo and in vitro by 
certain drugs. Common compounds used are dexamethasone, rifampicin and 
phenobarbital. Dexamethasone is reported to be ineffective in causing CYP induction 
in the dog, causing a decrease in CYP3A enzymes (Zhang et al., 2006).   Both 
rifampicin and phenobarbital are known to induce CYP3A12 and CYP3A26 in the 
Beagle, with phenobarbital also inducing CYP2C21 and CYP2B11. See Table 1.1 for 
known induction activity on human and canine CYP enzymes (Trepanier, 2006). 
 
3.2.9 Transplantation assay 
These are a crucial test for hepatocyte-like cells whose final purpose is to be used in 
vivo.  Tests that have been recommended include, rescue of liver/metabolic failure 
models, such as the FAH mouse, a model of fumarylacetoacetase deficiency, leading 
to tyrosinaemia, progressive liver/renal dysfunction and neurological abnormalities 
(Sancho-Bru et al., 2009). 
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3.3 Aims 
The aims were to assess if canine primary hepatocytes could be isolated from 
ischaemic liver. This in vitro source of hepatocytes would then be used to validate 
methods which would be used in testing stem cell derived hepatocyte-cells as well as 
providing a gold-standard against which these hepatocyte-like cells can be compared.  
Finally, the effect of different culture substrates on primary hepatocytes will be 
examined as this may impact on functionality of stem-cell derived hepatocytes.  
 
3.4 Materials and Methods 
3.4.1 Primary hepatocyte isolation 
Dogs euthanased for a reason unrelated to the study were used.  Liver tissue was 
acquired within 20 minutes of euthanasia.  A wedge of hepatic tissue with one cut 
surface and intact Glisson’s capsule was sectioned (between 20-100g).  This was 
placed in William’s Medium  E (Invitrogen, UK) and transported to the laboratory on 
ice.   The tissue was rinsed with Hank’s balanced salt solution (HBSS, Invitrogen, 
UK), placed in a Petri dish and 20-22g plastic catheters (Vygon, UK) inserted into 
the vessels on the cut surface.  Chelating buffer (Appendix 1) at 37
o
C was perfused 
at approximately 6mls/minute  using a 20ml syringe (BD, UK) for 15 minutes.  
HBSS was then perfused at the same rate for 10 minutes. Finally collagenase buffer 
(Appendix 1) was perfused for between 30-45 minutes until the tissue appeared 
spongy and digested.  The tissue was moved to a fresh Petri dish and 25mls of 
William’s medium E with 10% FCS and 100 U/mL penicillin G and 100 μg/mL 
streptomycin (all Invitrogen, UK) at 37
o
C added.  The liver capsule was then torn 
and the tissue gently agitated to release dissociated hepatocytes. The cell suspension 
was filtered through a 70µ cell strainer (BD, UK).  The remaining liver tissue was 
rinsed with a further 25mls of medium and this suspension also filtered.  The 
resultant 50ml suspension was centrifuged at 50g for 3 minutes to pellet mature 
hepatocytes.  The supernatant was removed, the pellet re-suspended and 
centrifugation repeated.   
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3.4.2 Plating density of hepatocytes 




 in William’s media E with 10% 
FCS and 100 U/mL penicillin G and 100 μg/mL streptomycin (all Invitrogen, UK) 
on collagen-coated wells.  After 3 hours to allow attachment, the wells were gently 
rinsed with PBS at 37
o
C before Hepatocyte culture medium (Lonza, UK) was added. 
 
3.4.3 Matrigel overlay 
Matrigel (BD, UK) was thawed overnight on ice at 4
o
C. A 0.25mg/ml dilution using 
cold HCM was prepared and then warmed to room temperature.  After hepatocytes 
had attached and had been rinsed with PBS, this solution was added to the wells; 2ml 
per 6 well, 1ml in 12 well and 0.1ml in 96 well.  These were then incubated 
overnight and solution gently aspirated and HCM used.  
 
3.4.4 Albumin ELISA optimisation 
The ELISA kit ( Dog albumin ELISA kit, Immunology Consultants Laboratory, Inc., 
Texas) was labelled as specific for canine albumin for use with serum, plasma and 
urine.  Recommended dilutions for serum were 1:20,000 and urine 1:1000.  
Therefore to assess dilution required for culture media supernatant and also any cross 
reaction with bovine albumin in the media, optimisation was required.  A volume of 
100µl of HCM was added to each well of a 96 well plate. Media from canine primary 
hepatocytes in the first 24 hours of culture was used as this would be expected to 
yield the highest concentrations of albumin. Media which had not been exposed to 
cells was included as a negative control.  These were serially diluted 1:10 to give 
concentrations: neat, 1:10, 1:100, 1:1000, 1:10,000 and 1:100,000.  The kit was used 
according to the manufacturer’s instructions and the plate read using a Victor3 plate 
reader (Perkin Elmer, USA). 
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3.4.5 Albumin measurement 
100µl of culture media was added to each well of a 96 well plate containing the cells 
of interest.  After 24 hours this was removed and albumin concentration measured as 
above.  Experiments were performed in triplicate and concentration in supernatant 
measured in duplicate.  Culture media was added to blank wells to give background 
readings.  This result was subtracted from the results.  
3.4.6 Indocyanine green uptake 
Indocyanine green (MP Biomedicals, UK) was diluted to 5mg/ml in DMSO (Sigma-
Aldrich, UK). This stock was diluted in the appropriate culture medium to a final 
working concentration of 1mg/ml and cells incubated in this solution for 30 minutes 
at 37
o
C and 5%CO2. Wells were then washed three times in PBS, culture media 
replaced and cells imaged.  
3.5 Results 
3.5.1 Canine primary hepatocytes can be isolated from 
ischaemic liver 
A total of 23 primary canine hepatocyte isolations and cultures were undertaken.  
Cell viability ranged from 10-92% (Appendix 2).     Initial viability was poor but 
generally improved to >75% after the first 9 isolations, which is described as being 
acceptable for hepatocyte culture experiments (Knobeloch et al., 2012).  Total cell 
yield varied markedly, again tending to increase with number of perfusions 




.  It is likely that this was due to a 
combination of amount of liver perfused, age of dog, amount of fibrous tissue present 
in the liver, time and uniformity of perfusion.   
 
3.5.2 Canine primary hepatocytes can be cultured in vitro 
After 24 hours, large polygonal cells, which were often binucleate with a high 
cytoplasm to nucleus ratio, were attached to the collagen-coated wells (Figure 3.3).   
Refractive borders were present between cells consistent with bile caniliculi. These 
cells maintained their morphology for approximately 7-10 days before changing 
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morphology, gradually detaching and/or being replaced by   colonies of smaller cells 
of a similar morphology or outgrowths of fibroblastic cells.   
 
Figure 3.3 Morphology of canine primary hepatocyte cultures 




 on type I 
collagen in William’s media E containing 10% foetal calf serum.  After 4 hours to 
allow attachment, media was replaced with serum-free hepatocyte culture media.   
Cells were imaged after 24 hours culture. A & B show hepatocytes from a 3 year old, 
entire male Rottweiler and C & D from 2 year entire male Mastiff.  White bar 
represents 100µm.   
 
3.5.3 Viable canine hepatocytes do not accumulate 
indocyanine green 
Primary hepatocytes were assessed for ICG uptake after between 1-3 days in culture.  
Uptake appeared patchy with the majority of hepatocytes showing no uptake and 
dead cells/cell debris on the top of the mono-layer staining (Figure 3.4A).  Cells 
around the periphery, which were less confluent took up the stain most readily with 
small contiguous areas also staining heavily (Figure 3.4B, C). Addition of ICG to 
hepatocytes which had been briefly exposed to 70% ethanol for 5 seconds before 
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washing with PBS and replacing culture media produced uniform uptake (Figure 
3.4D).   Scratch assay damaged hepatocytes also demonstrated strong uptake 
compared to undamaged cells (Figure 3.4E).  Finally, culture of hepatocytes in media 
containing MTT after exposure to ICG demonstrated no purple granule formation in 
cells stained with ICG (Figure 3.4F). This lack of overlap between tetrazolium 
production and ICG staining of the hepatocytes indicated that cells which were 
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Figure 3.4 Indocyanine green (ICG) uptake by canine primary hepatocytes 
A,B,C - Canine primary hepatocytes were cultured in media containing 1mg/ml 
indocyanine for 30 minutes, media aspirated, cells washed three times with PBS, 
fresh media replaced and cells photographed. D – Hepatocytes were washed for 5 
seconds with 70% ethanol before rinsing in PBS prior to ICG incubation. E- Scratch 
assay, cell monolayer was disrupted by drawing a 20µl pipette tip through it prior to 
ICG incubation. F – After ICG incubation and washing, cells were then incubated in 
1mg/ml MTT for 2 hours before washing three times in PBS. All images x100 apart 
from C x400. These images were representative from 3 primary hepatocyte cultures. 
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3.5.4 Canine hepatocytes stain with Periodic acid Schiff 
Canine primary hepatocytes demonstrated strong PAS staining between days 1-3; 
this became less pronounced in prolonged culture. Figure 3.5A shows PAS staining 
of canine primary hepatocytes after 24 hours’ culture, demonstrating intense pink 
staining consistent with the presence of intra-cytoplasmic glycogen. Figure 3.5B 
shows PAS staining of hepatocytes after 6 days in culture. Patchy, weak staining of 
cells is seen, consistent with loss of glycogen during culture. 
 
Figure 3.5 Periodic acid-Schiff staining of canine primary hepatocytes. 
Canine primary hepatocytes were cultured on type I collagen in HCM, washed with 
PBS and fixed in 4% paraformaldehyde for 30 minutes. Cells were then stained with 
periodic acid-Schiff and photographed.  A – D17913 hepatocytes after 1 day culture. 
B –Canine hepatocytes after 6 days culture (From dog ID-  D17913). Images x 200. 
These images were representative of 3 primary hepatocyte cultures. 
 
3.5.5 Primer optimisation of hepatocyte gene expression 
Primers were optimised and efficiency calculated using cDNA from D10513 day 0 
canine primary hepatocytes. Primers which had acceptable efficiency, dissociation 
curve and band size on gel electrophoresis were: β2 microglobulin, hypoxanthine 
guanine phosphoribosyl transferase, ribosomal protein L8, αfoetal protein, albumin, 
keratin 7,  keratin  18, transthyretin,  low-density lipoprotein receptor, glycogen 
synthase, α1-antitrypsin, CYP1A2, CYP2B11, CYP2C18,CYP2D15,CYP3A12 and 
CYP3A26.  Table 3.3 shows primers, sequence, calculated efficiencies, quality of 
dissociation curve and gel size of product.  
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HPRT F– TTATGGACAGGACTGAGCGG 
R - TTGAGCACAGAGGGCTAC 
82 98.3 59.18/56.23 √ √ 
B2MG F– TCCTCATCC TCCTCGCT 
R - TTCTCTGCTGGGTGTCG 
85 96.7 55.97/56.03 √ √ 
RPL8 F – CCATGAATCCTGTGGAGC 
R - GTAGAGGGTTTGCCGAT 
64 96.6 55.07/53.2 √ √ 
Albumin F – GTTCCTGGGCACGTTTTTGTA 
R- GCTTCATATTCCTTGGCGAGTCT 
92 97.4 60.94/62.78 √ √  
Keratin 18 F – TTGCTACCTACCGTCGCCTGT TGG 
R - ATCTTGCGGGTGGTGGTCTTC TGG 
109 98 58.33/58.33 √ √ 
Keratin 19 F– GCCCAGCTGAGCGATGTG C 
R -TGCTCCAGCCGTGACTTGATGT 
86 321 64.29/64.47 X √ 
Trans-
thyretin 
F – CGCTGGACTGGTACTTGTGT 
R -TCGGACAGCGTCTAGGACTT 





82 96.1 59.54/59.61 √ √ 
Glycogen 
synthase 
F – AGGCTCTCCGATCTTCTGGA 
R - CTTCGGTCGTTGGTGGTGAT 
127 96.6 59.74/60.32 √ √ 
HNF4 F – GAG ATG TTG CTG GGA GGG TCC 
R- CAC TCA CAC ATC TGT CCA TTGC 




R - GAAAGATCCAGGGTGATGCCATT 





123 61 63.48/62.07 X  
αfoetal 
protein 
F – ACCCCACCTGAGCTGATGGC 
R- TAAGATCAGCCGCTCCCTCGC 
112 72.5 64.39/64.31 X  




F- CTG AAA ACC CTC TTG AAT GCC A 
R -  TTT CTG GAA GAG GCC ACA GCT 
104 98.2 59.11/61.67 √ √ 
αfoetal 
protein 
F – TAG AAA ACC AGC TCC CTG CC 
R - CTG CAG CAA TCT GCA AGT CC 
85 73.7 59.67/59.83 √ √ 
CYP1A2 F – ACCATCCCCCACAGCACAACAAA 
R - GCTCTGGCCGGAATGCAAATGGAT 
140 101 65.87/66.12 √ √ 
CYP2B11 F – CTGCCCATCTTGGGGAACTT 
R- CCGTATGGCGTCTATCCCAC 
147 61.6 59.96/60.04 √  
CYP2B11 F - TGCGGAAAACTGAGGGAGTC 
R- CGCAGGAACTCAGGGTCTTT 
121 96.8 59.97/59.96 √ √ 
CYP2B11 F – AAAGGCTTATGGCCACCTCC 
R- TCTTGGAGCCTGAGGAAGGA 
108 74.3 60.03/59.88   
CYP2C18 F– TGGACCATACAGGGATTAGGAAT 
R- TCCGCAAAACTGTCAGGGAA 
85 91.9 58.42/59.82 √ √ 
CYP2D15 F – TGGTGTCCACCTCAATCACG 
R- GGGTCTGGTCTCCCATCTCT 
135 98.3 59.97/60.03 √ √ 
CYP3A12 F – GGCTATTTGGAAAGAAAGTTACTG 
R- AGTCCACTCGGTGCTTTTGT 
97 91.3 57.79/59.82 √ √ 
CYP3A26 F – AGAAACACAGATCTCCCTGAGAA 
R- CCTTAGGAAAGTCAGGCTCCA 
117 90 58.84/59.09 √ √ 
Keratin 7 F– GCG TGG GAGCCGTGAACATC 
R- CCG CCGCCGCTGGAGAA 
112 99.4 64.04/65.36 √ √ 
TAT F – TGCTCTGTCTATTGGCGACC 
R- CGAGTCCAGGGCATCTTTCA 
88 127 59.82/59.72   
Table 3.3 Primers tested for efficiency and specificity using cDNA from canine primary hepatocytes 
Primers assessed for specificity by dissociation curve and gel electrophoresis. Efficiency of between 90-105% was deemed acceptable. 
Primers in grey were not utilised as efficiency was unacceptable. HPRT - Hypoxanthine-guanine phosphoribosyltransferase, B2MG - β2 
microglobulin, RPL8 – ribosomal protein L8, TAT - tyrosine aminotransferase, HNF4 – hepatocyte nuclear factor 4.  
Chapter 3: Establishment & characterisation of primary canine hepatocyte cultures 
51 
3.5.6 The albumin ELISA kit is specific for canine albumin in 
hepatocyte supernatant 
Media unexposed to canine hepatocytes gave near identical readings to the 0 
standard, demonstrating no detection of bovine albumin or cross-reaction with other 
substances in the medium. Of the 10-fold dilutions of supernatant which had been 
exposed to canine primary hepatocytes for 24 hours, the 1:100 and 1:1000 dilutions 
produced an optical density that lay within the standard curve (Table 3.4).  The 
1:1000 sample produced an OD which was within the values obtained by the 
standards but towards the lower range. Dilutions of 1:100 were selected for use in 
subsequent experiments as it was expected that albumin concentrations would 
decrease over time and that stem cell derived hepatocyte-like cells would have less 
albumin production than primary hepatocytes. This dilution would allow lower 
values to remain on the standard curve.  Therefore the canine specific ELISA would 
be a useful test of albumin production in hepatocyte-like cells and the antibody did 
























0 0.064 0 3.316 
12.5 0.233 1:10 3.018 
25 0.424 1:100 1.667 
50 0.766 1:1000 0.301 
100 1.352 1:10,000 0.091 
200 2.112 1:100,000 0.078 
400 2.763 Control media 0.069 
Table 3.4 Optimisation of cell culture supernatant in canine albumin ELISA 
Canine albumin standards were prepared according to manufacturer’s directions. Cell 
media which had been incubated with freshly isolated canine primary hepatocytes for 
24 hours was used as test media along with media which had not been exposed to 
cells as a negative control.  Test media was diluted in ten-fold steps.  Optical density 
of the plate was read at 450nm. Shading on the right hand side table indicates 
dilutions which fell within the optical density of the standards. 
 
3.5.7 Canine hepatocytes take up LDL but not Ac-LDL 
Canine primary hepatocytes from dogs D21113, D17513 and D19713 were used. In 
each experiment, the negative control demonstrated very mild auto-fluorescence: the 
majority of cells strongly took up native DiI-LDL and only a few cells strongly took 
up DiI-Ac-LDL (Figure 3.6).  Canine primary hepatocytes appear to endocytose LDL 
strongly but not Ac-LDL. This would suggest that this occurs by specific LDL-
receptor transport rather than scavenging receptors.  The cells which strongly 
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endocytose Ac-LDL in the hepatocyte culture are most likely either macrophages 
(Kupffer cells if resident in the liver), or endothelial cells, as contaminants.   From 
these results, when assessing differentiation of stem cells to hepatocyte-like cells, at 
least in the canine species, LDL and not Ac-LDL should be used.  This is consistent 
with the literature describing the LDL receptor which is present on hepatocytes as 
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Figure 3.6 LDL and AcLDL uptake of primary hepatocyte cultures 
A, C, E – Phase contrast images of primary hepatocytes x 10 
B, D, F – x 20, DAPI as nuclear stain. B - negative control demonstrating low auto-fluorescence of hepatocytes, D – Hepatocytes 
incubated with 20µg/ml DiI-LDL for 3 hours demonstrating almost uniform LDL uptake. F – Hepatocytes incubated with 20µg/ml DiI-
AcLDL for 3 hours. A minority of cells fluoresce with Ac-LDL strongly with the majority of the hepatocytes remaining negative. 
These images are representative of three primary hepatocyte cultures.
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3.5.8 In vitro canine primary hepatocytes lose phenotype 
over time 
To assess how rapidly hepatocyte-specific gene expression decreased in vitro, cell 
pellets were collected daily from day 0-6 for gene expression. Primary hepatocytes 
from dogs 17513, 19713 and 41013 were used in these experiments.  
For all CYP genes examined there was a dramatic decrease over 48 hours, with 
greatest expression in freshly isolated hepatocytes (Figure 3.7).  
Albumin gene expression also reduced dramatically during the 6 days in culture 
(Figure 3.8). Although transthyretin and glycogen synthase decreased from 
hepatocyte isolation to the first 24 hours in culture, they remained stably expressed 
for the remaining culture period (Figure 3.8).  α1-Antitrypsin increased in the first 24 
hours culture in 17513 and 41013 but not 19713 and then reduced to remain stable 
and a similar order of magnitude as fresh hepatocytes (Figure 3.8).  LDL receptor 
expression increased slightly in D41013, remained stable in D19713 for the 6 day 
period and stable for the first 3 days in D17513 before decreasing slightly (Figure 
3.8).   Keratin 7 and 18 increased after 24 hours culture and remained increased 
compared to primary hepatocytes during the 6 days in culture (Figure 3.9). 
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Figure 3.7 Relative gene expression of canine specific CYP in D41013 canine 
primary hepatocytes over time.  
Reactions were performed in triplicate and genes of interest were normalised to three 
reference genes.  Experiment was performed in triplicate with hepatocytes D17513, 
D19713 also used. 
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Figure 3.8 Relative gene expression of albumin (ALB), α1-antitrypsin (a1AT), 
transthyretin (TTR), glycogen synthase (GlyS) and low-density lipoprotein receptor 
(LDLr) in  canine primary hepatocytes over time. 
Reactions were performed in triplicate and genes of interest were normalised to three 
reference genes.  Experiment was performed in triplicate with hepatocytes D17513, 
D19713 also used. 
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Figure 3.9 Relative gene expression of keratin 7 (K7) and keratin 18 (K18) in 
canine primary hepatocytes over time. 
Reactions were performed in triplicate and genes of interest were normalised to three 
reference genes.  Experiment was performed in triplicate with hepatocytes D17513, 
D19713 also used. 
 
3.5.9 Rifampicin and phenobarbital induces CYP gene 
expression in canine hepatocytes 
Induction of cytochrome P450 enzymes by drugs is one important factor in drug-
drug interactions and alterations in pharmacokinetics.  In production of canine 
hepatocyte-like cells for in vitro drug metabolism studies, this ability would be a 
prerequisite (Tsuchiya et al., 2012). Therefore this experiment was performed to 
assess the ability to induce CYP gene expression in the gold standard of primary 
canine hepatocytes and then provide a positive control during testing of possible 
hepatocyte-like cells derived from stem cell sources. Drugs which are commonly 
used in vitro to induce CYP activity are rifampicin (an antibiotic), dexamethasone 
and phenobarbital. Additionally, these drugs are used to boost the metabolic activity 
of cultured hepatocytes (Fraczek et al., 2013).  As dexamethasone is not reported to 
cause CYP induction in the dog, rifampicin and phenobarbital were used (Zhang et 
al., 2006). D19713 primary hepatocytes were cultured with rifampicin and 
phenobarbital for 72 hour before qPCR gene expression of CYP, and fold increase 
compared to unexposed controls was calculated (Figure 3.10 & Figure 3.11).  




Figure 3.10 CYP gene expression of canine primary hepatocytes after 72 hours 
exposure to control medium(HCM), 25µM rifampicin and 250 µM 
phenobarbitone.Relative expression of selected CYP genes. Gene expression was 
normalised to three reference genes.
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Figure 3.11 Fold increase of CYP gene expression after 72 hours of induction with A- 25µM rifampicin and B- 250µM 
phenobarbital.   
Primary hepatocytes 19713 were used. Fold increase was calculated using the Pfaffl method after normalising to three reference genes 
(Pfaffl, 2001). Boxes represent the interquartile range, or the middle 50% of observations. The dotted line represents the median gene 
expression. Whiskers represent the minimum and maximum observations.  Expression ratios were tested for significance by a pair wise 
fixed reallocation randomisation test. A – With rifampicin CYP3A12, CYP2B11 and CYP2D15 were significantly up-regulated 
(p=0.036, 0.024 and 0.024 respectively). With phenobarbital, CYP3A12, CYP2B11 and CYP2D15 were significantly up-regulated (p= 
0.049, 0.042 and 0.043 respectively).  




3.5.10 Rifampicin and phenobarbital do not significantly 
increase CYP activity as measured by cleaving PFBE-
Luciferin 
Various methods of assessing CYP activity in vitro have been used for primary 
hepatocyte cultures and also hepatocyte-like cells derived from stem cell sources 
(Asgari et al., 2013).  A luciferase assay system suitable for use with intact cell 
monolayers was used in this case (Promega P450-Glo Assay Luciferin-PFBE).  To 
allow for variation in cell number, the results were normalised against the optical 
density of the MTT cell viability assay. The results from 24 hours and 72 hours 
culture of canine primary hepatocytes with control media, rifampicin and 
phenobarbital are shown in Figure 3.12.  No significant difference was detected after 
24 hours’ culture. Although values were higher than basal after 72 hours’ culture 
with rifampicin and phenobarbital, this was not statistically significant.  Activity was 
significantly lower in the 72 hour sample compared to the 24 hour sample in both 
basal and rifampicin treated cells. This reduction is consistent with the reduction in 
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Figure 3.12 CYP activity of canine primary hepatocytes at 24 hours and 72 hours 
culture.  
CYP activity was measured using Promega Pro-Glo Luciferase-PFBE which was 
added to culture media for 3 hours. The medium removed, detection buffer added 
and luminescence measured using a luminometer.  MTT was used to assess cell 
viability. Luminescence was then divided by optical density to normalise for 
variation in cell number. There was a significant decrease in activity between the 
HCM 24 and 72 hours and also the rifampicin 24 and 72 hours.  HCM -  hepatocyte 
culture medium, basal activity. Rifampicin added at 25µM, phenobarbital at 250µM.  
 
3.5.11 Albumin production of primary hepatocytes 
reduces over time 
Albumin concentration of the supernatant was performed using D17513 and D41013.  
Consistent with the dramatic reduction in albumin gene expression previously noted, 
concentration reduced dramatically with a statistically significant difference over the 
first 24 hours (p=0.0128) and by approximately 50% between day 1 and 3 (Figure 
3.13). 
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Figure 3.13 Albumin production per 24 hours in µg/ml from D17513 primary 
hepatocytes.   
Canine albumin specific ELISA kit was used (Immunology Consultants Ltd). Media 
was collected every 24 hours and diluted 1:100. There was a significant reduction in 




3.5.12 Matrigel overlay improves hepatocyte viability 
As primary hepatocyte function decreased so dramatically, an experiment was 
designed to assess the effect of sandwich culture using Matrigel as an overlay.  If an 
improvement in qualitative or quantitative tests were demonstrated then these culture 
conditions may also improve function in hepatocyte-like cells derived from stem cell 
sources. Matrigel at 0.25mg/ml in HCM was overlain primary hepatocytes cultured 
on collagen type I. These were compared with hepatocytes cultured on collagen type 
I.  Cell morphology was examined and pellets for RNA extraction and real-time PCR 
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were collected on day 1 and 3 as well as freshly isolated hepatocytes.  Subjectively, 
hepatocytes with Matrigel appeared more confluent, with sharper demarcations 
between cells, consistent with bile caniliculi formation (Figure 3.14).  
 
Figure 3.14 Morphology of canine primary hepatocytes on type I collagen and type 
I collagen with Matrigel overlay.  




. After 4 hours 
to attach media was changed to either standard culture media or standard culture 
media supplemented with 0.25mg/ml Matrigel.  Hepatocytes were photographed 
after 24 hours culture in vitro. Images A and B are hepatocytes on standard collagen 
type I, images C and D are hepatocytes on collagen type I that were then overlain 
with 0.25mg/mml of Matrigel.  White bar represents 100µm. 
 
To assess the effect of the Matrigel overlay on hepatocyte viability, a cell viability 
assay was performed after 1, 3 and 6 days culture. This was performed using canine 
primary hepatocytes D17513 and D41013. Wells cultured with an overlay of 
Matrigel had statistically significant higher cell viability at all time points with all 










Figure 3.15  Cell viability of canine primary hepatocytes D19713 on collagen type 
I and Matrigel overlay on days’ 1,3 and 6. 
Canine primary hepatocytes from D41013 were plated as described in Figure 3.14. 
Following addition of 1mg/ml MTT solution, incubation for 3 hours and subsequent 
solubilisation, the optical density was read at 570nm using a plate reader. Results are 
the average of triplicate determinations ± SEM and the experiment repeated three 
times. 
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3.5.12.1 Hepatocyte gene expression is not consistently higher with 
Matrigel overlay 
Canine primary hepatocytes from D41013 were used and analysed at time points 1,3 
and 6 days. Matrigel overlay was changed daily. Fold increase in the Matrigel 
overlain hepatocytes in comparison to standard culture was calculated (Figure 3.16). 
No genes analysed were consistently significantly up-regulated at all time points. 
Glycogen synthase was mildly but significantly up-regulated at days 1 and 6 (p=0.01 
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Figure 3.16 Fold increase in gene expression of albumin, keratin18, transthyretin (TTR), α1-antitrypsin (a1AT) and glycogen 
synthase(GlySy) in Matrigel overlain hepatocytes compared to standard culture. 
Fold increase was calculated using the  Pfaffl  method (Pfaffl, 2001). Boxes represent the interquartile range, or the middle 50% of 
observations. The dotted line represents the median gene expression. Whiskers represent the minimum and maximum observations. 
Experiment was performed in triplicate. ns = not significant.
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3.5.12.2 Matrigel overlay does not improve albumin production. 
Supernatant from D17913 canine primary hepatocytes was collected from standard 
culture and Matrigel overlain hepatocytes after 24 and 72 hours and analysed for 
albumin concentration using the canine albumin specific ELISA. Cells were 
quantified using an MTT assay and albumin concentration was divided by this 
optical density to normalise for variation in cell number (Figure 3.17).  Although 
normalised values were higher  on day 1 and 3 in the Matrigel overlain hepatocytes 
this was not statistically significant. 
 
 
Figure 3.17 Comparison of albumin concentration of canine primary hepatocytes 
in standard culture and overlain with Matrigel. 
Hepatocytes were plated as described in Figure 3.14. Experiment was performed in 
triplicate. Media was collected at day 1 and day 3.  An MTT assay was then used to 
define cell number variation. Albumin concentration was measured in duplicate 
using ELISA and result was divided by MTT optical density to normalise for 
variation in cell number. Error bars represent standard error of mean. 
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Figure 3.18 Albumin production of D41013 hepatocytes on collagen and Matrigel 
overlay 
Hepatocytes were plated as described in Figure 3.14. Experiment was performed in 
triplicate. Medium was collected daily on days 1-5. Cells were trypsinised and 
counted. Albumin concentration was measured in duplicate using ELISA and the 
result was normalised to 1 x10
4
 cells. Values were analysed using a repeated 
measures ANOVA.  
 
Media from D41013 standard culture and Matrigel overlain hepatocytes was also 
analysed for albumin concentration.  In this experiment, as there was concern that the 
MTT assay results may not be directly comparable between days, the cells were 
trypsinised and counted.  Supernatant was collected every 24 hours for 5days. The 
experiment was performed in triplicate and samples were analysed in duplicate.  
Albumin concentration was normalised to 1 x10
4
 cells (Figure 3.18).  There was no 
significant difference between albumin production in standard culture and Matrigel 
overlain hepatocytes at any time point.  There appeared to be an increase in albumin 
production in both standard culture and Matrigel overlain hepatocytes between days 
1 and 2.   
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3.5.12.3 Matrigel overlay did not consistently increase hepatocyte 
CYP expression.  
Real time PCR was performed at time points 1, 3 and 6 days to compare CYP gene 
expression in canine primary hepatocytes on standard collagen type I to hepatocytes 
on collagen type I with a Matrigel overlay.  This was performed using D19713 and 
D41013 canine primary hepatocytes.  Relative gene expression of Matrigel overlain 
hepatocytes was compared to control hepatocytes (Figure 3.19,Figure 3.20 & Figure 
3.21). Any fold increase in CYP expression was mild (maximum of 4, generally <2) 
and not consistent apart from possibly CYP1A2 which was significantly increased in 
D17913 at time points 1 and 3 and in D41013 at time points 3 and 6 days.   
 




Figure 3.19 Fold increase of CYP expression in D19713 canine primary 
hepatocytes with Matrigel overlay days 1 and 3. 
Hepatocytes with Matrigel overlay were compared to hepatocyte with standard 
collagen type I basal substrate.  CYP genes were normalised to three reference genes. 
Fold increase was calculated using the Pfaffl  method (Pfaffl, 2001). Boxes represent 
the interquartile range, or the middle 50% of observations. The dotted line represents 
the median gene expression. Whiskers represent the minimum and maximum 
observations. ns = not significant. 
 







Figure 3.20 Fold increase of CYP expression in D41913 canine primary 
hepatocytes with Matrigel overlay days 1 and 3. 
Hepatocytes with Matrigel overlay were compared to hepatocyte with standard 
collagen type I basal substrate.  CYP genes were normalised to three reference genes. 
Fold increase was calculated using the Pfaffl  method (Pfaffl, 2001). Boxes represent 
the interquartile range, or the middle 50% of observations. The dotted line represents 
the median gene expression. Whiskers represent the minimum and maximum 
observations. ns = not significant. 
 




Figure 3.21 Fold increase of CYP expression in D41913 canine primary 
hepatocytes with Matrigel overlay day 6. 
Hepatocytes with Matrigel overlay were compared to hepatocyte with standard 
collagen type I basal substrate.  CYP genes were normalised to three reference genes. 
Fold increase was calculated using the Pfaffl  method (Pfaffl, 2001). Boxes represent 
the interquartile range, or the middle 50% of observations. The dotted line represents 
the median gene expression. Whiskers represent the minimum and maximum 
observations. ns = not significant. 
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3.5.12.4 Induced CYP activity is not increased by Matrigel overlay. 
D41013 hepatocytes were cultured with 50µM rifampicin, 500µM phenobarbital or 
control media. CYP activity was measured using the luciferase assay with 
normalisation against cell viability at time points 1 and 3 days (Figure 3.22). Basal 
CYP activity was significantly lower on day 1and 3 in the Matrigel cells compared to 
control cells (p=0.0178 and 0.0157 respectively).  Although on Matrigel day 1, 
rifampicin and phenobarbital treated cells had higher values, these were not 
significantly different to basal Matrigel CYP activity (p=0.0822). By day 3, Matrigel 
phenobarbital but not rifampicin treated cells had significantly higher activity than 
the basal cells (p=0.0098). There was no significant difference in CYP activity after 
phenobarbital treatment between collagen and Matrigel hepatocytes on day 1 or 3 
(p= 0.098 and 0.894). 
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Figure 3.22 CYP activity of collagen and Matrigel overlain canine primary 
hepatocytes. 
Hepatocytes were cultured in triplicate either on collagen or collagen/Matrigel 
overlay with HCM + vehicle, HCM + rifampicin or HCM+phenobarbital for 24 and 
72 hours. Luciferin-PFBE was added and cell cultured from 3 hours. Media was then 
aspirated, added to detection reagent and read in duplicate in a luminometer at 1 
second detection per well. Experiment was performed in triplicate and empty wells 
containing no cells were used as controls for background fluorescence.  Background 
fluorescence was subtracted from results.  Cells were then cultured in 1mg/ml MTT 
for 2 hours, and optical density measured. Luminescence was then divided by optical 
density. 
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3.6 Discussion 
After a period of familiarisation with techniques, confluent cell cultures could be 
reliably derived from ischaemic canine hepatic tissue. Variation in cell number and 
viability was likely to be due to multiple factors including, age and health of the dog, 
time between euthanasia and processing of tissue, temperature of storage, size of 
liver wedge perfused, amount of connective tissue and length of time of the perfusion 
performed for.  However after initial perfusions, many more hepatocytes than were 
required for each experiment were isolated.  Hepatocytes are fragile, 
cryopreservation tends to cause poor viability and loss of function (Terry et al., 
2006).  As a result, this option was not explored for these hepatocytes especially as 
the main use was to provide a gold-standard with which to compare stem cell derived 
hepatocyte-like cells.  As there is a shortage of human hepatocytes for clinical use, 
much effort has been put to improving cryopreservation techniques of human 
hepatocytes. At present, the most effective method involves purifying only high 
viability cells, pre-culturing with media supplements and using a programmable 
freezer which varies the rate of temperature decline and includes a “shock freezing” 
step to counteract the latent heat of fusion when ice crystals form (Hewitt, 2010).   
The cell density at which they are frozen at also appears critical, which is species 
specific (Hewitt, 2010).  As after some successful perfusions, the majority of 
hepatocytes were discarded as surplus to requirements, investigation of the optimal 
cryopreservation methods for canine hepatocytes would be a useful avenue of further 
investigation, allowing these cells to be available on demand rather than being 
limited to fresh liver tissue availability.  
The resultant cells were as described for in vitro hepatocyte preparations in multiple 
species, namely large polygonal cells, often bi-nucleate with a large cytoplasm to 
nucleus ratio.  The change in morphology over 7-10 days has also been described in 
multiple species (Knobeloch et al., 2012). 
Surprisingly, the majority of canine primary hepatocytes did not take up ICG and 
only damaged cells stained well. The first two papers that used ICG to demonstrate 
hepatocyte-like characteristics of differentiated stem cells both stated that “no effect 
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on viability was noted at 1mg/ml for 15 minutes”, suggesting that higher 
concentrations and/or longer incubation times may have affected viability (Wang et 
al., 2005; Yamada et al., 2002).  Zamule et al.  (2011) stated that 1mg/ml for 15 
minutes caused toxicity in human embryonic stem cells and used 100µg/ml.   ICG 
has been used as a method of assessing human hepatocyte viability, however 
concentrations greater than 1mg/ml were toxic to the hepatocytes (Ho et al., 2012).  
ICG is used in ophthalmic surgery however there is increasing concern over its use, 
as toxicity to retinal glial, ganglion and pigmented epithelial cells in vitro is reported 
at 0.25mg/ml for 15 minutes (Balaiya et al., 2011; Kawahara et al., 2007). Therefore 
there is evidence that ICG has the potential to be cytotoxic in vitro.  As a cell 
viability assay, MTT is reduced to formazan by NAD(P)H-dependent oxidoreductase 
enzymes in the cell cytoplasm. This occurs in metabolically active cells with a 
solubilisation step of the insoluble purple formazan granules to allow absorbance 
measurement (Berridge and Tan, 1993). This was used without the final 
solubilisation step in order that viable cells would be highlighted with the presence of 
intracytoplasmic purple granules.  This demonstrated that cells which took up ICG 
were subsequently not metabolically active and by inference were non-viable.  From 
this test it is unclear if viable cells may have been killed by subsequent toxicity from 
ICG uptake or the cells were non-viable prior to ICG addition. As chemically and 
physically damaged cells also took up ICG with the same degree of avidity, it is 
likely that dead/damaged canine hepatocytes stain with ICG.   The second step in 
ICG testing is subsequent release of intracellular ICG after washing cells and 
replacing with fresh media, which would be consistent with active transport into bile 
caniliculi.  One potential confounder is that as the dye solution is replaced with fresh 
media, diffusion would cause a loss of intracellular dye, potentially mimicking active 
excretion.  This was seen in the stained canine primary hepatocytes (data not shown).  
Aside from one study using ICG on suspensions of primary human hepatocytes, there 
is very little in the literature on using ICG in vitro in primary hepatocytes (Ho et al., 
2012). Zemel et al. (2009) noted that clusters of undifferentiated adipose-derived 
mesenchymal stem cells took up ICG, again raising concern about the purported 
specificity of the test. 
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Therefore ICG uptake does not appear to be a useful test of function in canine 
primary hepatocytes and would not then be used for assessing the success of stem 
cell differentiation into hepatocytes. 
Periodic acid-Schiff  staining stained fresh canine primary hepatocytes intensely and 
after a period in culture, staining became patchy and less distinct.  This did appear to 
be a good test of the presence of intra-cytoplasmic glycogen and would be used for 
testing the ability of hepatocyte-like cells to store glycogen.   
From culturing canine hepatocytes in LDL and Ac-LDL it was clear that canine 
hepatocytes avidly took up native LDL which was consistent with gene expression 
for the LDL receptor.  Unlike many other hepatocyte tests, LDL uptake did not seem 
to decrease during culture (data not shown) which was also consistent with gene 
expression as LDL receptor gene expression was one of the few hepatocyte function 
genes that increased during culture (Figure 3.8).  In contrast, only a few cells in 
culture endocytosed Ac-LDL.  Although the hepatic parenchyma consists mainly of 
hepatocytes it contains a wide variety of cells including macrophages and endothelial 
cells which are known to take up Ac-LDL (Arias et al., 2011; Horiuchi et al., 2003).  
It is probable that these cells would also be isolated and survive during culture and 
therefore it is suspected that these sparse Ac-LDL positive cells are macrophages, or 
endothelial cells, or both. This is consistent with the report by Babaev et al. (1989) 
who found that human primary hepatocyte cultures almost uniformly took up LDL 
with only 5% of cells in culture taking up modified LDL.  These were identified as 
macrophages or endothelial cells based on their ability to take up tagged 
formaldehyde-treated albumin and carboxylate microspheres.  
It is intriguing that Ac-LDL is used frequently as a test of hepatocyte-like cells from 
stem cell sources and testing LDL/Ac-LDL uptake of hepatocytes from a variety of 
species would help define if there are species differences in uptake.  To verify canine 
hepatocyte-like function, it is clear that LDL uptake and not Ac-LDL uptake should 
be used and this appeared to be a useful test of hepatocyte-like function.  
Chapter 3: Establishment & characterisation of primary canine hepatocyte cultures 
80 
In addition, a panel of genes optimised for real-time PCR were developed to test 
hepatocyte like cells.  These included 3 reference genes (RLP8, B2MG, HPRT), 
three for proteins  secreted by hepatocytes – albumin, α1-antitrypsin and 
transthyretin, one protein produced by hepatoblasts (αfoetal protein), two structural 
proteins – K7 found in hepatic progenitors and K18 found in mature hepatocytes, 
glycogen synthase an enzyme causing hepatic glycogen deposition, and LDL-
receptor, encoding for the LDL-specific receptor.  Primers for 6 genes encoding for 
CYP enzymes, 1A2, 2B11, 2C18,  2D15, 3A12 and 3A26 were also validated.  Of 
these, 1A2, 2B11, 2D15, 3A12 and 3A26 are known canine specific enzymes.  In 
particular CYP3A12 and CYP3A26 are orthologues of the human enzyme CYP3A4 
which is responsible for biotransformation of over 50% of pharmaceuticals (Fraczek 
et al., 2013). 
Consistent with the literature in many species, canine primary hepatocytes rapidly 
de-differentiated in culture with a rapid reduction in expression of many genes over 
time (Beigel et al., 2008; Fraczek et al., 2013; Rodriguez-Antona et al., 2002; 
Ubeaud et al., 2001).   Of most concern is the rapid reduction in CYP expression as 
continued expression and activity is crucial for toxicological studies.  
Culturing canine primary hepatocytes for 72 hours with rifampicin and phenobarbital 
caused significant up-regulation of CYP3A12, CYP2B11 and CYP2D15 genes with 
both drugs. In the literature, Makino et al. (2009) noted that phenobarbital increased 
CYP2B11 and CYP3A12 gene expression significantly, CYP3A26 was non-
significantly increased whilst CYP1A2 was significantly down-regulated. Examining 
protein expression, CYP1A2 was down regulated, and CYP2B11 and CYP3A12 
increased, consistent with gene expression (CYP3A26 was not examined).  In a study 
by Graham et al. (2006), both drugs were noted to up-regulate CYP3A12 and 
CYP3A26 with only phenobarbital up-regulating CYP2B11. It was stated that this 
lack of CYP2B11 induction by rifampicin was a previously overlooked species 
difference. Phenobarbital but not rifampicin was noted to increase CYP2B11 activity 
and both compounds increased CYP3A12 activity (Graham et al., 2002). The notable 
differences in the present study are that CYP1A2 was not decreased with 
phenobarbital and that CYP2B11 was significantly up-regulated with rifampicin in 
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contrast to the findings of Makino et al. (2009) and Graham et al.(2002).  
Additionally, CYP3A26 was not significantly increased with phenobarbital, 
consistent with Makino et al., (2009) but contrary to Graham et al.(2002).  The 
previous studies used  Beagle dogs whereas the present study utilised hepatocytes 
from a Staffordshire Bull-Terrier; therefore it is possible that there may be breed 
differences to induction of  CYP gene expression which could be further investigated. 
 
Keratin 7 and 18 gene expression increased after plating and remained elevated 
during the whole period. These are cytoskeletal proteins and an increase in structural 
genes has been noted in other studies (Beigel et al., 2008; Fraczek et al., 2013). 
Suggested explanations are de-differentiation, an increase in proliferating fibroblasts 
in culture or, most plausibly, hepatocytes reacting to cellular stress and sudden loss 
of surrounding architecture synthesising more cytoskeletal filaments. 
Of the three proteins examined, both albumin and transthyretin gene expression 
reduced dramatically over time whilst α1 acid-glycoprotein increased in the first 24 
hours then reduced to similar expression levels as primary hepatocytes. This was 
consistent in all three experiments. This has been noted in other species and one 
hypothesis, other than straightforward de-differentiation reducing gene expression, is 
that hepatocytes are demonstrating an acute-phase response as a result of the 
dissociation process, with negative acute phase proteins such as albumin and 
transthyretin decreasing, whist positive acute phase proteins such as α2-
macroglobulin and  α1 acid-glycoprotein increase (Beigel et al., 2008). 
 
The Promega Pro-Glo CYP34A Luciferase-PFBE kit provided luminescent readings 
which reduced over time (Figure 3.12), consistent with the reduction in CYP gene 
expression. No significant effect of culture with rifampicin or phenobarbital was 
noted.  The substrate is selectively metabolised by CYP3A enzymes, in the rat 
specifically by CYP3A1 and CYP3A2 and in human CYP3A4 with some CYP3A5 
and CYP3A7 activity (Garcia et al., 2008; Promega Technical Manual P450-Glo 
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Assays, 2013). In the dog, the orthologues to CYP3A4 would be CYP3A12 and 
CYP3A26. From the CYP gene induction experiment, CYP3A12 but not CYP3A26 is 
significantly induced by both rifampicin and phenobarbital (Figure 3.10). Therefore 
if the substrate is metabolised specifically by CYP3A26 in the dog this may account 
for the lack of significant difference in this assay between basal and CYP induced 
hepatocytes.  One of the fundamental reasons for this project’s production of in vitro 
canine hepatocytes is the problem of species differences in xenobiotic metabolism 
and this may be a case in point. It is possible that Luciferin-PFBE may be 
metabolised by another member of the CYP family in the dog.  Therefore the assay 
appears useful in measuring basal CYP activity but not the ability to induce CYP 
activity with phenobarbital or rifampicin.  
The albumin ELISA test was optimised and was specific for canine albumin.   A 
1:100 dilution of media which, coming from primary hepatocytes in the first 24 
hours of culture, would be reasonably be expected to contain the highest 
concentrations of albumin was selected as the dilution to be used for subsequent 
experiments as it was mid-way between the standard range and would allow a 
sufficiently dynamic range to be measured.  There was no cross-reactivity with 
bovine serum albumin in the culture media and consistent results were achieved. 
Albumin production in primary hepatocytes over time appeared consistent with the 
reduction in gene expression i.e. it fell dramatically, although from Figure 3.18 it 
appears that albumin production increased after 24 hours in both the standard culture 
and Matrigel overlain cells. Although this is possible, it is more likely that these are 
artefacts especially as in Figure 3.13 albumin production of D17513 decreased 
dramatically from day 1 onwards and from Figure 3.17, albumin production in the 
first 24 hours appears to provide the bulk of the total 72 hour production.  In respect 
of the D41013 experiment where cell numbers were directly counted, a far higher 
cell number was counted for the day 1 wells (average 3.1 x10
5
 on collagen and 3.6 
x10
5 




 respectively thereafter), which 
likely included non-viable and non-hepatocyte cells and therefore would have 
reduced the final value. As the media was changed daily, these cells would have been 
removed by day 2 and indeed cell numbers were approximately half day 1 counts for 
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the remaining days.    Therefore comparing albumin production between days with 
these methods is problematic and using total albumin concentration is likely to be 
more accurate providing plating density remains similar. However comparing 
different culture substrates effect on albumin production on the same day would be 
less likely to suffer from these problems and more likely to have differences in cell 
density therefore normalising to cell number by one of these methods would be more 
accurate.   
From the Matrigel overlay experiments, the hepatocytes morphologically appeared 
less flattened with more distinct borders compared to controls, also from the MTT 
assay, cell number was higher. Despite this, no consistent significant differences 
were seen in gene expression, CYP induction or albumin production.  In fact, basal 
CYP activity as measured by the luciferase assay was statistically significantly lower 
in the Matrigel overlain cells compared to the standard collagen cells.  This is in 
contrast to what has been reported in human and rat primary hepatocytes where 
Matrigel overlay allowed higher gene expression, enzyme basal activity and 
inducibility (Gross-Steinmeyer et al., 2005; Kocarek et al., 1993).  Repeating these 
culture conditions with other canine hepatocytes of various breeds would ensure this 
was a consistent finding.  At present, there appears to be no significant advantage to 
Matrigel overlay in primary hepatocyte or for hepatocyte-like cell culture.  LeCluyse 
et al. (2000) found that type of overlay did not appear to be significant, however 
restoration of cell shape and cell to cell contact may be most important, therefore 
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In summary this work has achieved:  
 Reliable methods of producing viable canine primary hepatocytes to use as a 
gold standard when assessing stem cell-derived hepatocyte-like cells. 
 A panel of primers optimised for real-time PCR.  These included 6 CYP 
genes, a crucial component in cells for toxicological testing.   
 Induction of CYP gene expression using phenobarbital and rifampicin  
 Luciferin-PFBE produced reliable results on canine hepatocytes to assess 
CYP activity however induction was not demonstrated 
 Optimisation of a canine-specific albumin ELISA for culture media 
 Clarification that native LDL and not Ac-LDL should be used for canine 
primary hepatocytes 
 Indocyanine green is not a useful test for canine primary hepatocytes, staining 
non-viable cells. 
 Matrigel overlay appears to offer no significant advantage to standard 
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Chapter 4: Isolation and culture of hepatic 
progenitor cells  
 
4.1 Abstract 
The liver contains hepatic progenitor cells (HPC) that have the potential to 
differentiate into functional hepatocytes.  If these can be isolated and expanded in 
vitro, they could provide a limitless supply of functional hepatocytes.  
In this chapter, the location and phenotype of hepatic progenitor cells (HPC) is 
discussed followed by methods of isolation that have been described in various 
species, including the dog.  Density centrifugation using Percoll and Ficoll to isolate 
the HPC compartment from normal canine liver was performed as well as immuno-
selection selection for CD133 positive cells using magnetic assisted cell sorting 
(MACS).  The Percoll method isolated very few cells, which were of a morphology 
consistent with HPC; however these failed to expand in culture.  Ficoll isolation 
yielded a much larger cell population of mixed morphology, appearing to be 
composed mainly of fibroblasts and macrophages. 
CD133 selection yielded a population apparently lower purity which was improved 
subsequently using dissociative enzymes.  Colonies of cells morphologically 
consistent with hepatic stem cells and hepatoblasts expanded in culture. Mechanical 
passaging appeared superior to using dissociative enzymes and laminin-coated 
tissue-culture plastic supported colony attachment. 
Further expansion of these cell types could not be achieved however CD133 
selection appears a viable method of HPC selection in the dog and would allow 
further characterisation and optimisation of culture techniques. 
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4.2 Introduction 
As hepatic progenitor cells have the ability to differentiate into hepatocytes when the 
ability of mature hepatocytes to contribute has been overwhelmed, there has been 
interest in isolating and expanding these cells in vitro.  This source could then be 
used as a source of hepatocytes.  As discussed in the introduction, these cells are 
located in the Canals of Hering, the junction between hepatocytes and 
cholangiocytes. It is stated that there are two main types of hepatic progenitor cell; 
the true hepatic stem cell (HpSC) and the hepatoblast (HB), although this point is 
still debated as to whether these are in fact the same cell type (Zhang et al., 2008). 
This contention may be due to the fact that HpSC differentiate to HBs and therefore 
the two cell populations are not distinct entities.  HpSC also have the ability to 
produce biliary progenitor cells whereas HBs are committed to the hepatocyte 
lineage. Oval cells in rodents proliferate in response to hepatic injury and are 
bipotential progenitor cells, it is thought that these may be derived from HpSC and 
are variably described as being either in very low numbers or absent in normal livers 
(Conigliaro et al., 2010; Dolle et al., 2010). 
 
4.2.1 Phenotype of HPCs 
 
There is debate as to the phenotype of these cells which is made more complex by 
apparent species differences and the fact that as these cells differentiate, morphology 
and phenotype, including  marker profiles, change (Darwiche and Petersen, 2010).  
Furthermore, the act of processing tissue with  dissociative enzymes to access and 
isolate the cellular compartment of interest, in this case hepatic progenitor cells, has 
been shown to potentially cause loss of cell membrane cluster of differentiation (CD) 
expression (Panchision et al., 2007). Differences between HpSC and HB have been 
defined upon marker expression e.g. HpSC do not express αfoetal protein whereas 
HB do.  Figure 4.1 highlights markers of hepatic progenitor cells in the human, rat 
and mouse. Marker profile varies between species and known markers are often 
expressed on many other cells.  The fact that the liver is a heterogeneous organ 
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composed of many cell types makes this especially problematic when using markers 
for cell isolation.  Specific markers tend to be intracellular and therefore prevent their 
use for isolation of viable cells for culture (Conigliaro et al., 2010).   
 
Figure 4.1 Markers of liver progenitor cells (LPC) or oval cells in human,  mouse 
and rat. 
Figure from Conigliaro et al. (2010).   
 
4.2.2 Methods of hepatic progenitor cell isolation 
There are three main methods which have been utilised, to isolate the hepatic 
progenitor cell compartment described in turn in the next three sections.  All three 
begin with the standard collagenase perfusion digestion of either the whole liver in 
situ in rodents or a wedge perfusion in larger animals.  Once single cell dissociation 
has been performed, hepatocytes are removed by low speed centrifugation to leave 
the non-parenchymal cell compartment which also contains the hepatic progenitor 
cells (Dolle et al., 2010).  It is likely that many HPCs are aggregated along with 
mature hepatocytes at this stage due to cell-cell adhesion, which reduces the 
available cells. At this point, there are three main methods which have been utilized; 
4.2.2.1 Isopycnic or density gradient centrifugation 
This consists of layering the non-parenchymal cell suspension over Percoll, 
Optiprep, Nycodenz or Ficoll, followed by centrifugation and removal of the fraction 
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of interest containing the HPCs.  This selects for cells based on density. The cells are 
then washed before being cultured.  
 
4.2.2.2 Immunoselection 
Magnetic assisted cell sorting (MACS) and fluorescence-activated cell sorting 
(FACS) have both been used to enrich populations based on positive and negative 
cell surface markers.  Markers which have been employed include: c-Kit, CD45, 
TER119, c-Met, EpCAM, Sca-1, CD133 (Prominin-1) (Dolle et al., 2010).  As stated 
earlier, markers are not specific and, as the liver is a heterogeneous organ with many 
cell types, pure populations are not achieved.  Wauthier et al. (2008) stated that 
human hepatic progenitor cells are highly susceptible to shear-stress during FACS 
and also buffer composition such that few human progenitor cells are viable for 
culture after the FACS process.  As a result, this group has used MACS exclusively 
since to isolate HPCs.  Although MACS has the potential for much higher viability 
of the resultant cells, the purity is much lower (Wauthier et al., 2008). 
 
4.2.2.3 Antigen selection for MACS sorting 
Epithelial cell adhesion molecule (EpCAM),  which is a transmembrane glycoprotein 
responsible for cell to cell adhesion in epithelial cells has been used to for MACS 
selection for both human and rodent HpSC and HB (Schmelzer and Reid, 2008; 
Schmelzer et al., 2007).   These HPC co-expressed CD133 and keratin 19. Keratin 19 
is an intracellular cytoskeletal protein and thus not available for viable cell selection.   
CD133 is another transmembrane protein, the function of which is unclear but has 
been shown to be expressed on haematopoietic and endothelial progenitor cells, as 
well as a marker for a putative cancer stem cell population (Irollo and Pirozzi, 2013).   
CD133 has been used to select for hepatic progenitor cells in rodents (Rountree et al., 
2011; Suzuki et al., 2008).   Canine hepatic progenitor cells have been shown to have 
increased gene expression of CD133 compared to primary hepatocytes whereas the 
status of EpCAM expression on canine HPCs is unknown. (Arends et al., 2009a).  
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4.2.2.4 Side population isolation 
The ability of cells to efflux the dye Hoechst33343 due to expression of the ABCG2 
transporter, coded by the multidrug resistance gene (MDR1), has been used to isolate 
a fraction of cells known as the “side population” (SP).  In the murine and human 
liver, the SP has been shown to have HPC characteristics. Some studies have selected 
against CD45 which is found on many cells of haematopoietic origin however, both 
CD45 positive and negative fractions can demonstrate hepatocyte differentiation in 
vitro (Hussain et al., 2005; Shimano et al., 2003; Terrace et al., 2009).  Many other 
cells in the liver other than HPC also express this transporter protein including 
haematopoietic stem cells (Forbes and Alison, 2006) 
 
It is of note that the vast majority of studies isolating the HPC compartment in 
rodents do so after experimental induction of a ductular reaction e.g. using carbon 
tetrachloride or galactosamine (Shupe et al., 2009).  This greatly increased the HPC 
percentage in the liver and as a result the number of cells isolated.  In human tissue, a 
period of ischaemia (up to 168 hours) has been shown to select for HPC by their 
apparent resistance to cold ischemia compared to the other resident cell types (Aupet 
et al., 2013; Stachelscheid et al., 2009).   The number or percentage of HPC isolated 
depends therefore not only on the starting tissue but also the method of selection.  As 
an approximate percentage, human hepatic stem cells are stated to make up 
approximately 0.5-2.5% of the parenchyma (Schmelzer et al., 2007). 
 
4.2.3 Culture of hepatic progenitor cells 
Many different substrates and culture media have been described for expansion of 
HPC.  For culture substrates, collagen type I is most commonly documented, 
although hyaluronic acid has been used (Fiegel et al., 2006; Gerbal-Chaloin et al., 
2010; Sasaki et al., 2008).  One group which has advanced the understanding of 
hepatic progenitor cells and the subdivision between HpSC and HB have published a 
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detailed methods paper  describing the options for culture, expansion and 
differentiation of human HpSC and HBs (Wauthier et al., 2008).    There is evidence 
that in vivo, HpSC are coordinated with angioblasts and hepatic stellate cell 
precursors and these cells interact, stimulating co-differentiation.  This is termed an 
epithelial-mesenchymal relationship. Culturing HpSCs with mesenchymal co-
cultures, mimicking co-culture with conditioned media or, if paracrine signals are 
known, in defined media is likely to be most successful.  Media has also been 
described by the methods paper, with Kubota’s media allowing expansion of human 
and rodent HpSC (Kubota and Reid, 2000). 
 
4.2.4 Morphology of HPC in vitro 
In vitro HpSC are reported be 7-10µm and form colonies which are densely packed 
whilst HB cells are approximately 10-20µm and form cord-like morphology with 
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Figure 4.2 Human hepatic stem cells (HpSC) and hepatoblasts (HBs) in vitro.  
A-E demonstrate HpSC colony at days 2, 4,8,10 and 14.  F demonstrates the 
morphological difference between hepatic stem cells and hepatoblasts. White bar 
represents 20µm.  Images from Schmelzer et al. (2007). 
 
4.2.5 Canine hepatic progenitor cells 
There have been two reports investigating isolation of the hepatic progenitor cell 
compartment of canine liver.  Arends et al. (2009b) utilized Hoechst 33343 after 
density centrifugation to isolate the side population from four normal canine livers. 
The SP comprised 2.8% + 1.2% of the total non-parenchymal fraction. Thirty percent  
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of these were CD45 negative by FACS. The cells were reported to be small (8-
10µm) and keratin7 positive on immune-staining. There was significantly higher 
ABCG2 gene expression between the CD45-ve SP and main population (MP) but it 
is not stated if the SP had significantly higher ABCG2 compared to the MP.  
Transporter inhibitors verapamil and reserpine also did not completely remove the 
SP and therefore lack of Hoechst 33343 fluorescence may not be specific for the 
presence of the ABCG2 transporter.  Extremely low cell numbers were isolated 
(approximately 1 x10
4
 cells in the SP) which prevented culture. 
Culture of canine hepatic progenitor cells has also been described (Arends et al., 
2009a). Prior to euthanasia the dogs received 10,000IU of heparin. After cell 
dissociation, the cell suspension was centrifuged in 55% Percoll to remove large 
hepatocytes (50g for 10 minutes) and the resultant cellular supernatant was pelleted 
and re-suspended in a proprietary hepatocyte culture media HCM (Hepatozyme, 
Invitrogen) or William’s media E and supplements (WME).  Cells cultured in WME 
were stated to be fibroblastic and died after 14 days.  Cells in HCM exhibited mature 
hepatocyte morphology with binucleate cells. After 2 weeks smaller cell colonies 
appeared which expanded and then appeared to differentiate towards hepatocyte-like 





Chapter 4: Isolation and culture of hepatic progenitor cells 
93 
 
Figure 4.3 Figure from Arends et al. (2009a) demonstrating morphology of 
cultured cells. 
Initial mature hepatocyte morphology with few smaller cells after 2 weeks arrowed 
(A), gradual expansion of small cells (B-D) and eventual increase in cytoplasm to 
nuclear ratio with some binucleate cells arrowed (F). Images x200. 
 
Cells were stated not to passage and expand readily and appeared to require 
surrounding hepatocytes or Matrigel. The smaller colonies were positive for keratin 7 
by immunostaining.  At the 2 week point, gene expression demonstrated that the 
colonies expressed significantly more Cyp1A2, albumin, keratin 7, 18, 19, αfoetal 
protein and CD133 than surrounding hepatocytes. 
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4.3 Aims 
The aims of this chapter were to assess if hepatic progenitor cells could be isolated 
and expanded from euthanased dogs without prior treatment with heparin. 
Additionally, methods to improve the selection of the hepatic progenitor 
compartment compared to the previous canine study were examined, specifically, 
density centrifugation with Percoll and Ficoll as described in human and rodent HPC 
isolations as well as MACS for CD133
+
  cells.    
The effect of Kubota’s culture media, which has been described as supporting the 
expansion of rodent and human HpSC was examined on the ability to expand and 
passage canine HPC.  Passaging using standard 0.25% trypsin, Accutase and 
mechanical dissociation was assessed.   Finally, laminin and collagen Type I coated 
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4.4 Methods 
4.4.1 Isolation of non-parenchymal cell fraction 
Canine hepatic tissue was processed as described in Chapter 3 to isolate a suspension 
of dissociated cells. The suspension was centrifuged for 5 minutes at 30g to pellet 
mature hepatocytes.  The supernatant was transferred to a fresh Falcon tube and 
centrifugation repeated to pellet any remaining mature hepatocytes.  The supernatant 
containing the non-parenchymal cell (NPC) fraction was then centrifuged at 400g for 
30 minutes to pellet these cells.  The cell pellet was re-suspended in HCM with 10% 
FCS (Lonza). 
 
4.4.2 Density centrifugation 
4.4.2.1 Percoll 
Nine parts Percoll (GE Healthcare) was diluted with 1part 1.5M NaCl to give a stock 
solution.  This was then further diluted to 20% and 50% with 0.15M NaCl.  A 
volume of 10mls of 20% was layered over 20mls of 50% in a 50ml Falcon tube.  The 
NPC suspension was layered over this and the tubes centrifuged for 15 minutes at 
500g.  The cell layer between the two Percoll concentrations was removed, 
resuspended and washed in HCM twice before being re-suspended in HCM and 
transferred to collagen-coated 6 well plates.  
4.4.2.2 Ficoll-Paque 
The NPC fraction was layered onto Ficoll-Paque (GE Healthcare) and centrifuged for 
15 minutes at 500g.  The cell layer to the top of the interface was removed, washed 
and plated as described in the Percoll section. 
 
4.4.3 Magnetic assisted cell sorting for CD133 
The system supplied by Miltenyi Biotech was used for MACS sorting.  NPC were re-
suspended in PBS containing 0.5% bovine serum albumin. Positive selection 
CD133/1 columns (Miltenyi Biotech) were used according to the manufacturer’s 
instructions.  Briefly, the column was placed in the magnetic holder and the cell 
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suspension passed through the column.  Negative cells passed through the column 
and were collected.  Positive cells were bound by the column until it was removed 
from the magnetic field, the column flushed with buffer and the resultant cells 
collected.  
4.4.4 PCR analysis of fold increase in gene expression 
Relative gene expression of CD133 and keratin 7 was calculated using B2MG and 
RLP8 as reference genes using MXPro QPCR software.    
 
4.4.5 Passaging of HPC colonies 
4.4.5.1 Enzymatic  
Cloning cylinders (ScienceLab, USA) were placed around selected colonies and 
0.25% trypsin EDTA (Invitrogen) or Accutase (Life Technologies) was added.  
Plates were then incubated at 37
o
C until dissociation was evident using microscopy.   
4.4.5.2 Mechanical passaging 
A 200µl pipette tip was used to gently loosen the edges of a colony which was then 
aspirated into a 1000 µl pipette for passaging. 
4.4.5.3 Kubota’s medium preparation 
Kubota’s medium was prepared as described by Kubota and Reid (2000) and the 






Chapter 4: Isolation and culture of hepatic progenitor cells 
97 
4.5 Results 
4.5.1 Percoll isolated cells are few in number and fail to 
expand 
Six HPC isolations were performed using Percoll (Appendix 4 lists HPC isolations 
performed).  The initial four appeared to have very few viable cells and a large 
amount of cellular debris after washing.  This made cell counting impossible.  After 
removing debris at 48 hours and culture for a further 4 days, few cells adhered to the 
collagen coated-plate and these appeared to be mixed morphology (Figure 4.4 A and 
B). In subsequent experiments, likely due to improved perfusion/digestion and cell 
handling techniques, there was less debris present and small clusters of adherent cells 
were visible (Figure 4.4C and D). These were of morphology consistent with HpSC   
i.e. compact rounded cells; however, these cells did not expand and over the 
subsequent seven days, gradually became detached or died during culture. 
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Figure 4.4 Morphology of cells after initial Percoll isolation 
Representative images from first four experiments (D19811a), a large amount of 
debris present with very sparse cells of mixed morphology (A, B).  Representative 
images from experiments 5-6, much less debris present and few colonies of compact 
round cells present (C, D). White scale bar represents 50µm.  
 
4.5.2 Ficoll centrifugation isolates a mixed cell population 
Three experiments were performed using Ficoll to isolate the HPC compartment 
using the NPC fraction from animals D18112a, D18112b and D8212.  In the first 
two, no viable cells were present after 48 hours’ culture.  In the last experiment, an 
extremely heterogeneous cell population was cultured with cells resembling 
macrophages and fibroblasts present in the largest quantities after 6 days’ culture 
(Figure 4.5). Few cells consistent with HpSC or HB morphology were evident and 
the culture was discarded after 14 days’ due to fibroblast overgrowth.  
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Figure 4.5 Cell morphology after Ficoll isolation and 6 days’ culture. 
Two representative fields shown (A and B). White bar represents 50µm. 
 
4.5.3 CD133 selection enriches for hepatic progenitor cells 
As expression of EpCAM on canine HPC was unknown, EpCAM
+
 HPC in other 
species co-express CD133, and Arends et al. (2009a) demonstrated CD133 
expression by canine HPC, CD133 was used for canine HPC isolation.   
 
4.5.3.1 Cell numbers 
The NPC fraction from D22212 was used for this experiment: 1.5 x10
8
 cells were 
sorted and a total of 1.3 x10
8
 cells were retrieved; 8.5 x10
7
 were in the negative 
fraction with 5.2 x10
7
 in the positive fraction.  This gave a positive percentage of 
38%.   
 
4.5.3.2 Morphology 
Twenty-four hours’ after attachment, the morphology of the two cells types appeared 
similar, with the majority of cells having the morphology of small hepatocytes with a 
large cytoplasm to nuclear ratio and, polygonal structure with clear demarcation 
between cells (Figure 4.6).   
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Figure 4.6 Morphology of CD133 positive and negative cells 24 hours after sorting 
CD133
+
 fraction (A, B) and negative fraction (C, D). Both contain small hepatocyte-
like cells with no obvious difference between the two cultures.  White scale bar 
represents 100µm.  
 
These cultures were continued with a media change every 2-3 days.  By day 7, 
mainly, but not exclusively in the CD133 positive cultures, small colonies of HB 
type cells appeared which expanded slowly, appearing to force out the resident cells.  
In the CD133 negative cultures, many more fibroblastic appearing cells were present 
which expanded and overgrew the plate.  By 14 these differences were dramatic 
(Figure 4.7).  Clusters of small round loosely adherent cells which appeared to attach 
to the underlying monolayer were also present in the CD133 positive population.  
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Figure 4.7 Morphology of CD133 positive and negative cultures after 14 days. 
CD133
+
 cells (A) demonstrating expansion of hepatoblast like cells (*).  Loosely 
adherent round cells marked by white arrows. CD133
-
 cells containing a majority of 
fibroblast-like cells.  White scale bar represents 50µm. 
 
4.5.3.3 Keratin 7 gene expression is higher in CD 133 positive fraction. 
RNA was extracted at the time of the initial sort and after culture for 14 days. After 
the initial sort, both CD133 and keratin 7 gene expression was higher in the CD133
+
 
fraction (Figure 4.8).   After 14 days’ culture, a differential between positive and 
negatively sorted cells remained but was less marked (Figure 4.9).  When the 
CD133
+
 cells at initial sort and adherent cells were compared, culture had caused a 




Chapter 4: Isolation and culture of hepatic progenitor cells 
102 
 
Figure 4.8 Fold increase of CD133 positive cells compared to CD133 negative cells 
of CD133 and Keratin 7.   




Figure 4.9 Fold increase of CD133 positive cells compared to CD133 negative cells 
of CD133 and Keratin 7 after 14 days in culture.   
CD133 negative cells are used as the calibrator. Error bars represent standard error of 
the mean. 




Figure 4.10 Comparison of CD133 and keratin 7 expression of CD133 positive 
cells before and after culture. 
Initial sort cells are used as the calibrator. Error bars represent standard error of the 
mean. 
 
4.5.4 Mechanical passaging is more effective than 
enzymatic 
Colonies from the CD133 positive cells were passaged using 0.25% trypsin, 
Accutase® and mechanical dissociation onto fresh 0.01% collagen-coated and 
100µg/ml laminin-coated wells.  Between 3-6 colonies were passaged by each 
method to each matrix type. All enzymatic methods failed to yield viable cells after 
transfer onto collagen and laminin plates.  Mechanical passaging achieved viable 
colonies on both collagen and laminin.  These cells formed colonies with the smaller 
round loosely adherent cells in the centre and larger HB-like cells at the periphery 
(Figure 4.11).  This appeared to be most organized in the laminin wells where the 
HB-like cells formed corded structures.   The structure of the colonies and 
morphology of both cell types appeared very similar to that described by Schmelzer 
et al. (2007) for human HpSC and HBs (Figure 4.12).  The canine colonies failed to 
continue expanding in both substrates and detached from the collagen-coated wells.  
The largest colony on laminin-coated wells was 900µm.  
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Figure 4.11 Colonies passaged onto collagen and laminin 
Colonies on collagen (A, B) contained small round cells in the centre with larger 
cells present in a haphazard pattern at the periphery. Laminin wells also contained 
dense colonies of round loosely adherent cells with larger cells forming corded 
structures at the periphery.  White scale bar represents 100µm.  
 
 
Figure 4.12 From Schmelzer et al. (2007) demonstrating human hepatic stem cells 
(HpSC) and hepatoblasts (HB) 
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4.5.5 Treatment with Accutase® reduces CD133 positive 
fraction 
As only a very small percentage (0.5-2.5%) of the NPC fraction would be expected 
to be positive for CD133,  and both positive and negative cell morphology appeared 
similar initially, it was suspected that cell-cell adhesions and clumping was falsely 
elevating the CD133 positive number (Schmelzer et al., 2007).   This has been 
reported to be a problem with MACS of the NPC fraction and the addition of an 
Accutase step has been recommended to inhibit re-aggregation (Wauthier et al., 
2008).   Therefore the NPC fraction was incubated in Accutase for 5 minutes prior to 
sorting and starting number was reduced 10-fold. 
Cells from D13912 were used for this experiment.  Due to the small cell numbers 
retrieved, all cells were plated.   After 24 hours in HCM, media was changed to 
Kubota’s media to select for HpSCs.   
4.5.5.1 Cell numbers  
Of the 1.5 x10
7
 cells sorted, a total of 1.1 x10
7
 cells were retrieved. 101 x10
5
 were in 
the negative fraction with 9 x10
5
 in the positive fraction.  This gave a positive 
percentage of 8.9%.   
 
4.5.5.2 Cell morphology 
There was a mix of morphologies in both fractions after 24 hours culture (Figure 
4.13).  Subjectively the positive fraction contained more small hepatocyte-like cells.   
Forty-eight hours’ in Kubota’s medium appeared to cause massive cell loss with only 
large macrophage-like cells remaining (Figure 4.14 A, B).   Canine primary 
hepatocytes were also cultured in Kubota’s media for 48 hours and became poorly 
adherent and changed morphology (Figure 4.14 C, D).  After 72 hours, no viable 
cells were present in the CD133 positive wells.  
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Figure 4.13 CD133 sorted cells after 24 hours culture 
CD133 positive fraction (A) contained more small hepatocyte-like cells compared to 
the negative fractions (B) were morphology was more heterogeneous.  Both fractions 
still contained a mix of cell morphologies. White scale bar represents 50µm.  
 
 
Figure 4.14  Cell culture of CD133 positive cells and primary hepatocytes after 48 
hours in Kubota’s media. 
CD133 positive wells (A, B) contained only very few large cells of macrophage 
morphology with loss of small hepatocyte-like cells.  Canine primary hepatocytes 
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4.6 Discussion 
4.6.1 Isodensity centrifugation isolates low cell numbers 
which do not expand 
Using Percoll, only a very small number of viable cells were isolated and large 
amounts of debris was also present in the fraction of interest.  The cells isolated 
appeared small, round cells which are morphologically consistent with HpSC.  These 
cells failed to expand in culture and were gradually lost.  The Percoll experiments 
were performed during the period where hepatic perfusion was being optimized and 
it is likely that the low cell yield and large amounts of debris are, in part, reflected by 
this.   Ficoll centrifugation appeared to isolate a much larger cell population but one 
that appeared heterogeneous with many fibroblastic and macrophage-like cells 
present.  As Ficoll is primarily aimed at isolation of haemopoietic mononuclear cells 
and mesenchymal stem cells this is perhaps unsurprising.  Characterisation of the 
resultant cells by immunocytochemistry for mesenchymal and macrophage markers 
would have further explored this likelihood.   Insufficient cells were isolated for 
FACS analysis.  
Schmelzer et al. (2007) stated that MACS sorting obtained the most satisfactory 
results and therefore this technique was pursued as an alternative.   It is possible that 
with refined tissue processing and cell handling, the Percoll technique may have 
yielded reasonable quantities of viable HPC.  The ability to vary Percoll density 
would also allow specific cell densities to be separated and may have further selected 
specifically for canine HPC.  
 
4.6.2 MACS sorting for CD133 positive NPC selects for 
hepatic progenitor cells 
The initial sort gave a much higher percentage of apparent CD133 positive cells than 
expected (38% versus 0.5-2.5% respectively).  After 24 hours culture, both positive 
and negative fractions appeared morphologically similar with mainly small 
hepatocytes present.  The most likely explanation for this is the continued presence 
of large numbers of hepatocytes in the “non-parenchymal cell fraction”.  Wauthier et 
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al. (2008) noted that cell aggregation was a problem during MACS sorting resulting 
in an impure population of cells due to insufficient dissociation during tissue 
processing resulting in antigen negative cells remaining bound to antigen positive 
cells as well as re-aggregation during the isolation process.  Despite this problem, 
CD133 positive cells demonstrated increased CD133 gene expression and also 
keratin 7 compared to CD133 negative cells, suggesting that MACS sorting was 
successful in enriching for CD133 positive cells.  Although keratin 7 is expressed in 
HPC it is also expressed in cholangiocytes and is therefore not specific (Arends et 
al., 2009a; Wauthier et al., 2008).  Treatment with cell dissociation agent has been 
recommended to reduce cell aggregation during sorting and this was performed 
during the next experiment (Wauthier et al., 2008).  Repeated exposure of the cells to 
enzymes has the disadvantage of reducing viability of these fragile cells (Wauthier et 
al., 2008). Use of Accutase reduced the percentage of CD133 positive cells to nearer 
the expected percentage.  Another option which has been described is to use serial 
MACS columns to further purify the cells expressing only the antigen of interest 
(Beier et al., 2007).  This would have the disadvantage of subjecting the cells to 
longer periods in sub-optimal conditions, likely further reducing their viability. 
 
4.6.3 Canine HPC can be expanded in vitro as primary 
culture 
Morphologically, dense colonies of cells consistent with the description of human 
hepatoblasts in vitro appeared in culture.  These appeared to arise at the edges of 
clusters of small bright round cells that appeared to be situated on top of the mono-
layer.  These cells may be consistent with hepatic stem cells as described by 
Wauthier et al. (2008).  Although present in higher numbers, these two cell types 
were not exclusive to the CD133 positive population, possibly reflecting the impurity 
of the two populations.  These cells, and particularly the HB expanded during 
culture.  Examination of CD133 and keratin 7 gene expressions after 14 days culture 
revealed down-regulation of both.  Human HpSC and HB are both reported to 
express CD133 but this is lost during differentiation towards hepatocytes (Wauthier 
et al., 2008).  Arends et al. (2009a) noted that keratin 7 expression of canine HPC 
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was lost during culture.  Therefore it is likely that cell differentiation was occurring 
during culture.   
It appeared that Kubota’s medium did not support the expansion of canine HPC 
although this would have to be confirmed as it is possible that other factors, for 
example, individual donor variation or the additional treatment with Accutase™ may 
also have contributed to reduced viability. The increased purity of CD133 positive 
cells i.e. reduce supporting cells, may also have affected viability of the HPC. 
 
4.6.4 Mechanical picking allows passaging of viable HPC 
colonies 
Enzymatic dissociation methods were unsuccessful in passaging the cells, however 
mechanical colony picking allowed viable colonies to be transferred.  This is 
identical to what has been described with human HPC where mechanical picking was 
recommended (Wauthier et al., 2008). Passaging onto collagen-coated plastic 
allowed viable cells to adhere however the morphology appeared to change with 
random organization of cells and less obvious HpSC-morphology.  A similar 
phenomenon has been reported by McClelland et al. (2008) where human HpSC 
became unstable on collagen type I. Laminin-coated tissue culture plastic appeared to 
give cell morphology most similar to that described for human HpSC with 
surrounding differentiated HB.  Further expansion after culture was minimal which 
prevented further characterisation of the cells.  Human HB colonies are reported not 
to expand to any great extend compared to HpSC (Schmelzer et al., 2007).  
Additionally, the isolated cells did not survive culture in Kubota’s medium which has 
been described for the culture of human HpSC.  It has been stated that Kubota’s 
medium does not support HB growth without the presence of feeder cells (Schmelzer 
et al., 2007).  In normal adult human hepatic tissue HpSC make up the overwhelming 
majority of HPC therefore, if this was the case in canine liver, expansion of cells 
would have been expected.  It is possible that mainly canine HB were cultured either 
due to HB isolation or differentiation of HpSC to HB during the initial isolation and 
culture period.   
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It is notable that canine HPC did not expand under low seeding density and appeared 
to expand most readily in contact with many other cells of mixed morphology.  
Particularly the smaller HpSC-like cells appeared to expand into colonies admixed 
with other cell types.  The hepatic stem cell niche has been described with HpSC 
partnered with angioblasts and hepatic stellate cells, both of which are also CD133 
positive (Hristov and Weber, 2004; Kordes et al., 2007).   It is likely that in some 
respects, the low purity of MACS sorting may be beneficial in the subsequent culture 
of HPC as a mixture of supporting cell types are required for HPC expansion in vitro 
(Wauthier et al., 2008).  Despite the expansion, the cell numbers and colony sizes 
remained small. Interestingly, co-culture of HpSC with mature hepatocytes or media 
conditioned by mature hepatocytes prevents expansion on human HpSC (Wauthier et 
al., 2008).   Therefore, the mixture of cells present may represent a double-edged 
sword; angioblasts, stellate and other mesenchymal cells supporting HPCs, whilst 
mature hepatocytes inhibit their expansion.   
 
4.6.5 Methods of improving expansion 
Further work at expanding these cells to a sufficient quantity to allow 
characterisation would be directed towards more tightly control culture conditions 
and utilizing co-cultures. The culture conditions for human HpSC and HB have been 
defined by Wauthier et al. (2008) who recommend co-culture with mitomycin-treated 
foetal mesenchymal feeder cells in a laminin coated Transwell™ system for HpSC.  
As the isolated canine cells appear to expand in concert with other cells, and laminin 
matrix allowed continued survival of passaged cells, this would appear to be a useful 
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4.6.6 Could HPCs arise from de-differentiated mature 
hepatocytes? 
Finally, there are recent papers that describe highly purified mature hepatocytes in 
culture which de-differentiate to HPC with bipotential differentiation capacity (Chen 
et al., 2012a; Krause et al., 2013). This raises the possibility that HPC were not 
isolated but rather that they arose in culture from contaminating mature hepatocytes. 
This is especially a problem with heterogeneous populations as above and in the 
previously published paper describing canine hepatic progenitor cell culture (Arends 
et al., 2009a).  Again, having a more precisely defined starting population and culture 
conditions would allow this possibility to be investigated.  Performing a similar 
experiment to Chen et al. (2012a) where highly purified canine hepatocytes are 
cultured and examined for the appearance of hepatic progenitor cells would assess if 
this can occur in canine hepatocytes.  Ultimately, as the aim is to culture a source of 
hepatic progenitor cells that could be expanded and differentiated to provide 
continual supply of mature hepatocytes in vitro, the source may be less important and 
culture of primary hepatocytes would provide a vastly more simple method of HPC 













 Percoll density centrifugation produced a very small number of cells, which 
failed to expand in culture. The poor cell yield may improve with 
optimisation. 
 Ficoll density centrifugation yielded a mixed cell population morphologically 
consistent with fibroblasts and macrophages. 
 CD133 MACS produced colonies morphologically consistent with HpSC and 
HB. 
 Mechanical passaging of colonies onto laminin-coated plastic was most 
successful 
 Cells expanded in mixed cell cultures, therefore co-culture systems as 
described for human HPC should be investigated for further expansion after 
passaging.
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Chapter 5: Mesenchymal stem cell isolation, 
characterisation and tri-lineage differentiation 
5.1 Abstract 
Mesenchymal stem cells (MSC) have been used to produce many tissue types in vitro 
and also appear to have profound immune-modulatory effects both in vitro and vivo. 
This chapter discusses progress made in isolating MSC and standardising 
characterisation of MSC in fundamental research.    The standard protocols for 
osteogenic, adipogenic and chondrogenic differentiation along with known 
transcription factors and cell signalling pathways are also described.  Canine-specific 
MSC research and clinical use of MSC to date are also defined. 
This chapter describes the isolation and characterisation of both canine bone marrow-
derived MSC and canine adipose tissue-derived MSC.  Both cell types could be 
isolated and cultured with standard protocols, with a greater yield of Ad-MSC.  
Strong adherence to plastic was noted, a minimum characteristic of MSC.  Both cell 
types demonstrated identical cell surface antigen characteristics i.e. positive CD44, 
CD105 and STRO-1 expression whilst lacking haematopoietic markers CD45, 
CD11b and CD19. Ad-MSC and BM-MSC were then differentiated along the 
standard mesodermal tri-lineage (i.e. osteogenic, adipogenic and chondrogenic 
differentiation) using published protocols.  These differentiated cells were analysed 
with cytochemical staining and also gene expression using real-time PCR.  Both Ad-
MSC and BM-MSC demonstrated convincing differentiation by staining.  Gene 
expression analysis demonstrated profound up-regulation of adipocyte genes in both 
cell types after the adipogenic protocol.  After the osteogenic protocol, Ad-MSC 
demonstrated dramatic up-regulation of osteoblast markers however the BM-MSC 
despite having extremely strong staining for calcification, showed no up-regulation. 
Chondrogenic differentiation demonstrated strong up-regulation of aggrecan in both 
cell types but no SOX9 up-regulation.   
The study demonstrates reliable isolation and expansion of both Ad-MSC and BM-
MSC cells in the dog. Both MSC cell types have been robustly characterised and can 
be utilised for further studies of differentiation including hepatocyte differentiation.  




5.2.1 Mesenchymal stem cell isolation 
Mesenchymal stem cells and their properties were first described in the 1960’s by 
Friedenstein et al. (1966) when they were isolated from bone marrow.  Since then, it 
has been recognised that MSC can be isolated from almost any tissue in the body 
(Crisan et al., 2008).  There is much debate about the origin of MSC, with  one 
hypothesis that they are perivascular pericytes (Bianco et al., 2010; Crisan et al., 
2011) or, as was originally termed by Friedenstein et al. (1966), simply a subset of 
fibroblasts (Haniffa et al., 2009; Hematti, 2012).  Whichever their provenance, MSC 
have been demonstrated to have the ability to differentiate in vitro not only into 
mesodermal tissue types but also to trans-differentiate into other tissue types such as 
neurones and  hepatocytes (Jeong et al., 2013; Lee et al., 2012).   
 
5.2.2 Defining mesenchymal stem cells 
One of the challenges in MSC research is the vast array of isolation methodologies 
and lack of standardization of what should define an MSC (Bourin et al., 2013; Shen, 
2013).  The cells which are isolated from tissues (e.g. adipose tissue) by digestion 
and centrifugation are termed the stromal vascular fraction (SVF). This fraction is a 
heterogeneous population, composed of stromal and haemopoietic stem and 
progenitor cells, endothelial cells, erythrocytes, fibroblasts, lymphocytes, 
monocyte/macrophages and pericytes (Bourin et al., 2013).  Subsequent culture, 
washing and passaging selects for tissue-derived stromal cells or MSC by removing 
the majority of haemopoietic elements.  Different isolation and culturing 
methodologies will produce populations of varying heterogeneity.     
This challenge has been partially addressed by Dominici et al. (2006) who defined 
minimal criteria for human BM-MSC and Bourin et al. (2013) for human Ad-MSC. 
Table 5.1 highlights the antigen combination recommended by Dominici et al. 
(2006).  Bourin et al. (2013) stated that in addition to these markers, CD13 and 36 
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positivity and CD106 negativity would distinguish cultured Ad-MSC from BM-
MSC.  Other markers which have been utilized to define MSC are CD44 and STRO-






CD105  CD45 
CD73 CD34 
CD90  CD14 or CD11b 
 CD79α or CD19 
 HLA-DR 
 CD14 or CD11b 
Table 5.1 Minimum cell antigen markers defined by the International Society for 
Cellular Therapy to characterise bone marrow MSC.  
 
As well as these cell surface markers, the cells should readily adhere to tissue culture 
plastic and demonstrate the ability to produce osteoblastic, chondrocytic and 
adipocytic lineages (Figure 5.1).  Dominici et al. (2006) stated that staining with 
Alizarin red/ Alcian blue and Oil Red O respectively would be sufficient to show 
differentiation; however, Bourin et al. (2013) recommended the addition of 
quantitative expression of lineage specific proteins or genes. The rational for this 
being that the compounds stained are not cell-type specific e.g. lipid may be present 
in hepatocytes and myocytes as well as adipocytes. 
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Figure 5.1 Common compounds used in MSC characterisation by differentiation 
Cytochemical stains commonly used are listed in blue boxes. DMEM – Dulbecco’s 
modified Eagle’s medium, HG – high glucose, ITS – insulin/transferrin/selenium 
premix.   
 
5.2.3 Regulation of MSC differentiation 
 
Cell signalling and gene expression to direct the fate of MSC either to remain as stem 
cells or towards differentiation is being elucidated.  These studies will help inform 
optimum conditions to both expand undifferentiated MSC in vitro and allow 
directed, and optimum, differentiation.   
5.2.3.1 Osteogenesis  
Runx2 is the major controlling transcription factor in differentiation of MSC towards 
osteoblasts (Figure 5.2) (Cook and Genever, 2013).  Experiments utilising 
overexpression demonstrated that Runx2 upregulates osteocalcin and collagen 1A1, 
causing osteogenesis both in vitro and in vivo. Conversely, in knockout mice 
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maturation arrest of osteoblasts was noted.  Dexamethasone, included in MSC 
osteogenesis protocols, has been demonstrated to enhance Runx2 activity by causing 
post-translational modification of the protein (Phillips et al., 2006; Shui et al., 2003).    
5.2.3.2 Adipogenesis  
 The major regulator is PPARγ, with forced expression in fibroblasts causing 
adipogenesis (Figure 5.2) (Tontonoz et al., 1994). PPARγ also inhibits osteogenic 
differentiation. Other regulators having a less marked effect include C/EBPα, thought 
to induce via a positive feedback loop with PPARγ and SREBP1 which enhances 
PPARγ expression (Cook and Genever, 2013).     
 
Figure 5.2 Major regulators and inhibitors of MSC osteoblastic and adipocytic 
differentiation 
BMP – bone morphogenic protein, PPARɣ - Peroxisome proliferator-activated 
receptor gamma. Adapted from Cook and Genever (2013). 
 
5.2.3.3 Chondrogenesis 
The master regulator of chondrogenesis is Sox9 where again knockout models 
demonstrate absence of chondrogenesis (Akiyama et al., 2002). This gene is 
expressed during chondrogenesis until the hypertrophic chondrocyte stage (the 
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terminal stage of chondrocyte differention), when transcription ceases. Two other 
Sox genes are involved, L-Sox5 and Sox6. These are distinct from Sox9 as they lack 
transactivation domains and appear to function by recruiting other regulators (Frith 
and Genever, 2008).  Runx2, important in osteogenesis, also appears to be important 
in chondrogenic differentiation, specifically the step to produce terminally 
differentiated hypertrophic chondrocytes (Cook and Genever, 2013).  Figure 5.3 
demonstrates the major signaling pathways in chondrogenic differentiation of MSC.  
 
 
Figure 5.3 Major regulators and inhibitors of MSC chondrogenic differentiation 
Adapted from Cook and Genever (2013). 
 
Regulation of gene expression is thought to be largely controlled Wnt and the TGF- 
β superfamily pathways (Williams and Hare, 2011). Canonical Wnt maintains stem 
cell multipotency but stimulates differentiation of committed cells during 
osteogenesis (Figure 5.2). Wnt acts as an inhibitor of adipogenesis by blocking 
C/EBPα and PPARγ expression.  In chondrogenesis, Wnt causes inhibition of initial 
differentiation from MSC to chondrocyte but again stimulates late differentiation to 
hypertrophic chondrocyte (Figure 5.3) (Cook and Genever, 2013).  
As part of the TGFβ superfamily, both TGFβ and bone morphogenic protein (BMP) 
are involved in MSC differentiation.  Both bind to their specific SMAD receptors. 
These then interact with SMAD4 and together translocate to the nucleus where they 
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activate transcription.  TGFβ and BMP have different and specific effects in MSC 
differentiation.  BMP upregulates Runx2, inducing osteoblast differentiation and also 
appears to upregulate Sox9, inducing chondroblast differentiation (Semba et al., 
2000).  TGFβ inhibits the osteogenic effect of BMP by suppressing Runx2 
transcription and also stimulates chondrogenesis via cascading through p38, ERK-1, 
and JNK MAP Kinase pathways (Alliston et al., 2001) 
 
5.2.4 Canine mesenchymal stem cell fundamental research 
There has also been a rapid expansion of laboratory research on canine MSC, from 
the first publication by Kadiyala et al. (1997) describing canine BM-MSC isolation 
and osteogenesis. Trilineage differentiation of this source was then described by 
Csaki et al. (2007). Other sources of canine MSC that have been described include 
umbilical cord blood (Lim et al., 2007), adipose tissue (Black et al., 2007), foetal 
adenexa (Filioli Uranio et al., 2011), muscle and periosteum (Kisiel et al., 2012).  
With many of the early reports, characterization was minimal and differentiation 
limited.  The more recent reports have demonstrated trilineage differentiation of 
almost all of these MSC sources (Filioli Uranio et al., 2011; Kisiel et al., 2012). 
Other cell types that have been derived from canine MSC include neuronal cells 
(Chung et al., 2013; Seo et al., 2009), and cells with some hepatocyte gene 
expression (Choi et al., 2013). 
The recommendations of cell surface antigen selection by ISCT have been adopted 
by some researchers in the canine MSC field although it is recognized that these 
markers may not apply across species (Dominici et al., 2006). There are the 
additional challenges in the field of canine MSC where a lack of antibodies specific 
for, or cross-reacting with the dog, can limit characterisation and that different 
methods (e.g. immunocytochemistry v’s FACS) and antibody selection differences 
between papers limits comparisons and may explain apparent differences in findings. 
Table 5.2 and Table 5.3 summarises markers and methods used in canine Ad-MSC 
and BM-MSC reports. 
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Paper Markers positive/method of 
testing 
Markers negative/method of 
testing 
Takemitsu et al. 
(2012) 
CD29,44, moderate CD90/FC CD34,CD45/FC 
Oh et al. (2011) CD29,44,90/FC CD31,34,73,105/FC 
Requicha et al. 
(2012) 
CD73,90/105/qPCR  
– rapid down regulation 
during passage 
nil 
Vieira et al., 
(2010)    
CD29,44,90/FC CD13,14,34,45,73,105,117/FC 
Kisiel et al. 
(2012) 
CD90- equivocal, CD44/ICC 
 
CD34,45,146/ICC 
Park et al. (2013) CD44, D54,90/FC CD3,18,34,45,49d,80/FC 
Ock et al. (2012) CD90,105/FC CD45/FC 
Kang et al. (2012) CD44,73,90,105/FC CD14,34,45/FC 
Ryu et al. (2012) CD44,73,90,105 CD14,3445 
Reich et al. 
(2012) 
CD90/FC --- 
Csaki et al. 
(2007) 
CD90,105/ICC CD34/45/ICC 
Table 5.2 Studies describing cell antigen characteristics of canine Ad-MSC 
FC- flow cytometry, ICC – immunocytochemistry, qPCR – real-time PCR. 
 






Takemitsu et al. (2012) CD29,44, moderate CD90/FC CD34,CD45/FC 
Quintanilha et al. (2013) CD29,44,90/FC CD11b,45/FC 
Reich et al. (2012) CD90/FC --- 
Hodgkiss-Geere et al. 
(2012) 
CD44,STRO-1/ICC CD34,45/PCR 




Ock et al. (2012) CD90,105/FC CD45/FC 
Kang et al. (2012) CD44,73,90,105/FC CD14,34,45/FC 
Ryu et al. (2012) CD44,73,90,105 CD14,3445 
Table 5.3  Studies describing cell antigen characteristics of canine BM-MSC 
FC- flow cytometry, ICC – immunocytochemistry, qPCR – real-time PCR. 
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5.2.5 Clinical trials and experimental use of MSC in the dog 
As yet there is little information on clinical trials of MSC in the dog.  Treatment of 
osteoarthritis has been the most studied with one randomized double-blinded control 
trial consisting of 18 dogs with coxo-femoral osteoarthritis which were treated with 
autologous Ad-MSC.  Outcomes were subjective clinical scores which improved 
significantly over time and relative to control animals (Black et al., 2007). A 
subsequent study used the same cell type in 14 dogs with humero-radial OA without 
blinding or a control group. Subjective clinical scores significantly improved over 
time (Black et al., 2008).  In both studies the primary author was employed by, and 
the study sponsored by, a commercial veterinary stem cell company offering 
treatment for canine OA.  There have been two further studies utilising canine 
autologous Ad-MSC in naturally occurring osteoarthritis.  Both were extremely small 
studies (n=4 and 8) with no similarly affected control group. One study had purely 
subjective outcomes which were reported to be positive (Guercio et al., 2012),whilst 
the other reported an improvement in force plate gait analysis, leading to the 
conclusion that MSC were an appropriate treatment for severe hip joint osteoarthritis 
(Vilar et al., 2013).  Pogue et al. (2013) used allogeneic canine Ad-MSC in 15 
Dobermans with dilated cardiomyopathy.  Although the treatment appeared safe, 
there were no apparent beneficial effects.   
Experimentally, more rapid dermal wound healing has been documented in wounds 
treated with allogenic canine BM-MSC compared to a vehicle control with a 
concomitant reduction in local inflammation (Kim et al., 2013).  Beagles with 
induced spinal cord injury demonstrated improved functional recovery after 
treatment with allogenic Ad-MSC which had been neuronally differentiated 
compared with vehicle controls (Park et al., 2012). Healing of experimental cartilage 
defects has also been reported to be improved by intra-articular injection of 
autologous BM-MSC (Mokbel et al., 2011). Finally, autologous BM-MSC were used 
in a canine model of ischaemic heart disease, where an improvement in cardiac 
function compared to a control group was noted (Silva et al., 2005). 
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5.2.6 Clinical use of MSC 
As MSC have been shown to have immunomodulatory effects in addition to their 
ability to differentiate, there has been a huge interest in using these cells 
therapeutically. This has been tempered by legislation in the human field which 
defines stem cell therapies as drugs, therefore requiring stringent conditions of 
culture, as well as proof of safety and efficacy (European Medicines Agency, 2011). 
As a result, clinical use of MSC stem cell treatments does not occur in the USA or 
Europe.  The exception to this is as part of clinical trials and there are 39 human 
trials listed using MSC in the European Union clinical trials register as of December 
2013 (www.clinicaltrialsregister.eu).   This same interest has inevitably also occurred 
in veterinary medicine, however there are no such restrictions on the use of stem cell 
therapies in veterinary medicine (Cyrano ski, 2013).  As a result, stem cell therapy is 
offered commercially by a number of companies and individuals as well as even 
basic equipment to produce autologous “stem cells” on-site in veterinary practices (in 
reality this isolates the VSF).  In the UK, private veterinary practices are offering 
MSC treatment for conditions as diverse as arthritis, inflammatory bowel disease, 
renal disease, neurological disease and skin disease.  Case reports are appearing in 
the literature, for example, Case et al. (2013) reports a dog with gastrocnemius 
tendon strain that was treated with autologous mesenchymal stem cells. These 
practices are of concern as there is minimal to no phenotyping of the cells, the 
treatments are as yet unproven for these conditions and the long-term safety of these 
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5.3 Aims 
The aims were to isolation, culture, characterise and perform tri-lineage 
differentiation of canine bone marrow and adipose mesenchymal stem cells/stromal 




5.4 Materials and methods 
5.4.1 Isolation of canine bone marrow mesenchymal stem 
cells 
The distal femoral epiphysis from recently euthanased dogs was removed using a 
hacksaw. A Jamshidi bone marrow biopsy needle (Baxter) was inserted into the 
medullary cavity via the trochanteric fossa and approximately 40mls of DMEM low 
glucose containing Glutamic-I (Invitrogen, UK), with 10% FBS (Invitrogen, UK) 
and 100 U/mL penicillin G and 100 μg/mL streptomycin (both Invitrogen, UK) 
injected with the resultant cell suspension collected from the distal segment. This 
was transported on ice to the laboratory. 
The cell suspension was diluted 1:1 with PBS and 20mls layered onto 15mls Ficoll 
Piqué Premium (GE Life Sciences) in a 50ml Falcon tube.  This was then centrifuged 
at 450g for 30 minutes without brake.  The cell containing interface was removed to 
a fresh Falcon tube, PBS added and pelleted at 150g for 5 minutes. The cells were 
then re-suspended in 30mls of MSC media, transferred to a T150 and incubated at 
37
o
C and 5% CO2. After 48 hours, media was removed, the flask washed with 
warmed PBS and fresh media added.  Media was changed every 2-3 days and cells 
passaged once confluent.  
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5.4.2 Isolation of canine adipose stromal cells  
Approximately 10g of falciform fat was excised from dogs which had been recently 
euthanased and placed in chilled MSC media.  After transport to the laboratory, this 
was finely chopped into 2-4mm pieces, placed in a 50ml Falcon tube and warmed 
PBS containing 100 U/mL penicillin G, 100 μg/mL streptomycin and 1mg/ml 
collagenase Type I (Sigma-Aldrich) added to the 45ml mark.  This was then 
incubated with constant shaking at 37
o
C for 2 hours.  10% FCS was then added to 
inactivate the enzymes and the tube centrifuged at 300g for 5 minutes.  The cell 
pellet was re-suspended in MSC media and filtered with 70µm cell strainer (BD 
Biosciences).   The cells were then re-pelleted, suspended in 30ml MSC media 
transferred to a T150 and incubated at 37
o
C and 5% CO2. After 48 hours, media was 
removed, the flask washed with warmed PBS and fresh media added.  Media was 
changed every 2-3 days and cells passaged once confluent. 
 
5.4.3 Cryopreservation of MSC 
At passage 2/3, cells were trypsinised and counted as previously described. Cells 
were centrifuged at 400g for 5 minutes and re-suspended in freezing medium: 10% 
dimethyl sulphoxide (DMSO) (Sigma-Aldrich), 40% FCS and 40% MSC media.  
Cells at a density of 2 x 10
6
/ml were placed in 1ml cryovials (Nunc, UK) and these 
placed in an isopropanol chamber (Mr Frosty, Nalgene, USA) in a -70
o
C freezer 
before being transferred to either -150
o
C or liquid nitrogen storage for longer term 
archiving. 
Cells were rapidly thawed in a 37
o
C water bath before adding the liquid to pre-
warmed media.  Cells were then centrifuged at 150rpm for 5 minutes and re-
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5.4.4 Isolation of canine peripheral blood mononuclear cells  
A volume of 9mls of blood was collected from the jugular vein of a recently 
euthanased dog into a 10ml syringe containing 1ml acid-citrate dextrose (Sigma-
Aldrich).  This was gently mixed for 20 seconds and transported on ice to the 
laboratory.  After dilution 1:1 with PBS the blood was layered over 10ml of 15mls 
Ficoll Paque Premium (GE Life Sciences) in a 50ml Falcon tube.  This was then 
centrifuged at 450g for 30 minutes without brake.  The cell containing interface was 
removed to a fresh Falcon tube, PBS added and pelleted at 150g for 5 minutes.  
These cells were then counted and re-suspended in PBS with 1% bovine serum 
albumin (Sigma-Aldrich).   
 
5.4.5 Immunofluorescence Analysis 
Cells were cultured in four chambered slides (BD Biosciences) until they were 
approximately 50% confluent.  Media was removed, the cells washed with PBS and 
then fixed with 4% paraformaldehyde for 30 minutes.  The cells were washed with 
PBS three times, permeabilised with 100% ethanol for 5 minutes before repeating the 
wash step. Blocking buffer (PBS containing 10% goat serum (Invitrogen) and 0.1% 
Tween 20 (Sigma-Aldrich, UK) was added for 1 hour at room temperature.  This was 
then aspirated and the appropriate dilution of antibody in PBS containing 1% goat 
serum and 0.1% Tween added (Table 5.4). Slides were incubated at 4
o
C overnight 
and then washed three times in PBST. The secondary antibody, again diluted in PBS 
containing 1% goat serum and 0.1% Tween was added and incubated at room 
temperature in the dark for 1 hour.  Slides were then rinsed three times with PBST 
and 4', 6-diamidino-2-phenylindole (DAPI) at a concentration of 200ng/ml for 30 
minutes added.  The slides were then washed with PBST and examined using 
fluorescent microscopy (Zeiss, Aviovert 40) and Zeiss Aviovision 4.7 software. 
Secondary only and no antibody controls were also performed for each cell type and 
antibody. 
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Table 5.4 Primary and secondary antibodies used for immunocytochemistry 
5.4.6 Flow cytometry analysis  
 
Cells were suspended in FACS buffer (PBS with 1% bovine serum albumin [BSA]) 
at a concentration of 1 x10
7
 cells/ml and 100ul added to 5ml Falcon tubes (BD 
Biosciences).  Primary antibodies and, where required, secondary antibodies are 
listed in Table 5.5. For CD11b staining 20µl blocking reagent: 2.4G2 (anti-Fc 
receptor [BD Pharmingen]) were added for 10 minutes at room temperature prior to 
antibody addition. After incubation at 4
o
C in the dark with antibody for 30 minutes, 
cells were washed in FACS buffer by centrifugation at 4ºC, 250g, for 5 minutes three 
times. Samples were re-suspended in 500μl of FACS buffer and kept on ice in the 
dark for analysis. Samples were run on a FACSCalibur and results acquired with 
CellQuestPro (both BD Biosciences).  Post-acquisition analysis was performed using 
FlowJo (Treestar, USA). No antibody and isotype controls were run for each cell 
type and experiment.  Canine peripheral blood mononuclear cells were used as 
positive control for CD45 and CD19 and canine bone marrow-derived macrophages 
(donated by Breno Beirao) a positive control for CD11b.  
 




Primary antibody Dilution Isotype Flurophore /secondary 
CD11b MCA1777S, AbD  
Serotec 
1:10 IgG1 Goat anti mouse Alexa 
Fluor 488 A-11001, Life 
technologies 
CD19 ab24936, Abcam 1:100 IgA FITC 
CD45 MCA1042G, AbD  
Serotec 
1:10 IgG2 Phycoerythrin 
 
Table 5.5 Cell surface markers and antibodies used for flow cytometry 
 
5.4.7 Adipogenic and osteogenic differentiation of MSC 
MSC cells were passaged into 6 well and 12 well plates.  Once 60-70% confluence 
was achieved, commercially available media was used for adipogenesis and 
osteogenesis (STEMPRO® Adipogenesis Differentiation Kit and STEMPRO® 
Osteogenesis Differentiation Kit, Invitrogen, respectively). Control cells were 
maintained in standard MSC media.  After 14 days, RNA was extracted from the 6 
well plate cells as previously described and cells in the 12 well plates were used for 
lineage specific staining described below.  
 
5.4.8 Chondrogenic differentiation of MSC 
A total of 2.5 x 10
5
 MSC were aliquoted into 1.5ml polypropylene 1.5ml 
microcentrifuge tubes (Fischer Scientific, UK). These were then spun at 500g for 5 
minutes to pellet the cells.  MSC media was then aspirated and either fresh MSC 
media or chondrogenic media added.  Five tubes of each cell and media type were 
run.  After 12 hours the cell pellet was gently detached from the bottom to become 
free-floating by pipetting.  Media was then changed every 2-3 days for 21 days. 
Pellets were then harvested and three fixed in 4% formaldehyde and Toluidine blue 
staining performed. RNA extraction was performed on the remaining 2 pellets in 
each experiment. 
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5.4.9 Oil Red O staining for lipid 
Oil Red O power (300mg) (Thermo, UK) was dissolved in 100ml of isopropanol to 
give stock solution. Six mls of stock was mixed with 4mls of distilled water and 
incubated for 10 minutes.  After this, the solution was passed through filter paper 
(Whatmann, UK) and used within 2 hours.  
Media was aspirated from the wells and the cells rinsed in PBS before being fixed in 
10% formaldehyde for 30 minutes. The wells were then gently rinsed with distilled 
water then 60% isopropanol added for 5 minutes. This was then aspirated and the Oil 
Red O solution added.  The wells were then incubated for 5 minutes before the 
solution rinsed with distilled water until the rinse became clear.  1ml of distilled 
water was added to the wells and the cells imaged under phase contrast microscopy 
(Zeiss, Aviovert 40) and Zeiss Aviovision 4.7 software. 
 
5.4.10 Alizarin red staining for calcification 
2g of Alizarin red powder (Sigma Aldrich, UK) was added to 100ml of distilled 
water and the pH adjusted to 4.1-4.3 with 10% ammonium hydroxide.  Media was 
aspirated from the wells and the cells rinsed with PBS.  Absolute ethanol was added 
to the wells for 30 minutes then aspirated and the wells allowed to dry. The Alizarin 
red solution was then added for 5 minutes, removed and the wells carefully rinsed 
three times with distilled water.  The wells were examined grossly for staining as 
well as under phase contrast as described above.  
 
5.4.11 Toluidine Blue staining for chondrogenesis 
Pellets were embedded in paraffin wax blocks and sections cut using a microtome. 
Toluidine blue staining was performed by Neil MacIntyre of the R(D)SVS pathology 
service.   Dewaxing was performed using xylene for 15 minutes, descending 
concentrations of ethanol (100, 95, 90, 70, and 0%) for 10 minutes each. The sections 
were rinsed in distilled water and submerged in 1% aqueous Toluidine blue solution 
(Sigma Aldrich) for 30 minutes at room temperature. The slides were then rinsed in 1 
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part distilled water and 4 parts 1% HCl in 70% ethanol for  5 seconds.  The slides 
were then rinsed in distilled water, dried and mounted using DPX mountant (VWR, 
UK).  
 
5.4.12 Primer optimization to perform MSC differentiation 
analysis 
Samples of adipose tissue, cartilage and trabecular bone <5mm 
3
 were taken from 
recently euthanased dog and submerged in RNALater.  These samples were stored at 
4
o
C for 24 hours before being transferred to -20
o
C for long-term storage. After 
thawing, 20mg of each tissue was placed 2ml plastic tubes containing 1.4mm 
ceramic beads (Fast Prep Lysing Matrix D tubes, MP Biomedical) with 600µl RLT 
Buffer (Qiagen) with the addition of 1:100 β Mercaptoethanol (Gibco).  Tissue was 
disrupted using a Fast Prep 24 Instrument (MP Biomedical) for 30 seconds at level 5, 
placed on ice for 30 seconds then repeated until no tissue mass was visible.  The 
tissue lysate was placed in a fresh Eppendorf tube and 1 volume of 70% ethanol 
added.  RNA was extracted using RNA Easy Mini Kit (Qiagen).   The solution was 
then mixed and 700µl transferred to an RNA Easy mini column. The column was 
centrifuged at 10,000g for 15 seconds, the flow-through discarded and this procedure 
repeated with any remaining solution.  A volume of 350µl of RW1 was added to the 
column and centrifugation repeated at 10,000g for 15 seconds and flow-through 
discarded. DNA digestion was performed using 10µl of DNase solution in 70µl RDD 
which was pipetted onto the column membrane and incubated at room temperature 
for 15 minutes. A volume of 350µl of RW1 was again added to the column and 
centrifugation repeated at 10,000 for 15 seconds and flow-through discarded.  500µl 
of RPE buffer was added and the sample centrifuged at 10,000g for 2 minutes.  The 
column was then placed into a new collection tube and centrifugation was repeated 
for 1 minute to ensure complete ethanol removal.  The column was then placed in a 
1.5ml Eppendorf, 30µl of nuclease free water added to the column and centrifugation 
performed at centrifuged at 10,000g for 1 minute.  The resultant samples were chilled 
on ice and quantity and quality assessed by spectrophotometry using Thermo 
Nanodrop™ (Thermo, USA). RNA was reverse transcribed to cDNA using 
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Omniscript® reverse transcription kit (Qiagen, UK) and primer efficiency and 
specificity were tested as described in Chapter 2.   
 
5.5 Results 
5.5.1 Canine bone marrow and adipose-derived 
mesenchymal stem cells can be isolated from 
ischaemic tissue. 
A total of 8 bone marrow and 7 adipose derived MSC cultures were undertaken 
(Table 5.6).  All but one bone marrow culture produced viable MSC’s which could 
be expanded. 






















D17513 Labrador ME 120 1 femur 
 






D19713 SBT FE 72 2 femurs ≈ 10g 
falciform 
Both viable 





D19913 Beagle FE 6 --- 
 
 ≈ 10g 
falciform 
Viable 
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5.5.2 Canine adipose and bone marrow mesenchymal stem 
cells can be expanded in vitro 
Both expanded at a similar rate with Ad-MSC requiring passaging earlier due to the 
higher plating density (Figure 5.4). 
Chapter 5: Mesenchymal stem cell isolation, characterisation & differentiation 
132 
 
Figure 5.4 Cells derived from D231112 and cultured on plastic with MSC culture medium.  
A&B Bone marrow-derived MSC 48 hours after plating, C&D BM-MSC after 14 days of culture. E&F Adipose-derived MSC 48 hours 
after plating, G&H Ad-MSC after 7 days of culture. White bar represents 100µm. 
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5.5.3 Ad-MSC and BM-MSCs express stem cell markers 
CD105, CD44 and STRO-1 
Both Ad-MSC and BM-MSC were examined for CD105, CD44 and STRO-1 
expression using immunofluorescence. Both MSC types had strong cytoplasmic 
staining for CD105 (endoglin) (Figure 5.5) and STRO-1 (Figure 5.6). CD44 staining 
was stronger on the Ad-MSC but both cell types were positive (Figure 5.7). All 
negative controls confirmed the specificity of antibody binding.  
 
Figure 5.5 Immunofluorescence analysis for CD105 (Endoglin) expression of Ad-
MSC and BM-MSC 
Ad-MSC (A) and BM-MSC (C) were positive for CD105 (Alexa Fluor 488). Nuclei 
counterstained with DAPI. Negative controls Ad-MSC (B) and BM-MSC (D) with 
secondary antibody only and DAPI nuclear staining. White bars represent 50µM. 
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Figure 5.6 Immunofluorescence analysis for STRO-1 expression of Ad-MSC and 
BM-MSC 
Ad-MSC (A) and BM-MSC (C) were positive for STRO-1 (Alexa Fluor 488). Nuclei 
counterstained with DAPI. Negative controls Ad-MSC (B) and BM-MSC (D) with 
secondary antibody only and DAPI nuclear staining. White bars represent 25µM. 
 
Figure 5.7 Immunofluorescence analysis for CD44 expression of Ad-MSC and 
BM-MSC 
Ad-MSC (A) and BM-MSC (C) were positive for CD44 (Alexa Fluor 488). Nuclei 
counterstained with DAPI. Negative controls Ad-MSC (B) and BM-MSC (D) with 
secondary antibody only and DAPI nuclear staining. White bars represent 25µM. 
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5.5.4 Isolated cells lack haematopoietic markers 
Adipose-derived MSC were uniformly negative for CD45 whilst only 3.42% of BM-
MSC were positive (Figure 5.8). The population of freshly isolated canine white 
blood cells were 92.3% positive for CD45, as would be expected for a pan-leucocyte 
marker. This served as a positive control. The negative population in the leucocytes 
would most likely be contaminating erythrocytes.  Both Ad-MSC and BM-MSC 
were uniformly negative for CD19. The positive control canine white blood cells had 
a positive population of 4.25% which would be within the range of B lymphocytes 
present in peripheral blood(Faldyna et al., 2001). For marker CD11b, 57.2% of the 
bone marrow-derived macrophages were positive. Neither Ad-MSC nor BM-MSC 
were positive for CD11b (Figure 5.10). 
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Figure 5.8 CD45 expression of canine white blood cells, Ad-MSC and BM-MSC by 
flow cytometry 
Freshly isolated canine white blood cells as positive control (A). Canine Ad-MSC 
from D231113 (B) and BM-MSC from D231113 (C).  CD45 stained cells in blue and 
isotype control in red. 
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Figure 5.9 CD19 expression of canine white blood cells, Ad-MSC and BM-MSC by 
flow cytometry 
Freshly isolated canine white blood cells as positive control (A). Canine Ad-MSC 
from D231113 (B) and BM-MSC from D231113 (C).  CD19 stained cells in blue and 
isotype control in red. 
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Figure 5.10 CD11b expression of canine white blood cells, Ad-MSC and BM-MSC 
by flow cytometry 
Freshly isolated canine white blood cells as positive control (A). Canine Ad-MSC 
from D231113 (B) and BM-MSC from D231113 (C).  CD11b stained cells in blue 
and isotype control in red. 
 
5.5.5 Optimisation of adipocyte, osteoblast and chondrocyte 
primers 
Two genes expressed by chondrocytes (Sox9 and aggrecan), two expressed by 
osteoblasts (osteonectin [SPARC] and osteopontin) and three expressed by 
adipocytes (Fatty acid binding protein 4[FAB4], lipoprotein lipase [LPL] & leptin) as 
well as three reference genes (MRPS7, MRPS25 & GAPDH) had good efficiency, 
dissociation curve and were the expected size on gel electrophoresis (Table 5.7). 
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R - CAGCAGCTCGTGTGACAACT 
62 97.6  58.33/58.33 √ √ 
MRPS25 
Ref 
F – TCTTGGGGAAGAACAAGGAA 
R - AGTGGGCTGGGTGAGAAAG 
72  101.3 59/60 √ √ 
GAPDH 
Ref 
F – GGGAAGATGTGGCGTGAC 
R - GAAGGCCATGCCAGTGAG 
123 96.9  60/60 √ √ 
Aggrecan 
Cart 
F –  ATCAACAGTGCTTACCAAGACA 
R-  ATAACCTCACAGCGATAGATCC 
122 107.8 56.5/56.4 √ √ 
Sox9 
Cart 
F –   GCTCGCAGTACGACTACACTGAC 
R -  GTTCATGTAGGTGAAGGTGGAG 
101    110 63/ 58.4  √ √ 
SPARC 
Osteo 
F – CCACCCGCTTCTTTGAGAC 
R- TCACCAGATCCTTGTCAATATCC 
111 104.3 60/60 √ √ 
Osteopontin 
Osteo 
F –  CATATGATGGCCGAGGT 
R -  CAAGTGATGTGAAGTCCTCCTC 
114 97.4 60.94/60.78 √ √ 
FAB4 
Adipose 
F–  GACTTTTCTGTCATCCGC 
R - TCAACAGACCCTGAAATA 
117 92.3 58.4/57.9 √ √ 
LPL 
Adipose 
F –  ACACATTCACAAGAGGGTCAC 
R - CTCTGCAATCACACGGATG 
134 108.1 57.9/56.7 √ √ 
Leptin 
Adipose 
F –  CTATCTGTCCTGTGTTGAAGCTG 
R= GTGTGTGAAAATGTCATTGATCCTG 
103 104.2 60.6/59.3 √ √ 
Table 5.7 Genes optimised to characterise adipogenic, osteogenic and chondrogenic differentiation of MSC 
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5.5.6 Canine Ad-MSC and BM-MSC can become adipocytes 
After culture for 14 days in adipogenic media, both cell types had multiple small 
refractile intracytoplasmic vacuoles present. These stained with Oil Red O, 
demonstrating the presence of lipid.  The BM-MSC had larger numbers of vacuoles 
per cell compared to the Ad-MSC. Undifferentiated Ad-MSC and BM-MSC were 
negative on Oil Red O staining (Figure 5.11). Both MSC types demonstrated 
significant gene expression increases in FAB4 and LPL. In both cases leptin was not 
increased with a significant, but small-fold decrease in Ad-MSC seen (Figure 5.12). 
   
Figure 5.11 Oil Red O staining for lipid of Ad-MSC and BM-MSC 
Undifferentiated Ad-MSC (A) and BM-MSC (C). Ad-MSC (B) and BM-MSC (D) 
after 14 days in adipogenic media. White bar represents 50µm.   
 




Figure 5.12 Fold increase of adipocyte gene expression. 
Ad-MSC (A) and BM-MSC (B) cultured in adipogenic media compared with control MSC media. Boxes represent the interquartile 
range, or the middle 50% of observations. The dotted line represents the median gene expression. Whiskers represent the minimum and 
maximum observations.  FAB4 – fatty-acid binding protein 4, LPL –lipoprotein lipase. ns = not significant.
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5.5.7 Canine Ad-MSC and BM-MSC can differentiate into 
osteoblasts 
Undifferentiated BM-MSC demonstrated slight staining with Alizarin red, both 
grossly and microscopically while undifferentiated Ad-MSC showed no staining 
(Figure 5.13 A, C). Both cell types, which had been cultured in osteogenic media for 
14 days had obvious red spicules grossly, and microscopically (Figure 5.13 C/D, 
E/H). This was most pronounced in the BM-MSC.  Examining gene expression for 
osteopontin and osteonectin, there was no large fold change in osteonectin and a 
small fold decrease in BM-MSC (Figure 5.14B).  In the differentiated Ad-MSC both 
osteopontin and osteonectin demonstrated large fold increases, which were 











Figure 5.13 Alizarin Red staining for calcification of BM-MSC and Ad-MSC 
Undifferentiated BM-MSC (A, B). BM-MSC after 14 days in osteogenic media (C, 
D). Undifferentiated Ad-MSC (E, F). Ad-MSC after 14 days in osteogenic media. 
White bar represents 50µm. 




Figure 5.14 Fold increase of osteopontin and osteonectin expression 
Ad-MSC (A) and BM-MSC (B) cultured in osteogenic media compared with control MSC media.  Boxes represent the interquartile 
range, or the middle 50% of observations. The dotted line represents the median gene expression. Whiskers represent the minimum and 
maximum observations. SPAR – osteonectin. ns = not significant.




5.5.8 Canine Ad-MSC and BM-MSC can differentiate into 
chondrocytes 
The positive control of mast cells demonstrated metachromatic purple staining, 
indicating the staining protocol was effective (Figure 5.15A).  The Ad-MSC and to a 
lesser extent BM-MSC showed diffuse metachromatic staining throughout the pellet 
which was not present in the control pellets (Figure 5.15B, D). The BM-MSC control 
pellets were of much smaller diameter than the TGFβ pellets. Both cell types 
demonstrated large fold increases in aggrecan which was significant. Sox9 
expression was no different between control MSC and MSC in chondrogenic media 
in both cell types (Figure 5.16).  
 
Chapter 5: Mesenchymal stem cell isolation, characterisation & differentiation 
146 
 
Figure 5.15 Toluidine blue staining of Ad-MSC and BM-MSC cell pellets 
Positive control of dermal mast cell tumour (A). Ad-MSC (B) and BM-MSC (D) 
pellets cultured in chondrogenic media with TGF-β for 21 days. Ad-MSC (C) and 
BM-MSC (E) cultured in chondrogenic media without TGF-β for 21 days. All 
images x 200. 




Figure 5.16 Fold increase of Aggrecan and Sox9 expression 
Ad-MSC (A) and BM-MSC (B) cultured in chondrogenic media compared with control MSC media.  Boxes represent the interquartile 
range, or the middle 50% of observations. The dotted line represents the median gene expression. Whiskers represent the minimum and 
maximum observations. AGG – aggrecan. 




5.6.1 Cells morphologically consistent with MSCs can be 
isolated from canine ischaemic bone marrow and 
adipose tissue 
This study has demonstrated that canine MSC could be reliably isolated from both 
bone marrow and adipose tissue in a range of breeds, ages and sexes. The only poor 
yield was from bone marrow of a 10 year old, entire male, Labrador.  It is possible 
that the age of the animal may have been the reason for the poorer yield, although 
good yields were obtained from other mature animals and adipose tissue from the 
same animal produced a successful culture.   Morphologically, cells from both tissue 
types were consistent with descriptions of MSC in the literature, namely fibroblast-
like cells with multiple projections, although Ad-MSC subjectively contained less 
cytoplasm (Hematti, 2012). After 48 hours, it was a consistent finding that many 
more cells were adhered to the culture plastic from the adipose tissue than bone 
marrow. This finding has been shown in many species, however there is debate as to 
whether this is purely a dilution effect of blood as when direct weight comparisons 
were made, no difference in yield was detected (De Ugarte et al., 2003; Kern et al., 
2006; Strioga et al., 2012). In this case, the difference in yield may be purely a 
function of the different methods of collection with collagenase digestion of adipose 
tissue yielding more cells than simple flushing of the bone marrow medullary cavity. 
Collagenase digestion of bone marrow may yield a higher concentration of BM-MSC 
than flushing.  Both MSC types readily adhered to tissue culture plastic therefore 
fulfilling one of the minimal criteria of mesenchymal stem cells (Dominici et al., 
2006).    
 
5.6.2 The isolated cells fulfil cell surface antigen criteria of 
MSC 
Previously in our laboratory, BM-MSC have been isolated and demonstrated to 
express CD44 and STRO-1 by ICC (Hodgkiss-Geere et al., 2012).  This present 
Chapter 5: Mesenchymal stem cell isolation, characterisation & differentiation 
149 
study confirmed this finding in BM-MSC and also demonstrated that Ad-MSC also 
express these markers.  In addition, both MSC types express CD105, one of the 
markers highlighted by Dominici et al. (2006).  An important aspect of MSC 
phenotyping is to ensure that there is not significant contamination by 
haematopoietic cells. This is most convincingly performed by flow cytometry 
(Dominici et al., 2006). These would be most likely to be present in the BM-MSC 
due to cohabitation of the bone marrow niche.  Using the pan-leucocyte marker 
CD45, a small percentage (3.4%) of the BM-MSC was positive, consistent with this 
hypothesis, whilst no CD45 positive Ad-MSC were detected. Neither Ad-MSC nor 
BM-MSC populations contained CD11b nor CD19 positive cells, demonstrating 
cultures were free of monocytes/macrophages and B cells.  
 
5.6.3 Isolated canine Ad and BM-MSC are capable of tri-
lineage mesenchymal differentiation 
Using standard staining to demonstrate adipocyte, osteoblast and chondrocyte 
differentiation, both cell types were convincingly positive for all lineages.  Toludine 
blue metachromatic staining of cartilage pellets, although present, was less dramatic 
than that demonstrated by Requicha et al. (2012).   Both cell types also demonstrated 
significant increases in aggrecan gene expression, the major proteoglycan in articular 
cartilage produced by chondrocytes (Kiani et al., 2002).  Interestingly, both cell types 
showed no increase in Sox9, which is the master-regulator of chondrogenesis.  As 
one of the functions of Sox9 is to bind to the aggrecan promoter and upregulate 
aggrecan expression, this appears an unusual result (Sekiya et al., 2000).  One 
possible explanation for this apparent paradox is that gene expression during 
differentiation is dynamic and Sox9 gene expression is shut-off during final 
maturation of chondrocytes into hypertrophic chondrocytes (Murakami et al., 2000). 
Therefore it is possible up-regulation of Sox9 was missed in these samples.  Analysis 
at a range of time points would clarify this. Another possibility is that 
chondrogenesis is dysregulated and stimulation of gene expression is down-stream of 
Sox9 expression. From the literature there appears to be variation in Sox9 
expression. Reich et al. (2012) detected an increase in Sox9 with BM-MSC but a 
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decrease with Ad-MSC. This was corroborated with more convincing cartilage 
formation in BM-MSC by histology and up-regulation of Collagen 2A1 only in BM-
MSC. Other authors have demonstrated convincing chondrogenic differentiation of 
both canine Ad-MSC and BM-MSC with Sox9 expression and also convincing 
chondrogenic differentiation with no Sox9 up-regulation (Csaki et al., 2007; 
Requicha et al., 2012; Vieira et al., 2010).  Innes et al. (2013) failed to get 
convincing differentiation of Ad-MSC using the same media formulation as the 
present study.  These disparate results need to be viewed with knowledge that a 
donor age-related reduction in differentiation ability of MSCs has been 
demonstrated, along with variation in ability according to donor site and passage 
number (Guercio et al., 2013; Kanawa et al., 2013; Vieira et al., 2010; Volk et al., 
2012).   
The optimum conditions for chondrogenic differentiation are under constant 
refinement. The Requicha et al. (2012) chondrogenic media also contained sodium 
bicarbonate and L-proline which may improve differentiation. Also FGF has been 
demonstrated to up-regulate Sox9 expression therefore addition of this growth factor 
to chondrogenic media may enhance chondrogenesis (Murakami et al., 2000).   Ad-
MSC, appear to lose sensitivity to TGFβ during culture by down regulation of the 
TGF-β receptor. Receptor expression can be restored by the addition of bone 
morphogenic protein (BMP), which also directly up-regulates Sox9; therefore this 
may be a useful addition to chondrogenic media (Hennig et al., 2007; Semba et al., 
2000).  Finally, temporal variation in growth factors may also be important. It has 
been shown that a specific protocol of sequential addition of TGFβ and BMP, 
importantly including a period without growth factors, improved chondrogenesis in 
human BM-MSC at least (Handorf and Li, 2014).   
Both cell types produced nodules which stained strongly with Alizarin red, indicating 
calcification after 14 days culture in osteogenic media. Undifferentiated BM-MSC 
exhibited mild staining which became dramatic after differentiation. Interestingly, 
there was no up-regulation of the osteoblast markers osteopontin and osteonectin in 
these cells. This may be that these genes were sufficiently expressed in the basal 
state, consistent with the initial staining results or as osteoblast gene expression 
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during differentiation has been shown to be dynamic in BM-MSC and Ad-MSC, the 
period of up-regulation may have been missed in this experiment (Kulterer et al., 
2007; Requicha et al., 2012).  
Both cell types demonstrated the presence of lipid vacuoles after adipogenic 
induction as well as many fold significant increases in FAB4 and LPL. In both cell 
types there was no increase in leptin expression. In the studies of canine Ad-MSC by 
Vieira et al. (2010), and canine umbilical cord vein MSC by Zucconi et al. (2010), 
leptin expression was demonstrated in the undifferentiated cells. In the present study, 
leptin was also detectable by qPCR in the undifferentiated cells therefore this may 
explain the lack of increase in gene expression.  Leptin is a hormone produced by 
adipocytes in proportion to their total mass in vivo (Maffei et al., 1995). It has been 
proposed that one of signalling triggers is physical distension of the adipocyte by fat 
vacuoles (Hamilton et al., 1995). Although multiple lipid vacuoles were present in 
the differentiated adipocytes, there was no evidence of cell membrane distention.  
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5.7 Summary 
 Reproducibly isolated cells consistent with MSC from both adipose and bone 
marrow tissue 
 Both cell types express CD44, CD105 and Stro-1 
 Both cell types lack haematopoietic markers CD45, CD11b and CD19 
 Cells can be readily expanded and differentiated to adipogenic, osteogenic 
and chondrogenic cells.  
 Both adipose and bone marrow can provide a source of MSCs which can be 
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Chapter 6: Mesenchymal to hepatocyte 
differentiation 
6.1 Abstract 
Differentiation of mesenchymal stem cells (MSC) into hepatocyte-like cells has been 
demonstrated in many species. Canine adipose and bone marrow-derived 
mesenchymal stem cells isolated and characterised as described in chapter 5 were 
cultured in conditions described to produce hepatocyte-like cells in other species.  
The effect of DNA demethylation and preventing histone deacetylation, with 5AZA 
and valproic acid respectively, on differentiation capacity was also examined. Cells 
were assessed using the tests validated with primary canine hepatocytes.  
Undifferentiated adipose and bone marrow-derived MSC were positive for LDL 
uptake.  This was confirmed to be via the specific LDL receptor by lack of Ac-LDL 
uptake, Immunofluorescence demonstrating the presence of LDL receptor on the cell 
membrane and LDL-receptor gene expression at the same level as canine primary 
hepatocytes. Mouse and human bone marrow-derived MSC were also assessed for 
LDL receptor presence by LDL/Ac-LDL uptake and immunofluorescence.  Both of 
these species MSC were also found to express the LDL receptor.  Undifferentiated 
adipose and bone-marrow-derived MSC’s also demonstrated albumin gene 
expression.  Both these characteristics have been attributed to a hepatocyte-like 
phenotype.  
During differentiation both cells types exhibited a dramatic change in morphology 
from fibroblastic to epithelial. A reduction in vimentin and fibronectin gene 
expression was noted, consistent with this.  The only evidence of a hepatocyte-like 
phenotype was an increase in α1anti-trypsin in differentiated BM-MSC. Both DNA 
demethylation and histone deacetylator inhibitors did not improve hepatocyte 
differentiation.  
Although differentiation capacity is donor and culture condition dependant, this data 
suggests that canine adipose and bone marrow-derived do not undergo differentiation 
to a hepatocyte-like phenotype using these differentiation protocols. 
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6.2 Introduction 
Since the discovery that MSC have the ability to differentiate beyond cells of 
mesodermal lineage, termed transdifferentiation, there has been great interest in 
production of hepatocyte-like cells in vitro from MSC’s (Seo et al., 2005).  The first 
report of this was by Schwartz et al. (2002) utilising human, murine and rat BM-
MSC.  This paper provided robust analysis of the resultant cells. These cells became 
epithelioid and stained positively for albumin, keratin 18 and hepatocyte nuclear 
factor 3β.  PCR analysis revealed increased gene expression of albumin, keratins 18 
and 19, transthyretin and selected cytochrome enzymes. Albumin and urea release 
into the supernatant was demonstrated along with positive staining for glycogen.  Seo 
et al. (2005) provided the first demonstration that adipose-derived MSC could also be 
differentiated into hepatocyte-like cells using human adipose tissue.  This again was 
convincingly demonstrated with a change to epithelioid morphology, gene 
expression of α-foetal protein and albumin as well as urea production.   Since these 
initial reports, there have been many subsequent papers detailing production of 
hepatocyte –like cells from MSC in a variety of species. In part, these studies have 
attempted to improve the degree and efficiency of differentiation as this, 10 years on 
since the first report, is still stated to be inadequate (Wu and Tao, 2012).  Although 
similar basic protocols are utilised, differences in growth factor/chemical 
concentrations, culture times and confirmatory tests make comparisons between 
reports difficult.  As stated in the previous chapter, age of donor, site of MSC harvest 
and passage number are significant factors in the efficiency of mesodermal lineage 
differentiation. It is likely that these also are important in transdifferentiation 
efficiency, further complicating the picture.  
 
6.2.1 Growth factors and compounds used in hepatocyte 
differentiation 
The majority of MSC to hepatocyte-like cell reports have based their differentiation 
protocols on what is known about key growth factors and chemicals required during 
foetal liver development as well as empirical evidence (Snykers et al., 2009a). 
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The three growth factors which are commonly used in MSC to hepatocyte 
differentiation are fibroblast growth factors (FGF), Oncostatin M (OSM) and 
hepatocyte growth factor (HGF).   
 
6.2.1.1 Fibroblast growth factors 
Fibroblast growth factors have diverse roles with main functions including 
angiogenesis, wound healing and neurogenesis (Ornitz and Itoh, 2001). As the name 
suggests are potent stimuli for fibroblastic proliferation.  FGF appears to be an 
important stimulus at the endodermal specification stage of hepatogenesis (Wu and 
Tao, 2012).  FGF-1, FGF-2 and FGF-8 are produced by the adjacent cardiac 
mesoderm during hepatic foregut endoderm specification. It has been shown that 
FGF-8 knockout is lethal prior to hepatogenesis and FGF-8 has only partial 
hepatogenic activity. Purified FGF1 & 2 efficiently specified hepatic differentiation.  
FGF-4 receptors are expressed in the endoderm during hepatogenesis (Wells and 
Melton, 1999; Zaret, 2001). In stem cell to hepatocyte differentiation, both FGF-2 
and FGF-4 have been utilised in protocols (Al Battah et al., 2011). 
 
6.2.1.2 Oncostatin M 
OSM is a member of the IL-6 cytokines, originally isolated from lymphoma cells. In 
embryogenesis, the foetal liver is infiltrated by haematopoietic stem cells (HSC); 
thereby becoming a major site of haematopoiesis for a period of embryogenesis 
before the liver abruptly switches from haematopoiesis to further hepatic 
differentiation. This change is controlled in part by OSM which is released from the 
HSC and induces maturation of hepatocytes in mid to late foetal development 
(Kamiya et al., 2001; Kinoshita et al., 1999).  For hepatocyte differentiation of stem 
cells, OSM concentrations range from 10-30ng/ml (Al Battah et al., 2011). 
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6.2.1.3 Hepatocyte growth factor 
HGF was originally identified to be increased in the serum of partially 
hepatectomised rats and was able to cause in vitro hepatocyte proliferation 
(Matsumoto and Nakamura, 1997). Subsequently it has been identified that HGF is 
secreted by mesenchymal cells during embryonic development and binds to 
hepatocyte growth factor receptor (HGFR), which is encoded by c-Met, a proto-
oncogene. HGFR is a tyrosine kinase receptor which upon activation initiates the 
invasive growth programme (Gentile et al., 2008). The interaction of HGF and 
HGFR regulates epithelial development and morphogenesis of various organs during 
embryogenesis including the kidney, mammary gland, lung and liver. During liver 
formation and maturation, HGF appears to play a role in in the early post-natal 
period (Nakamura et al., 2011). Concentrations of HFG used in MSC to hepatocyte 
differentiation range from 5-50ng/ml with 20ng/ml most commonly used (Schwartz 
et al., 2002; Talens-Visconti et al., 2007). 
 
Both OSM and HGF therefore appear to induce hepatic maturation but act via 
different signalling pathways with OSM acting via STAT-3 and HGF acting via an as 
yet unknown STAT-3 independent means (Kamiya et al., 2001).  
 
Other compounds commonly added to media during differentiation are 
dexamethasone, nicotinamide, insulin, transferrin and selenium (Wu and Tao, 2012). 
For many of these compounds, evidence of efficacy is empirical and the method of 
action is unknown. Steroids have been shown to up-regulate HGFR expression and 
also promote differentiation by suppression of cell division.  
Addition of DMSO to primary hepatocyte cultures has been shown to improve 
function via “re-differentiation” of hepatocytes whereby they regain function which 
was lost during in vitro culture (Su and Waxman, 2004).  As a result of this, DMSO 
has also been used during hepatocyte differentiation of mesenchymal stem cells 
(Snykers et al., 2009a).  The mechanism of DMSO action has not been defined 
Chapter 6: Mesenchymal to hepatocyte differentiation 
 157 
although histone hyper-acetylation has been postulated (Snykers et al., 2007). Use of 
DMSO is not without risk, as although DMSO is commonly used for 
cryopreservation during cell culture, it has the potential to be toxic and has been 
shown to reduce stem cell viability, reduce stem cell markers and decrease 
functionality of ESC-generated hepatocyte-like cells (Pal et al., 2012).  
 
6.2.2 Epigenetic modification 
Gene expression can be regulated by modifications which do not change the DNA 
sequence. This has been termed epigenetic modification.  Methylation of DNA i.e. 
the binding of a methyl group to cytosine-guanine dinucleotides (CpG) suppresses 
expression of those genes either by physically interfering with transcriptional binding 
proteins or also by binding of proteins containing a methyl-CpG-binding domain 
(MBD), which in turn attracts histone deacetylases modifying histone to produce a 
compact chromatin structure. This has the effect of reducing gene expression.  After 
DNA replication and cell division, maintenance methylation by DNA 
methyltransferase 1 (DNMT1) acts transfer the methylation status down to the 
resultant 2 DNA “offspring”.  
In the production of induced pluripotent stem cells (iPSC), it has been shown that 
DNA methylation serves as an “epigenetic memory” in that iPSC produced from 
different cell types retain a memory affecting their ability to differentiate whereby 
the most efficient differentiation is towards a cell type related to the cell or origin 
(Kim et al., 2010).  As an example of this, iPSC produced from pancreatic β cells had 
a methylation pattern that was unique, with increased histone acetylation of key 
genes including insulin.  As stated above, acetylation of histone allows a more open 
structure, favoring gene expression. These β cell-derived iPSC differentiated more 
efficiently into β cell than iPSC from other tissues or embryonic stem cells (Bar-Nur 
et al., 2011). 
There has been much interest in modifying the epigenetic memory of stem cells to 
enhance their pluripotent potential (Moschidou et al., 2013; Rajasingh et al., 2011).  
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Two main classes of compound have been used: DNA methylation inhibitors; 5Aza-
2-deoxycytidine (5AZA), zebularine and histone deacetylase inhibitors; valproic 
acid, trichostatin A (TSA) and sodium butyrate.  
6.2.2.1 5AZA and zebularine  
These are analogues of cytidine for which they substitute during replication.  These 
then covalently bind DNMT causing enzyme degradation. As they intercalate within 
genomic DNA, this may cause mutation and cytotoxicity (Christman, 2002; Yoo et 
al., 2004). These compounds have also been used to enhance the differentiation 
ability of MSC’s (Naeem et al., 2013; Seeliger et al., 2013). Specifically, in 
differentiation towards hepatocyte-like cells, Seeliger et al. (2013) demonstrated that 
pre-treatment of human Ad-MSC with 5AZA improved the subsequent functional 
abilities of hepatocyte-like cells compared to untreated cells.   Sgodda et al. (2007) 
utilized 5ASA prior to hepatocyte induction of rat Ad-MSC.  No untreated cells were 
differentiated to assess the effect of 5AZA on efficiency or function of 
differentiation. 
6.2.2.2 Valproic acid  
Chen et al. (2009) showed that incubation with 2.5mM valproic acid for 72 hours 
prior to differentiation improved hepatocyte gene expression and function of mouse 
BM-MSC and Dong et al. (2013) demonstrated the same effect with 5mM valproic 
acid on human BM-MSC.  Trichostatin A has also been used to improve hepatocyte 
differentiation of human BM-MSC (Snykers et al., 2007). 
6.2.2.3 Sodium butyrate  
This appears to improve primary hepatocyte culture function is also a histone 
deacetylase inhibitor.  This has been used in embryonic stem cell and induced 
pluripotent stem cell to hepatocyte differentiation to improve efficiency of 
differentiation (Perry et al., 1979; Sharma et al., 2006; Zhang et al., 2011). There is 
one report of sodium butyrate use in MSC differentiation at present where pre-
treatment decreased the efficiency of adipogenic and chondrogenic differentiations 
but enhance osteogenic differentiation (Lee et al., 2009). 
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Figure 6.1 Epigenetic control of gene transcription 
Hypermethylation of DNA and deacetylation of histones will tend to down-regulate 
gene expression. Binding of transcription factors (TF) is blocked by non-permissive 
chromatin resulting from methyl-binding proteins (MeBPs) binding to methylated 
cytosine and recruitment of HDAC co-repressor complexes. DNMT inhibitors such 
as 5AZA (5-AZA-C) and histone deacetylase (HDAC) inhibitors (valproic acid 
[VA], Trichostatin A[TSA], sodium butyrate [SB]) modify chromatin structure to 
produce an open and transcriptionally active configuration allowing transcription 
factor access and favouring gene expression. Modified from Snykers et al. (2009b). 
 
6.2.3 Canine MSC to hepatocyte differentiation 
There is one report in the literature describing canine MSC to hepatocyte 
differentiation.  Choi et al. (2013) differentiated canine amniotic and BM-MSC’s 
using a conditioning step of 20ng/ml EGF and 10ng/ml  bFGF and then 2 step 
conditioning of; 20ng/ml HGF and 5ng/ml bFGF, finally  20ng/ml OSM, 1µM 
dexamethasone and 5mmol/l nicotinamide.  Demonstration of hepatocyte function 
was restricted to gene expression using end-point PCR and gel electrophoresis.  
Amniotic cells expressed albumin, tyrosine aminotransferase and α1-anti-trypsin 
whilst BM-MSC only exhibited α1-anti-trypsin expression.  No functional assays 
were performed. 
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6.3 Aims 
The aims of this chapter were to produce functional canine hepatocyte-like cells from 
canine adipose and bone marrow-derived mesenchymal stem cells isolated and 
characterised in Chapter 5. Protocols published and proven to be successful in other 
species will be used.  The effect of DNA demethylating compounds and histone 
deacetylase inhibitors will also be investigated. The success of attaining a 
hepatocyte-like phenotype will be judged on methods validated using canine primary 
hepatocyte cultures in Chapter 3. This includes gene expression, cytochrome activity, 
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6.4 Materials and Methods 
6.4.1 Primer efficiency 
Primers for E-cadherin, fibronectin, vimentin and β-catenin were donated by 
Alexandro Cervantes.  Efficiency was assessed using 10-fold dilutions of cDNA 
from canine hepatic tissue using the method described in Chapter 2.  
 
6.4.2 Culture of mouse and human BM-MSC 
6.4.2.1 Mouse 
Murine bone marrow mesenchymal stem cells were purchased from Life 
technologies (Gibco Cat. No. S1502-100).  These were thawed by swirling the 
cryopreservation vial in a 37
o
C water bath before transferring to a 15ml falcon tube 
and slowly adding 10ml warm DMEM/F12 medium containing 10% foetal calf 
serum and 100 U/mL penicillin G and 100 μg/mL streptomycin (all Invitrogen, UK).  
This was centrifuged at 300g for 5 minutes and the cells re-suspended in 10 mLs of 




. Media was 
changed every 3 days and cells passaged when 80% confluent using the method 
detailed in Chapter 2.  
6.4.2.2 Human 
Human bone marrow derived mesenchymal stem cells were purchased from Life 
technologies (Gibco Cat. No. A15652). These were thawed and processed in the 
same manner as the mouse cells except for the fact that MesenPRO RS™ Medium 
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6.4.3 5-Aza-2′-deoxycytidine (5AZA) toxicity assay 
Stock 5AZA solution was prepared by dissolving 5-Aza-2′-deoxycytidine (Sigma 





 of both Ad-MSC and BM-MSC were plated into 96 well plates in standard 
MSC media.  After 24 hours, concentrations of 5, 10, 15,20,25,30 and 50µM of 
5AZA were added to 3 wells of each cell type. Control cells had vehicle equivalent 
to the 50 µM concentration added. After 24 hours, media was replaced with fresh 
MSC media and cell viability was assessed using the MTT assay at time points 24 
and 48 hours. 
6.4.4 Hepatic differentiation of mesenchymal stem cells 




 in 6 well plates (RNA extraction), 
12 well plates (Periodic acid Schiff staining) and 96 well plates (Cytochrome 
activity) and cultured in standard MSC media for 48 hours prior to commencing 
experiments.  
6.4.5 Experiment 1 - Differentiation according to Lee et al. 
(2004) 
Canine BM-MSC from D231112 were used. A 2 day pre-induction step in serum-
deprived Iscove's Modified Dulbecco's Media containing 20ng/ml of bFGF and 
epidermal growth factor was performed before the two step differentiation process 
performed (Figure 6.2). Cells were collected for real time PCR analysis on days 15 
and 20. 
 
Figure 6.2 Protocol used during MSC to hepatocyte-like cell differentiation.  
Based on protocol described by Lee et al. (2004). EDGF – epidermal-derived growth 
factor, HGF – hepatocyte growth factor, bFGF – basic fibroblastic growth factor, 
OSM – oncostatin M.  
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6.4.6 Experiment 2 - Differentiation according to Talens-
Visconti et al. (2007) 
Both Ad-MSC and BM-MSC from D231113 were used. Figure 6.3 shows the 
protocol used. 
 
Figure 6.3 Protocol for MSC to hepatocyte differentiation modified from Talens-
Visconti et al. (2007) 
EDGF – epidermal-derived growth factor, HGF – hepatocyte growth factor,  bFGF – 
basic fibroblastic growth factor. 
 
Cells were photographed to assess morphology at time points 0,14 and 30 days. Cells 
from a 6 well plate were harvested at time points 0,14 and 30 days for PCR analysis. 
Undifferentiated Ad-MSC and BM-MSC which had been in culture for 30 days were 
also harvested as controls.   DiI-LDL uptake was assessed at time points 0 and 14 
days. Cytochrome P450 activity was assessed at time points 0, 14 and 30 days using 
the Promega Luciferin assay. At each time point, three wells had rifampicin added at 
a concentration of 50µM for 48 hours prior to cytochrome activity measurement in 
an attempt to induce cytochrome activity.  PAS staining was performed at time 
points 0 and 30 days.  AD23113 primary hepatocytes were used as a positive control.  
6.4.7 Experiment 3 - Does a longer differentiation protocol 
allow transdifferentiation to hepatocyte-like 
phenotype? 
A protocol based on both Lee et al. (2004) and Talens-Visconti et al. (2007) was 
used (Figure 6.4).  Cells were plated onto collagen coated plates as before and 
photographed and harvested for PCR analysis at time points 0 and 50 days. 
Cytochrome activity was assessed as in experiment 1. 
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Figure 6.4 Experiment 3 protocol for MSC to hepatocyte differentiation 
Modified from both Lee et al. (2004) and Talens-Visconti et al. (2007). EDGF – 
epidermal-derived growth factor, HGF – hepatocyte growth factor,  bFGF – basic 
fibroblastic growth factor, OSM – oncostatin M. ITS – Insulin/transferrin/Selenium 
supplement (Sigma-Aldrich, UK). 
 
6.4.8 Experiment 4 – Does prior 5AZA treatment allow 
transdifferentiation to hepatocyte-like phenotype? 
A differentiation protocol according to Talens-Visconti et al. (2007) was again 
utilised using Ad-MSC and BM-MSC from D231113 after 24 hours’ culture in MSC 
media with the addition of 20µM 5AZA . Cell morphology was photographed and 
real-time PCR was performed at time points 0 and 18 days. 
 
Figure 6.5 Protocol for experiment 4 
5AZA - 5-Aza-2′-deoxycytidine, EDGF – epidermal-derived growth factor, HGF – 
hepatocyte growth factor, bFGF – basic fibroblastic growth factor. 
 
6.4.9 Experiment 5 - Does prior valproic acid treatment allow 
transdifferentiation to hepatocyte-like phenotype? 
Valproic acid sodium salt (Sigma Aldrich, UK) was dissolved at a concentration of 
150mg/ml in standard MSC medium to provide stock solution.  Cells Ad-MSc and 
BM-MSC from D19713 were treated with 5mM valproic acid for 72 hours in 
standard MSC media prior to repeating the protocol used in experiment 2.  
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6.5 Results  
 
6.5.1 PCR efficiency of epithelial and mesenchymal genes 
Primers for E-cadherin, fibronectin, vimentin and β-catenin had acceptable 
efficiency, dissociation curves and obtained the expected product size on gel 
electrophoresis tissue (Table 6.1). 
Chapter 6: Mesenchymal to hepatocyte differentiation 
 166 









E-cadherin F – TGACAGCTACACGTTCACCG 
R-  TGCATCCTTCAAAACTCACCCT 
80 101.3 60.3/60.16 √ √ 
Fibronectin F – GACCTAGAGGTCATCGCTGC 
R- CAGGGCTGTTTCCTCCTGTT 
115 97.7 60/55.00 √ √ 
Vimentin F – GGACCAGCTCACCAACGACA 
R - GCATCTCCTCTTGCAACTTCTC 
99 98.3 62/60.62 √ √ 
β-catenin F – GGAATGGCTACCCAAGCTGA  
R - AAGACTGTTGCTGCCAGTGA 
91 96.3 59.74/59.8 √ √ 
Table 6.1 Primer details and efficiency obtained using 10-fold dilutions of hepatic tissue 
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6.5.2 Canine BM-MSC do not differentiate to hepatocyte-like 
cells with a 20 day protocol 
 
6.5.2.1 Morphology 
Compared to BM-MSc which had been maintained in standard MSC media, there 
was significant cell loss during the protocol with many cells detaching during media 
change.  Only small pockets of cells remained (Figure 6.6).  The cells subjectively 
had a higher cytoplasm to nucleus ratio and were more polygonal than 
undifferentiated MSC but had not assumed an epithelial morphology demonstrated 
by Lee et al. (2004) and other papers documenting hepatocyte differentiation.  
 
Figure 6.6 Morphology of D231112 BM-MSC before and after differentiation 
protocol  
A- Day 0, undifferentiated BM-MSC, B- cells at day 20 after differentiation protocol, 
C – undifferentiated BM-MSC after 20 days in culture. White bar represents 50µm. 
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6.5.2.2 Gene expression 
RNA yield from time point 20 days was inadequate for real-time PCR analysis due to 
the low cell numbers. Sufficient RNA was collected from day 15 for limited analysis. 
cDNA from fresh canine hepatocytes were used as a positive control. No increase in 
albumin, transthyretin, cytochrome 1A2 or keratin-18 gene expression was noted 
between day 0 and 15 (Figure 6.7). 
 
 
Figure 6.7 Real time PCR analysis of BM-MSC D231113 hepatocyte 
differentiation 
 Genes of interest compared against geometric mean of B2MG, HPRT and RPL8. 
TTR – transthyretin, Cyp1A2 – cytochrome 1A2. 
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6.5.3 Thirty day protocol causes change in morphology but 
not gene expression 
In view of the apparent cell loss during differentiation, and the fact that cell density 
appears to be crucial to differentiation efficiency i.e. approaching confluence 
improves differentiation, MSC’s were plated onto collagen-coated plates prior to 
differentiation which prevented cell loss (Snykers et al., 2009a). 
 
6.5.3.1 Morphology 
There was a gradual but dramatic change in morphology from fibroblastic 
mesenchymal morphology to cells, which had a much higher cytoplasm to nucleus 
ratio and appeared epithelioid with a cuboidal cobblestone appearance to the 
monolayer (Figure 6.8).  This change in morphology was consistent with what had 
been described by Talens-Visconti et al. (2007) for Ad-MSC and Lee et al. (2004) 
for BM-MSC. No cell loss was evident on this occasion.   




Figure 6.8 Morphology of Ad-MSC and BM-MSC that had hepatocyte differentiation based on Talens-Visconti et al. (2007). 
A-D = Ad-MSC, E-H = BM-MSC. Time points from left to right, 0, 6, 14, 30 days. White bar represents 100µm. 
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6.5.3.2 PCR analysis  
Analysis of the early markers of hepatocyte differentiation (αfoetal protein and 
keratin 7), demonstrated that expression actually decreased during differentiation of 
both Ad-MSC and BM-MSC (Figure 6.9 and Figure 6.11). Compared to the primary 
hepatocytes used as a positive control, gene expression of cytochrome P450 enzymes 
and mature hepatocyte markers albumin and keratin 18 was many magnitudes 
smaller in all stages of the Ad-MSC’s (Figure 6.9, Figure 6.10, Figure 6.11 & Figure 
6.12).   Only Cyp3A12 expression was increased in the day 30 Ad-MSC cells 
compared to day 0 and the undifferentiated controls. From the BM-MSC 
differentiation, Cyp1A2 and 2D15 increased during differentiation.  For all 
cytochrome genes, expression was several orders of magnitude below the positive 
controls. Of note was that undifferentiated Ad-MSC and BM-MSC expressed 
albumin.  In view of the lack of increase in early hepatocyte markers and lack of 
other hepatocyte gene expression increase, there was no convincing progression of 









Figure 6.9 Real time PCR analysis of Ad-MSC D231113 hepatocyte differentiation 
K7- Keratin 7, AFP - αfoetal protein.  
Hepatocytes – D231113 primary hepatocytes used as positive control. Undiff – 
undifferentiated Ad-MSC maintained in MSC media for 30 days. 
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Figure 6.10 Real time PCR analysis of Ad-MSC D231113 hepatocyte 
differentiation 
K18 – keratin 18, TTR – transthyretin, a1AT – α1-antitrypsin. Hepatocytes – 
D231113 primary hepatocytes used as positive control. Undiff – undifferentiated Ad-
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Figure 6.11 Real time PCR analysis of BM-MSC D231113 hepatocyte 
differentiation 
K7- Keratin 7, AFP - αfoetal protein.  
Hepatocytes – D231113 primary hepatocytes used as positive control. Undiff – 
undifferentiated BM-MSC maintained in MSC media for 30 days. 




Figure 6.12 Real time PCR analysis of BM-MSC D231113 hepatocyte 
differentiation 
K18 – keratin 18, TTR – transthyretin, a1AT – α1-antitrypsin. Hepatocytes – 
D231113 primary hepatocytes used as positive control. Undiff – undifferentiated 
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6.5.3.3 Undifferentiated Ad-MSC and BM-MSC take up LDL 
Surprisingly, both undifferentiated Ad-MSC and BM-MSC strongly took up LDL 
after 3 hours’ incubation (Figure 6.13).  Identical results were also observed at days 
14 and 30. 
 
 
Figure 6.13 DiI-LDL uptake of undifferentiated D231113 Ad-MSC and BM-MSC. 
A – Ad-MSC after culture in DiI-LDL, B – Ad-MSC negative control 
C – BM-MSC after culture in DiI-LDL, D – BM_MSC negative control. 




6.5.3.4 Undifferentiated Ad-MSC and BM-MSC demonstrate non-
specific Periodic acid Schiff staining 
Faint but distinct staining was present at days 0, 14 and 30 in both Ad-MSC and BM-
MSC, suggestive of glycogen storage. Figure 6.14 shows representative staining at 
days 0 and 14 along with PAS staining of primary hepatocytes during culture. 
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Figure 6.14 Periodic acid Schiff staining of canine primary hepatocytes, Ad-MSC and BM-MSC during differentiation 
A- primary hepatocytes in culture 24 hours, B – primary hepatocytes in culture 72 hours, C – primary hepatocytes in culture 6 days, D – 
Ad-MSC undifferentiated, E – BM-MSC undifferentiated, F - Ad-MSC after 14 days on differentiation protocol, G -  BM-MSC after 14 
days on differentiation protocol.  White scale bar represents 100µm. 
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In view of this positive PAS staining which was present in undifferentiated cells and 
differentiated cells with no other demonstration a hepatocyte phenotype; this was 
further investigated with examination of glycogen synthase gene expression.  
Glycogen synthase expression was measured at time points 0,14 and 30 days as well 
as in canine primary hepatocytes after culture for 1,3 and 6 days as a positive control.  
Glycogen synthase expression was normalised to three reference genes (HPRT, 
B2MG and RPL8).  
This demonstrated no, or minimal expression of glycogen synthase at any time points 
of differentiation (Figure 6.15).  As glycogen synthase activity is integral to glycogen 
accumulation this lack of gene expression would suggest that PAS staining was non-
specific. 
 
Figure 6.15 Glycogen synthase gene expression of Ad-MSC, BM-MSC and 
primary hepatocytes 
Undiff – undifferentiated MSCs cultured for 30 days. 
 
 
6.5.3.5 No CYP activity can be demonstrated during differentiation 
Using the luciferase assay, there was no appreciable cytochrome activity at any of 
the time points, either basal activity or after induction with rifampicin (Figure 6.16).  
Some cell containing wells had lower luminescence than the cell free control wells, 
hence the negative values for some results.  
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Figure 6.16 Cytochrome activity of Ad-MSC and BM-MSC at days 0, 14 and 30 
CYP activity was measured using Promega Pro-Glo Luciferase-PFBE which was added to culture media for 3 hours. Media removed, 
detection buffer added and luminescence measured using a luminometer.  Background values from cell-free wells were subtracted from 
result.  Experiments were performed in triplicate. r – rifampicin treatment for 48 hours.  
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6.5.4 Extending to day 50 with a maturation step increases 
gene expression of α1anti-trypsin and transthyretin 
As Lee et al. (2004) had continued their differentiation protocol for up to 6 weeks; a 
final maturation step was added.  
 
6.5.4.1 Morphology 
As with the previous experiment, there was a dramatic change in morphology, most 
evident in the BM-MSC cells to a more epithelioid pattern (Figure 6.17).  The Ad-
MSC morphology after 50 days was more heterogeneous with some cells still 
assuming a fibroblastic appearance.  
6.5.4.2 PCR Analysis 
The results after 50 days of differentiation demonstrated increases in α1 anti-trypsin, 
and transthyretin in both cell types (Figure 6.18 & Figure 6.19).  No other hepatocyte 
genes demonstrated increased expression however.  




Figure 6.17 Morphology of Ad-MSC and BM-MSC during hepatocyte differentiation during experiment 3 
A-C – Ad-MSC, D-F – BM-MSC. A - D day 0, B, C, E & F day 50.  White bar represents 50µm. 
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Figure 6.18 Ad-MSC hepatocyte differentiation relative gene expression 50 day experiment. 
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 Figure 6.19 BM-MSC hepatocyte differentiation relative gene expression experiment 3 
K18 – keratin 18, TTR – transthyretin, a1AT – α1-antitrypsin. Hepatocytes – D231113 primary hepatocytes used as positive control. 
Undiff – undifferentiated BM-MSC maintained in MSC media for 30 days. 
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6.5.4.3 Cytochrome activity, basal and rifampicin 




Figure 6.20 CYP activity at day 50 of experiment 3. 
CPS – counts per second of luminescence after subtraction of luminescence from no 
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6.5.5 Pretreatment with 5AZA does not enhance 
transdifferentiation 
6.5.5.1 5AZA cell viability assay 
As 5AZA can be cytotoxic, a viability assay was performed at a range of 
concentrations (Juttermann et al., 1994). At 24 hours, all concentrations of 5AZA 
had caused a decrease in Ad-MSC viability compared to the control. There was no 
effect on BM-MSC at 24 hours.  An obvious dose response in both Ad-MSC and 
BM-MSC was noted 48 hours after treatment with 5AZA.  As 20µM had been used 
in previously published papers and caused an approximately 50% reduction in 
viability, this concentration was selected for the subsequent experiment (Seeliger et 
al., 2013; Sgodda et al., 2007).   
 
Figure 6.21 Cell viability assays at 24 and 48 hours after exposure to 5AZA for 24 
hours 
OD 570nm – value after subtraction of no cell control optical density. Each 
concentration was performed in triplicate. Error bars represent standard error of 
mean.  
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6.5.5.2 Cell morphology 
The largest change in morphology appeared to be in the BM-MSC where they 
assumed epithelial-type morphology however little change in morphology was noted 
in the Ad-MSC (Figure 6.22). 
 
Figure 6.22 Morphology of Ad-MSC and BM-MSC during hepatocyte 
differentiation during experiment 4 
A – Undifferentiated Ad-MSC; D – undifferentiated BM-MSC; C&D Differentiated 
Ad-MSC; E&F Differentiated BM-MSC. White bar represents 100µm. 
 
6.5.5.3 PCR analysis   
6.5.5.3.1 Hepatocyte and hepatocyte pre-cursor genes 
Compared to time point 0 and undifferentiated cells, aside from a small increase in 
α1 antitrypsin in the BM-MSC, there was no increase in any of the hepatocyte/ 
hepatocyte pre-cursor genes analysed after 18 days in the differentiation media.    
 
6.5.5.3.2 Mesenchymal and epithelial gene expression 
Examination of genes expressed by mesenchymal cells demonstrated a reduction in 
vimentin, β catenin and fibronectin expression after differentiation by Ad-MSC 
(Figure 6.25).  This was mirrored by the BM-MSC apart from β catenin which 
increased (Figure 6.26).  










Figure 6.23 Ad-MSC hepatocyte differentiation relative gene expression after 5AZA pre-treatment 
K18 – keratin 18, TTR – transthyretin, a1AT – α1-antitrypsin. Hepatocytes – D231113 primary hepatocytes used as positive control. 
Diff – BM-MSc after differentiation protocol.  Undiff – undifferentiated BM-MSC maintained in MSC media for 18days. 
















Figure 6.24 BM-MSC hepatocyte differentiation relative gene expression after 5AZA pre-treatment 
K18 – keratin 18, TTR – transthyretin, a1AT – α1-antitrypsin. Hepatocytes – D231113 primary hepatocytes used as positive control. 
Diff – BM-MSc after differentiation protocol.  Undiff – undifferentiated BM-MSC maintained in MSC media for 18days. 
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Figure 6.25 Mesenchymal and epithelial markers of Ad-MSc before and after 
differentiation and 5AZA pre-treatment 
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Figure 6.26 Mesenchymal and epithelial markers of BM-MSc before and after 




6.5.6 Treatment with valproic acid (a histone deacetylase 




Again a dramatic change in morphology occurred with both cells types taking on a 
more epithelioid morphology (Figure 6.27).  




Figure 6.27 Morphology of Ad-MSC and BM-MSC after valproic acid treatment 
and hepatocyte differentiation 
A – undifferentiated Ad-MSC, B – Ad-MSc after differentiation protocol. C- 




6.5.6.2 Gene expression analysis  
A reduction in vimentin expression was again demonstrated in both the Ad-MSC and 
BM-MSC, consistent with the change from a mesenchymal morphology. No increase 
in hepatocyte/hepatocyte precursor gene expression was noted after pre-treatment 
with valproic acid.  An increase in α1 antitrypsin was again present in BM-MSC.  
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Figure 6.28 D19713 Ad- MSC hepatocyte differentiation relative gene expression after valproic acid treatment 
K18 – keratin 18, TTR – transthyretin, a1AT – α1-antitrypsin. 
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Figure 6.29 D19713 BM- MSC hepatocyte differentiation relative gene expression after valproic acid treatment 
K18 – keratin 18, TTR – transthyretin, a1AT – α1-antitrypsin. 
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6.5.7 DiI-LDL uptake is specific for the LDL receptor in 
canine Ad-MSC and BM-MSC 
To assess if LDL uptake was consistent in MSC, LDL and Ac-LDL uptake was 
performed with canine Ad-MSC and BM-MSC from 3 animals (D231113,D17513, 
D19713) and three canine  primary hepatocyte culture (D231113, D19713, D20913).  
LDL-receptor gene expression relative to three reference genes was also performed 
on three canine primary hepatocyte cultures and two each of Ad-MSC and BM-MSC.  
Finally, immunocytochemistry using an anti-LDL receptor antibody was undertaken 
using hepatocytes, Ad-MSC and BM-MSC from D19713. 
 
6.5.7.1 Ad-MSC and BM-MSC do not take up DiI-Ac-LDL 
All MSC’s and primary hepatocytes took up DiI-LDL strongly as was previously 
demonstrated (Figure 6.30).  Isolated cells in all cultures avidly took up DiI-Ac-LDL 
however the majority were negative. These cells would be consistent with 
contaminating endothelial or macrophage cells.  The lack of uptake of Ac-LDL 
suggests that LDL uptake is via the specific LDL receptor rather than scavenging 
receptors.   
 
6.5.7.2 Ad-MSC and BM-MSC express the LDL receptor 
Gene expression in all Ad-MSC and BM-MSC was within the range demonstrated by 
canine primary hepatocytes (Figure 6.31).




Figure 6.30 DiI-LDL and DiI-Ac-LDL uptake of primary hepatocytes, Ad-MSc and BM-MSC from D17913. 
A-C Primary hepatocytes, D-F Ad-MSC, G-I BM-MSC. A, D, G – DiI-LDL, B, E, H – Dil-Ac-LDL, CFI – control.  Nuclei 
counterstained with DAPI. White scale bar represents 100µm.





Figure 6.31 Relative gene expression of LDL-receptor on canine primary 
hepatocytes, Ad-MSC and BM-MSC. 
Gene expression was normalised to three reference genes. 
 
 
6.5.7.3 LDL receptor expression  
Using an anti-LDL receptor antibody, immunocytochemistry demonstrated the 
presence of the receptor on all three cell types  (Figure 6.32). 
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Figure 6.32 Immunocytochemistry using LDL-receptor antibody on D17913 
primary hepatocytes, Ad-MSc and BM-MSC. 
Strong positive staining was seen in primary hepatocytes (A), Ad-MSC (C) and BM-
MSC (E). Negative controls were performed with the secondary antibody only 
(B,D,F) and no antibody controls (not shown). Nuclei were labelled with DAPI. 
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6.5.8 Human and mouse bone marrow MSC also 
demonstrate LDL uptake and LDL receptor expression 
 
To assess if this finding was a species-specific response, mouse and human BM-
MSC’s were tested for LDL uptake and LDL receptor expression.  
6.5.8.1 Mouse and Human BM-MSC LDL and AcLDL uptake 
As with the canine BM-MSC, both mouse and human MSC’s avidly took up DiI-
LDL but not DiI-Ac-LDL, suggesting the presence of the specific LDL receptor 
(Figure 6.33).  Unlike the canine Ad-MSC and BM-MSC, no isolated cells took up 
DiI-Ac-LDL, likely reflecting that the higher passage number (8 for mouse and 4 for 
human) than the canine MSC’s and therefore loss of other contaminating cell types
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.   
 
Figure 6.33 DiI-LDL and DiI-Ac-LDL uptake of mouse and human MSC 
A-C mouse MSC, D-F human MSC. Cells were cultured in 20µg/ml of DiI-LDL (A, D), DiI-Ac-LDL (B, E) or standard MSC media for 
3 hours. Nuclei were labelled with DAPI. White scale bar represents 100µm. 
Chapter 6: Mesenchymal to hepatocyte differentiation 
 206 
 
6.5.8.2 Mouse and human BM-MSC LDL receptor expression 
Immunocytochemistry using anti-LDL receptor antibody confirmed the presence of 
the receptor on the cell membrane of both mouse and human MSC’s (Figure 6.34). 
 
 
Figure 6.34 Immunocytochemistry using LDL-receptor antibody on mouse and 
human BM-MSC 
Strong positive staining was seen in mouse BM-MSC (A), and human BM-MSC (C). 
Negative controls were performed with the secondary antibody only (B, D) and no 
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6.6 Discussion   
 
6.6.1 Hepatic gene expression and function in 
undifferentiated canine mesenchymal stem cells 
Surprisingly, undifferentiated exhibited some of the characteristics which were 
anticipated to only be present in hepatocytes or differentiated hepatocyte-like cells. 
Specifically, albumin gene expression, LDL uptake and faintly positive PAS staining 
were demonstrated. 
6.6.1.1 Albumin gene expression 
Albumin gene expression is often used as one of the methods of demonstrating 
achieving of hepatocyte-like cells (Snykers et al., 2009a).  During this study, albumin 
gene expression was demonstrated in both undifferentiated canine Ad-MSc and BM-
MSC’s. Albumin gene expression has been demonstrated in the pancreas, kidney, 
bone and microglial cells and is therefore not specific to hepatocytes (Beerheide et 
al., 2002). Albumin synthesis has been documented from bone and microglia (Fanali 
et al., 2012).  Furthermore, PCR and immunofluorescence has demonstrated albumin 
gene and protein expression in human umbilical cord matrix cells, human BM-MSC 
and human Ad-MSC (Campard et al., 2008; Lee et al., 2004; Zemel et al., 2009).   
 
6.6.1.2 LDL uptake 
Uptake of LDL by both undifferentiated Ad-MSC and BM-MSc was another finding 
which was anticipated only to occur after successful hepatocyte differentiation as 
again it is commonly used to demonstrate hepatocyte differentiation.   This was then 
confirmed by demonstrating gene expression of the LDL receptor and also presence 
of the receptor on the cell membrane by immunocytochemistry.  This then 
necessitated removing this test from the assessment of resultant hepatocyte-like cells.   
To assess if this was a species-specific phenomenon, mouse and human MSC’s were 
tested with LDL uptake and anti-LDL receptor antibodies and found to also be 
positive.   
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It has been demonstrated that mouse BM-MSC express LDL-oxidised receptors 
(LOX-1) and take up DiI-oxidised-LDL (the biological analogue to acetylated-LDL) 
and also express LOX-1 by gene expression and Western blot (Zhang et al., 2013a; 
Zhang et al., 2013b).  In the present study, canine Ad-MSC and BM-MSC were 
found not to take up Ac-LDL.  Liesveld et al. (1989) showed that human BM-MSC 
took up DiI-LDL in standard McCoy’s media with 10% FCS, whilst culture in 
McCoy’s’ with 25% serum and 1µmol/L hydrocortisone, this reduced and DiI-Ac-
LDL uptake increased.  Therefore these apparent differences may be an artefact of 
culture conditions rather than a fundamental cellular difference.  Both the mouse and 
human BM-MSC’s were cultured under the conditions recommended by the supplier 
and produced identical results to the canine MSC’s i.e. no DiI-Ac-LDL uptake but 
avid DiI-LDL uptake.   
Finally, in line with the theory that MSC are fibroblast populations, it has been 
demonstrated that fibroblasts express the LDL receptor, take up LDL but not 
modified LDL (Drevon et al., 1981; Gross and Webb, 1986; Haniffa et al., 2009; 
Quaschning et al., 1997; Sasaki and Cottam, 1982).  Therefore in this respect, the 
presence of LDL receptors and specific uptake of LDL on MSC’s is not surprising.  
 
Assessing the effect of culture conditions on LDL receptor expression and the cells 
ability to take up LDL and Ac-LDL would be useful to assess if canine MSC 
demonstrate the same plasticity as human BM-MSC in regard to LDL and Ac-LDL 
uptake.  
 
The presence of albumin gene expression and LDL uptake in MSC’s serves to 
highlight the fact that no one single test or even limited range of tests is adequate to 
demonstrate successful differentiation of cells to a hepatocyte-like state (Hengstler et 
al., 2005).   
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6.6.1.3 Periodic acid-Schiff staining 
Undifferentiated Ad-MSC and BM-MSC appeared to stain with PAS to a similar 
intensity as primary hepatocytes in culture, although no increased expression of 
glycogen synthase was detected by real-time PCR.  It is most likely that staining was 
not specific for glycogen as other polysaccharides and proteoglycans which may be 
produced by mesenchymal stem cells will also stain positive (Rajan and Klein, 
1982).  Indeed although it is uncommon that PAS staining of undifferentiated MSC’s 
are documented, there are previous reports of MSC to hepatocyte differentiation 
where  undifferentiated MSC’s are PAS positive (Prasajak and Leeanansaksiri, 
2013).  To improve the specificity of this stain, pre-treatment of one sample with 
diastase which would depolymerise glycogen and should then give a negative result 
would help guard against non-specific staining (Lee et al., 2004).  
 
6.6.2 Gene expression evidence of transdifferentiation 
Morphologically, both Ad-MSC and BM-MSC demonstrated a change from 
fibroblastic to epithelial in all culture conditions tested. This was most pronounced in 
the BM-MSC’s.  Examination of gene expression markers for mesenchymal and 
epithelial cells showed a down-regulation of vimentin and fibronectin (mesenchymal 
markers) but no corresponding increase in E-cadherin and β-catenin (epithelial and 
hepatocyte markers), suggesting that transdifferentiation was not complete (Schmelz 
et al., 2001).  
 
6.6.2.1 Gene expression evidence of hepatocyte-like cells 
Examination of hepatocyte gene expression also yielded no evidence of up-
regulation after differentiation, the exception being α1 anti-trypsin which was 
increased in BM-MSc after the protocol used in experiment 3. Interestingly, Choi et 
al. (2013), who demonstrated canine amniotic MSC’s ability to express tyrosine 
aminotransferase, α1 anti-trypsin  and albumin after hepatocyte differentiation, also 
differentiated canine BM-MSC which only expressed α1 anti-trypsin.  For both cell 
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types, α1 anti-trypsin is the most convincing band on the documented gel 
electrophoresis.   To temper enthusiasm that the increase in α1 anti-trypsin may be 
the first sign that a hepatocyte-like state may be achieved, Beerheide et al. (2002) 
demonstrated α1 anti-trypsin expression in undifferentiated stem cells.  
 
Therefore, at present, only canine amniotic fluid mesenchymal stem cells have been 
described as demonstrating limited gene expression of hepatocytes after 
differentiation (Choi et al., 2013). This would be consistent with the hypothesis that 
these stem cell sources have a greater differentiation potential than adult stem cell 
sources (Lee et al., 2004). Amniotic MSC’s have been shown to have a higher self-
renewal capacity than adult MSC’s (>300 population doublings versus <25 
respectively) as well as expressing more of an embryonic stem cell phenotype 
compared to adult MSC’s (Joo et al., 2012; Wagner et al., 2008).  
Although successful production of hepatocyte-like cells from MSC’s has been 
described in  many species including human, mouse, rat, pig and horse, there are also 
reports of failed transdifferentiation from healthy human and rat BM-MSC’s  
(Bruckner et al., 2013; Lange et al., 2005a; Snykers et al., 2009a; Snykers et al., 
2007). 
 
6.6.3 Effect of epigenetic modification on hepatocyte 
differentiation 
Two methods were used to try and improve the pluripotent potential of the MSC; 
DNA demethylation using 5AZA and histone hyperacetylation using valproic acid. 
Neither compound appeared to allow hepatic differentiation. 
5AZA concentrations described in MSC to hepatocyte differentiations range from 1-
20µM therefore the concentration utilised (20µM) was at the top of this range 
(Snykers et al., 2009a).  Performance of a DNA methylation assay would have been 
useful to confirm efficacy of 5AZA incubation in these cells (Seeliger et al., 2013). 
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Similarly, although the valproic acid concentration was at the high end of published 
concentrations (2- 5mM), the efficacy may have been documented by Western blot 
or immunofluorescence analysis (Chen et al., 2009; Dong et al., 2013; Kisseberth et 
al., 2008). 
 
6.6.4 Further options to improve transdifferentiation 
efficiency 
6.6.4.1 Epigenetic modification 
Other compounds which should be tested include: trichostatin A (a DNA 
methytransferase inhibitor) which has been demonstrated to dramatically improve 
hepatic differentiation of human BM-MSC’s and also DMSO (a histone deacetylase 
inhibitor) which added towards the end of differentiation enhanced differentiation 
(Seo et al., 2005; Snykers et al., 2007). Finally, it has been suggested that utilising 
both types of compound may improve differentiation efficiency dramatically 
(Snykers et al., 2009b). 
 
6.6.4.2 Culture conditions 
At present, the majority of stem cell to hepatocyte differentiation protocols uses a 2D 
culture system on simple basal substrates (e.g. collagen type I) with solely the stem 
cell to be differentiated present.  In vivo, hepatocytes are in a complex environment 
with diverse surrounding cell types and extracellular matrix (Palakkan et al., 2013).  
Beginning to reconstruct this in vitro improves primary hepatocyte function and 
transferring this same rationale to hepatocyte differentiation of stem cells has proven 
successful (Snykers et al., 2009a). Options for improving differentiation with 
modified culture conditions include the following stratagies; 
6.6.4.3 Co-culture 
Culturing MSC with primary hepatocytes was initially performed to enhance the 
longevity and function of the primary hepatocytes; however, it has since been 
demonstrated that this also improves the differentiation of MSC’s towards a 
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hepatocyte phenotype therefore this may be a useful method (Lange et al., 2005b; 
Mizuguchi et al., 2001; Qihao et al., 2007). 
6.6.4.4 Modification of basal substrate 
Although collagen was used to reduce cell loss during differentiation and is also the 
standard substrate on which primary hepatocytes are cultured, there has been much 
research into different culture substrates with various synthetic and natural substrates 
shown to improve resultant function of stem cell differentiated hepatocyte-like cells 
(Hay et al., 2011; He et al., 2013; Yamazoe et al., 2013). Culture of cells in a 3D 
system or artificial bioreactor has also been shown to improve the efficiency of 
differentiation of stem cells (Nagamoto et al., 2012) 
6.6.4.5 Direct induction  
Introduction of specific transcription factors has been used to directly produce 
hepatocyte-like cells from mesenchymal cells.  Huang et al. (2011) demonstrated that 
mouse fibroblasts could be directly transduced into functional hepatocyte-like cells 
by lentiviral introduction and over-expression of Gata4, Hnf1α, Foxa3 and 
inactivation of p19, which mimics expression during embryogenesis.  These genes 
have been shown to increase during Ad-MSc to hepatocyte differentiation, therefore 
this may be a useful method in the dog (Li et al., 2013a). Manipulation of gene 
expression via over-expression of microRNA (miRNA) has also been utilised in 
hepatocyte production from stem cells (Cui et al., 2013). As miRNA are highly 
conserved between species, an identical protocol may be used in canine MSC. 
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Chapter 7: Production of canine induced 




Induced pluripotent stem cells (iPSC) are adult cells that have been re-programmed 
to return to an embryonic stem cell-like state. These can then be differentiated into 
all cell types and are therefore another potential source of hepatocyte-like cells. This 
chapter discusses the common methods of inducing pluripotency, characterisation of 
the resultant cells and methods of hepatocyte differentiation.  Insertion of a 
polycistronic plasmid containing Yamanaka transcription factors into canine 
epidermal keratinocyte progenitor (CPEK) cells and attempted production of canine 
iPSC is described. Colonies with iPSC compatible morphology, expressing the 
fluorescent protein tag coded by the plasmid, were produced and demonstrated to be 
alkaline phosphatase positive. The presence of plasmid DNA in the cells’ genomic 
DNA was confirmed.  After colony picking, alkaline phosphatase activity was 
reduced, and integration of the plasmid into the genome appeared to be lost.  Using 
real time PCR, no difference in Nanog or Sox9 expression compared to non-induced 
CPEK was found. 
Canine iPSC from parental sources - canine embryonic fibroblasts, bone marrow 
mesenchymal stem cell and adipose-derived mesenchymal stem cells, were then 
differentiated towards hepatocyte-like cells using a published protocol.  The resultant 
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7.2 Introduction 
7.2.1 Induced pluripotent stem cell production 
The first production of induced pluripotent stem cells (iPSC) was described by 
Takahashi and Yamanaka (2006) where four factors, OCT4, Sox2, c-Myc and KLF4 
were inserted into mouse embryonic stem cells and fibroblasts using a lentiviral 
vector.  Overexpression of these factors produced an embryonic stem cell like state.    
One drawback is the very low efficiency of conversion achieved, ~0.1% or below. 
Exogenous gene expression only appears to be required for initial activation of self-
renewal and then is dispensable. This has been demonstrated by using doxycycline 
inducible transgenes confirming that only 10-14 days of expression was required 
(Stadtfeld et al., 2008a).   To be truly fully reprogrammed to a pluripotent state, the 
exogenous factors should be silenced and cells maintain pluripotency by endogenous 
gene expression.  iPSC which still have transgene expression are classed as Class I 
iPSC and are partially reprogrammed, whilst those which are maintained by 
endogenous gene expression with silencing of exogenous genes are defined as Class 
II. Reprogramming is a gradual process and key markers along the process appear to 
be; alkaline phosphatase activation and fibroblast gene silencing, expression of SEA-
1, then silencing of exogenous genes and upregulation of endogenous Oct-4 and 
Nanog (Stadtfeld et al., 2008a). The method of gene delivery affects the probability 
of transgene silencing. Using retrovirus, exogenous gene silencing occurs via 
methylation of DNA whereas constitutively active lentivirus is more likely to 
produce incompletely silenced transgenes, and as a result may prevent differentiation 
(Sommer et al., 2010; Takahashi and Yamanaka, 2006).   
 
Production of iPSC by the lentiviral methods and Yamanaka factors  has since been 
described in a wide variety of species - human, pig, rabbit, horse, dog and snow 
leopard (Breton et al., 2013; Cheng et al., 2012; Takahashi et al., 2007; Tancos et al., 
2012; Verma et al., 2012; Whitworth et al., 2012). 
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There are two major concerns in using this method to induce pluripotency aside from 
low efficiency: 
 c-Myc is an oncogene and teratoma formation is common (Okita et al., 2007) 
 Random integration of multiple transgenes may activate endogenous 
oncogenes and/or cause mutation 
 
As a result, there has been a concerted effort to refine the induction of pluripotency.  
c-Myc was found to be dispensable, but at the cost of reduced efficiency (Wernig et 
al., 2008).   Subsequently, many other factors were discovered which, in combination 
can induce pluripotency; Lin28, Glis1, Esrrb,Tbx3, Utf1(Wang et al., 2013a). 
Substitutes for Oct4 have also been discovered; Cebpa, Hnf4a, Gata3, Gata4, Gata6, 
Grb2, Pax1, and Sox7 (Shu et al., 2013). 
Two main methods of alleviating the problem of insertion of exogenes into the 
genome have been developed – non-integrating methods and developing the ability 
to excise the integrated gene. 
 
7.2.1.1 Non-integrating methods 
Vector based 
Delivery of the factors via adenovirus allowed induction of pluripotency without 
genomic integration, again with greatly reduced efficiency (Stadtfeld et al., 2008b).   
Circular polycistronic plasmids (containing all four factors on one plasmid) have also 
been used as non-integrating methods of induction.  Repetitive transient transfection 
is used to allow expression of the factors for the requisite length of time without 
genomic integration (Gonzalez et al., 2009).  Vectors based on oriP/Epstein-Barr 
nuclear antigen-1(EBNA1) can be maintained in the nucleus under drug selection 
without integrating (Yu et al., 2009).  With these methods, there is still concern that 
vector fragments may still integrate with the host genome (O'Malley et al., 2009). 
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Protein delivery 
A further method of avoiding genomic integration which has been pursued is by 
replacing gene delivery with the resultant proteins.  Purification of Oct4, Sox2, Klf4 
and C-Myc protein and addition to culture media with valproic acid has been used to 
produce iPSC (Zhou et al., 2009).    
 
Micro RNAs 
microRNAs (miRNAs) are non-coding RNAs that bind complementary messenger 
RNA causing degradation or translational silencing.  These were initially used to 
enhance efficiency of iPSC production; however, miRNAs have been used alone to 
produce mouse and human iPSC (Anokye-Danso et al., 2011; Miyoshi et al., 2011).  
 
Chemical -induced pluripotency 
Hou et al. (2013) developed a cocktail of small molecules which acted to re-
programme mouse cells to a pluripotent state thus completely avoiding the need for 
transgene expression. The combination of molecules, which includes valproic acid,  
was found to activate Oct4 and Sox2.  These are thought to be “master” pluripotency 
genes in that they activate other down-stream pluripotency genes.  
 
Stimulus-triggered acquisition of pluripotency (STAP) 
Obokata et al. (2014b) have demonstrated a radical new method of iPSC production 
that did not require exogenous factors.  Exposure of neonatal murine lymphocytes to 
pH 5.4-5.8 for 30 seconds caused Oct-4 expression, subsequent expression of 
pluripotency markers, and the ability to differentiate to the three germ layers and 
produce teratomas in NOD SCID mice.  This conversion was also demonstrated in 
multiple types of differentiated cells. These cells were non-proliferative in standard 
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iPSC media but culture in adrenocorticotropic hormone (ACTH) and LIF allowed 
expansion.   One unique characteristic of these STAP cells compared to ESC and 
iPSC was the ability to differentiate into trophoblast, thus demonstrating 
pluripotency broader than ESC and iPSC (Obokata et al., 2014a). This method would 
avoid genetic manipulation and appears very straightforward.  At present, the method 
has only been proven in immature murine cells therefore it is unknown if the method 
is applicable in adult cells or other species (Smith, 2014). 
 
7.2.1.2 Excisable transgenes 
An alternative route rather than avoiding integration is to have an excisable 
integration site.  To this end, two main vectors have been developed: the Cre/Lox 
and piggy/Bac system (Figure 7.1). 
Cre/Lox system  
LoxP is a 34-base pair which, if present as a pair in a specific orientation on the 
genome, will allow the enzyme cre-recombinase to excise DNA between the two 
LoxP sites.  Kaji et al. (2009) utilised this system in designing a plasmid containing 
all four factors which, after successful re-programming could be excised with a 
separate Cre-recombinase plasmid transfection. This method was successfully used 
to re-programme mouse and human cells.  One disadvantage of this system is that 
excision of the vector is not complete - one LoxP site and DNA external to the LoxP 
sites remain which may act as mutagens.  
Piggy/Bac  
This is a transposon/transposase system which is completely excised leaving no 
residual footprint. These have been used to produce mouse and human iPSC (Kaji et 
al., 2009; Woltjen et al., 2009). 
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Figure 7.1 Methods of factor removal 
Vector with LoxP sits (Black triangles), transient Cre expression removes the 
reprogramming factors with one LoxP and exogenous DNA remaining. (b) piggyBac 
transposons (blue squares) capable of being completely removed with transient 
piggyBac transposase (PBase) expression. Modified from O'Malley et al. (2009). 
 
With both of these systems, cells with minimal copies of the vector need to be 
identified, integration sites mapped, the vector excised and validation of  clones 
being factor-free.  This is time consuming and, as a result, the newer non-integration 




7.2.1.3 Methods of DNA delivery (Transfection) 
The three main methods of nucleic acid delivery which avoid the use of viral vectors 
can be divided into chemical, non-chemical and particle based methods of 
transfection.  
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Particle-based methods 
These methods include the “gene gun” where DNA is attached to gold nanoparticles 
and delivered to the cell nucleus but also magnetic assisted transfection and 
impalefection using nanostructures which are inserted into cells. Particle-based 
methods are not commonly used in iPSC production. 
Chemical-based methods 
These methods include calcium phosphate precipitation of DNA which then allows 
DNA entry to the cell nucleus, branched organic compounds and dextran-bound 
endocytosis of the DNA (Friedmann and Rossi, 2007).   The most commonly 
employed chemical-based method is using liposomes, known as lipofection.  DNA is 
carried in lipid vesicles which merge with cell membranes. This method is relatively 
highly efficient compared to the others (Felgner et al., 1994). 
 
Non-chemical methods 
The majority of these methods result in pores developing in the cell membrane 
allowing DNA entry.  This can be achieved using laser, sonic waves, water, or 
electroporation.  Of these, electroporation is most commonly employed. This 
involves subjecting cells to a high voltage pulse in suspension with the plasmid 
which results in transient cell membrane permeability via pore development, 
allowing the plasmid to enter the cells (Potter, 2001).  
 
7.2.1.4 Transient and stable transfection 
Once plasmid DNA has been delivered into the cell, the majority of it does not 
become integrated into the host cell’s genomic DNA and is only transiently 
expressed whilst the plasmid DNA is present (generally days).  Plasmid DNA is lost 
by degradation or a dilutional effect during mitosis (Kim and Eberwine, 2010).  One 
method of allowing expression for the required length of time is repeated transfection 
Chapter 7: Production of canine iPSC and hepatocyte differentiation 
 220 
with the exogenous DNA (Gonzalez et al., 2009).   Stable transfection occurs when 
the exogenous DNA integrates with the genomic DNA (Figure 7.2).  As a result, 
exogenous integrated DNA is replicated along with genomic DNA during mitosis.  
Selection of the cells can occur if the exogenous DNA contains a resistance gene e.g. 
neomycin resistance which confers geneticin (G418) resistance to plasmid containing 
cells (Southern and Berg, 1982).  
 
Figure 7.2  Transient and stable transfection 
A – Exogenous DNA is integrated into the host cell genome allowing gene 
expression and transfer after mitosis. B – Transient transfection can be carried out 
with either RNA or DNA.  This allows gene expression; however, the exogenous 
nucleotides are either degraded or diluted during mitosis.  
 
7.2.2 Canine induced pluripotent stem cells 
The first report of canine iPSC production was by Shimada et al. (2010), using 
lentiviral transfection with the Yamanaka factors to transfect canine embryonic 
fibroblasts. Post-transfection, cells were cultured on mouse embryonic fibroblasts 
(MEF) in LIF, valproic acid and bFGF containing media.  Additionally, inhibitors of 
mitogen-activated protein kinase (MEK), glycogen synthase kinase 3β (GSK3β) and 
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TGF-β were used.  The resultant cells were shown to differentiate to endoderm, 
mesoderm and ectoderm.   
Luo et al. (2011) reported production of iPSC from canine adult fibroblasts, again 
using lentiviral transfection of the four Yamanaka factors and subsequent culture on 
MEF. Only LIF and bFGF was required to maintain pluripotency. These cells were 
also shown to have the ability to differentiate towards the three germ layers.  A 
comparison between adipose stromal cell and fibroblast derived canine iPSC using 
the same method was also described (Lee et al., 2011).  Canine adipose stromal cells 
were found to have double the reprogramming efficiency of fibroblasts.  
A further report of canine iPSC from adult fibroblasts using lentiviral transfection of 
the Yamanaka factors has been published (Koh et al., 2013).  These cells were both 
LIF and bFGF dependent, along with a requirement for MEK and GSK3β inhibition.  
Whitworth et al. (2012) reported lentiviral production of canine iPSC using the 
Yamanaka factors as well as Lin28 and Nanog.  Interestingly, unlike the previous 
three studies, these cells could be maintained without b-FGF and required only LIF. 
It was hypothesised that this difference was that the solely LIF dependent cells had 
been reprogrammed to an inner cell mass-like ground state.  
One key criticism of the studies describing canine iPSC formation is that teratoma 
formation has been a stumbling block.  Teratoma formation is considered to be the 
gold standard in assessing pluripotency (Zang et al., 2012).   Of the studies so far, 
only Lee et al. (2011) has successfully demonstrated teratoma formation, whilst 
Whitworth et al. (2012) documented occasional tumour formation resembling germ 
cell tumours.  
 
Another point of note is the paucity of reports on directed differentiation of canine 
iPSC to terminally differentiated cells.  At present, there is only one report, utilising 
the protocol of Luo et al. (2011) to produce iPSC which were then differentiated into 
megakaryocytes, producing platelets using a co-culture system (Nishimura et al., 
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2013).  This may reflect instability in maintaining pluripotency once the exogenous 
transgenes have been silenced or continued expression of transgenes blocking 
differentiation.  
 
7.2.3 Differentiation of iPSC to hepatocyte-like cells 
The majority of differentiation protocols follow the main stages of embryonic 
development from pluripotency, to definitive endoderm (DE), foregut endoderm 
(FE), hepatic progenitors and finally mature hepatocytes.  The majority of protocols 
utilize RMPI 1640 and activin A, often with B27 supplement to induce the step to 
DE.  Further differentiation to hepatocytes has been achieved using either RMPI or 
knock-out serum replacement media. Growth factors used for DE to hepatocytes 
include FGF and bone morphogenic protein.  Finally, a maturation step with 
oncostatin M and hepatocyte growth factor is used.   Refinement of protocols has 
achieved up to 90% of cells expressing αfoetal protein (a hepatoblast marker) prior to 
the maturation step.  Although iPSC can be efficiently differentiated towards a 
hepatocyte-like state, the cells are characterised as intermediate between foetal/adult 
rather than mature hepatocytes, with expression of albumin, hepatocyte nuclear 
factor 4a,α1 anti-trypsin, transthyretin, transaminotyrosine and cytochrome P450 
(Gerbal-Chaloin et al., 2014).   Functionality demonstrated after differentiation 
includes glycogen storage, ammonia to urea conversion, cholesterol uptake, albumin 
production, LDL uptake and cytochrome enzyme activity.  In concert with 
differentiation halting at a foetal phenotype, functionality compared to primary 
hepatocytes is greatly reduced (Hannan et al., 2012).  Recently, a 3-dimensional 
collagen matrix was used to produce iPSC-derived hepatocytes which were 
functionally closer to mature hepatocytes than those in 2D culture; therefore, 
improving culture conditions may assist in the final maturation step (Gieseck Iii et 
al., 2014). 
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The addition of Wnt3a at the induction step to DE has also been reported in iPSC to 
hepatocyte differentiation (Chen et al., 2012b).  Wnt signaling during embryogenesis 
is complex. It has been demonstrated that Wnt is required for mesoderm specification 
and that both Wnt and activin are required for primitive streak induction and activin 
for hepatic commitment (Gadue et al., 2006).  Activin and Wnt3a have both been 
shown to be important in hepatic differentiation of both human embryonic and 
induced pluripotent stem cells (Hay et al., 2008; Sullivan et al., 2010).  
At present, there are no reports of hepatocyte-like cell production from canine iPSC.  
 
7.3 Aims 
The aims of this chapter were to produce canine induced pluripotent stem cells using 
the Cre/Lox vector containing Oct4, Sox2, Klf4 and C-Myc created by Kaji et al. 
(2009). This would enable the transgenes to be excised once pluripotency had been 
achieved. Canine iPSC would then be differentiated towards a hepatocyte-like 
phenotype using a published protocol for human iPSC, and the success measured 
using tests validated in Chapter 3 (Chen et al., 2012b).  
 
7.4 Methods 
7.4.1 Plasmid expansion 
The plasmid pCAG2LMKOSimO (Figure 7.1) was gifted by Keisuke Kaji (Kaji et 
al., 2009).  DH5α bacteria (18258-012, Invitrogen) were thawed on wet ice.  After 
mixing, 100µl was placed into a chilled 1.5ml polypropylene tube. A volume of 5ul 
of pCAG2LMKOSimO plasmid was added and the contents gently mixed. The tube 
was then held on ice for 30 minutes, at 42
o
C for 45 seconds, then in ice for 2 
minutes. One ml of Lysogeny broth (LB) was added and the tube shaken at 225rpm 
for 1 hour at 37
o
C. This was then diluted 1:100 with LB also at 37
o
C and 100µl 
spread onto LB agar with ampicillin at 100µg/ml.  Agar plates were cultured 
overnight at 37
o
C.  Plates were examined and single colonies were picked with a 
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200µl pipette tip, transferred to 5ml of LB with 100µg/ml ampicillin and incubated 
for 10 hours before being transferred to 200ml of the same broth, and again 
incubated overnight at 37
o
C.   Plasmid stocks were archived by mixing 800µl of 






Figure 7.3 A - Plasmid map of pCAG2LMKOSimO designed by Keisuke Kaji. B – 
Demonstrating cleavage of protein at 2A linkages. 
Plasmid contains both ampicillin (Amp) and neomycin (Neor) resistance genes. The 
4 pluripotent expression factors are linked by 2A peptides which skip on protein 
translation allowing separation of proteins.  mOrange is a fluorescent protein.  LoxP 
sites flank the transgenes allowing subsequent excision using crea-recombinase.  
 
7.4.2 Plasmid purification 
The LB broth was centrifuged at 4000g for 10 minutes and supernatant removed. 
Plasmid purification from the bacterial cell pellet was carried out using an anion-
exchange column (HiPure plasmid purification kit, Invitrogen) according to the 
manufacturer’s instructions.  Eluted DNA was suspended in 500µl of nuclease-free 
water. Yield and purity were measured using spectrophotometry (NanoDrop 1000, 
Thermoscientific). 
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7.4.3 Culture of canine epidermal keratinocyte progenitors 
(CPEK) 
CPEK were purchased and expanded in in proprietary media (CellnTech advanced 
cell systems, Switzerland).  These were initially seeded at a density of 4 x103/cm
2
.  
These were expanded and passaged at 80% confluence using 0.25% trypsin-EDTA 
(Life Technologies).  
 
7.4.4 Optimisation of CPEK transfection by electroporation 
An Amaxa Nucleofector 2b (Lonza) was used with the corresponding keratinocyte 
nucleofection kit (Lonza).  CPEK were trypsinised and trypsin neutralised with 
media containing 10% foetal bovine serum. Cells were counted and suspended in 
nucleofector solution at a concentration of 1 x10
7
/ml.  Two µg of pmaxGFP per 
100µl of cell suspension was added and gently mixed. 100µl of suspension was 
added to each electroporation cuvette.  Each cuvette was inserted into the 
nucleofector device and programs used were S1, U12, W1, T20, T13 and no program 
control.  500µl of warm culture media was added to each cuvette and each 
transfection transferred to one well of a 6 well plate. Cells were incubated for 24 
hours at 37
o








Chapter 7: Production of canine iPSC and hepatocyte differentiation 
 226 
7.4.5 Linearisation of pCAG2LMKOSimO 
Restriction endonuclease PuvI (New England Biolabs Inc.) was used to linearise the 
plasmid.  The solution (Table 7.1) was incubated at 37
o







NEB Buffer 5µl 
H2O 15µl 
PvuI 5 µl 
Table 7.1 Restriction endonuclease incubation conditions 
 
7.4.6 Gel electrophoresis to confirm linearisation of plasmid 
1.5µl each of linearized and circular plasmid were run in a 0.8% agarose gel with a 
1Kb ladder (1Kb Plus DNA Ladder, Invitrogen) and Gel Red (Biotium) at 80 volts 
for 2 hours.   The gel was imaged under UV (Gel Doc XR+ System, BioRad). 
 
7.4.7 Inactivation of SNL feeder cells 
Confluent SNL feeder cells (Cambridge Biosciences) were inactivated with 
Mitomycin C (Sigma) at a concentration of 10µg/ml for 2 hours at 37
o
C. Cells were 
then washed three times with PBS and dissociated with 0.25% Trypsin-EDTA before 




on gelatine-coated tissue culture dishes as feeder 
cells.  
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7.4.8 G418 kill curve 
CPEK were cultured in 24 well plates and 0, 50,100 µg/ml, then increasing 
concentrations by 100 µg/ml to a maximum concentration of 2000µg/ml of G418 
was added to the culture media.   Media was changed every 3 days and wells 
examined daily to assess cell viability.  
 
7.4.9 Transfection of CPEK with pCAG2LMKOSimO 
1 x10
6
 were transfected with 2µg of pCAG2LMKOSimO vector using program U17 
and W1.  No plasmid and also GFP plasmid sample were used as controls.  After 
transfection, cells were plated onto SNL feeders and after 10 days G418 at the lowest 
concentration which caused complete cell death of untransfected CPEKs was added.   
 
7.4.10 Alkaline phosphatase staining 
Alkaline phosphatase staining was performed using an alkaline phosphatase 
leucocyte kit (Sigma-Aldrich).  Cells were fixed in citrate-acetone-formaldehyde 
solution for 30 seconds at room temperature then rinsed in distilled water.  Freshly 
prepared alkaline dye solution was added for 15 minutes and the wells protected 
from light. A final rinse was performed for 2 minutes using distilled water and well 
examined grossly and microscopically for red/pink positive staining.  
 
7.4.11 Genomic DNA extraction 
Cells were collected by removing media, rinsing in PBS and then using a cell scraper 
to collect cells in 1ml of PBS.  This was transferred to a 1.5ml polypropylene tube 
and centrifuged at 1500rpm for 5 minutes to pellet the cells.  Genomic DNA was 
extracted from cells using DNeasy blood and tissue kit (Qiagen). Genomic DNA 
extraction was carried out according to the manufacturer’s instructions. Yield and 
purity were measured using spectrophotometry (NanoDrop 1000, Thermoscientific). 
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7.4.12 PCR to confirm presence of plasmid 
pCAG2LMKOSimO 
Primers described by Kaji et al. (2009) were used to confirm the presence of plasmid 
DNA in  transfected CPEK genomic DNA (Figure 7.4 and Table 7.2).  
 
Figure 7.4 Diagram of vector demonstrating location of primer annealing 
locations and product size From Kaji et al. (2009). 
Primer Sequence 
IRESmOrange GGCCACAACCATGGTGAGCAAGGGCGAGGA 
BGH R  TAGAAGGCACAGTCGAGG 
Table 7.2 Primer sequence used for plasmid presence in cell genomic DNA 
End point PCR was performed using Qiagen HotStarTaq DNA polymerase and Bio-
Rad iCycler.   Table 7.3 shows reaction components.  An initial denaturation step of 
95
o
C for 5 minutes was followed by 35 cycles of 95
o
C for 1 minute, annealing at 
54
o
C for 1 minute and extension at 72
o
C for 1 minute.  A final extension at 72
o
C for 
5 minutes was performed.  No template controls using distilled water were also run. 
The final reaction solution was run on a 1.5% agarose gel at 80 volts with a 1Kb 
ladder (Invitrogen).  The gel was visualized with UV and the Gel Doc XR+ System 
(BioRad). 
Component Volume per reaction 
PCR buffer 10 µl 
dNTP mix  2 µl 
IRESmOrange 1 µl 










to make 100 µl total 
Table 7.3 PCR mix components 
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7.4.13 Real Time PCR primers optimisation 
Total Sox2 and canine Nanog primers as used by Kaji et al. (2009) and Vaags et al. 
(2009), respectively were used. Efficiency, dissociation curve and product size was 
assessed using transfected CPEK cDNA.  
 
7.4.14 Relative expression of Sox2 and Nanog in 
transfected CPEK clones 
cDNA from transfected CPEK clones and untransfected CPEK was diluted 1:20 and 
qPCR performed as previously described.  Fold increase of Sox2 and Nanog 
compared to untransfected CPEK was calculated using MXPro QPCR software 
(Agilent Technologies, USA). 
 
7.4.15 SNF conditioned iPSC media 
10mls of incomplete iPSC media (Knockout DMEM, 10% ES-grade FBS, L-
glutamine, 100 U/mL Penicillin G and 100 μg/mL Streptomycin, 0.1mM β-
Mercaptoethanol, 1 x non-essential amino acids) was incubated with confluent, 
inactivated SNL cells for 24 hours before removal, filtration with 0.2µ filter and the 
addition of 10ng/ml of human recombinant leukemia inhibitory factor (Millipore, 
USA) and human basic fibroblast growth factor.  
 
7.4.16 Matrigel-coated tissue culture plates 
Reduced growth factor Matrigel (BD Biosciences) was thawed overnight on ice and 
diluted 1:20 in SNL conditioned iPSC media.  Tissue culture plates were coated with 
a volume of 160µl/cm
2
.  Plates were then incubated at 37
o
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7.4.17 Hepatocyte differentiation of iPSC 
Canine iPSC produced by Alison Thompson using a lentiviral polycistronic Cre-
excisable system (SCR511, Millipore) were used for this stage.  Cell lines, Ad-MSC 
4f and BM-MSC 4f were derived from mesenchymal stem cells from d231113 which 
failed to transdifferentiation into hepatocyte-like cells from their mesenchymal state 
(Chapter 6: Mesenchymal to hepatocyte differentiation).  iPSC derived from canine 
embryonic fibroblasts (CEF) using the same system were also differentiated.  
The protocol described by Chen et al. (2012b), based on Hay et al. (2008), was used 
for hepatocyte differentiation (Figure 7.5). Induced pluripotent stem cells (iPSC) 
were passaged from SNL feeder cells at 70% confluence onto Matrigel-coated plates 
using a 1:3 split.  SNL conditioned-media was replaced daily until 60% confluence 
was achieved, upon which the protocol was followed. At time points 0 and 10days, 
cells were harvested for RNA extraction, supernatant in contact with the cells for 24 
hours harvested for albumin and urea quantification, PAS staining and CYP activity 
performed as previously described.  For PAS staining, one well was incubated with 
0.1% w/v diastase for 30 minutes at room temperature to assess specificity for 
glycogen.   Cells were photographed prior to removal from SNL feeders, and at time 
points 0, 3, 6 and 10 days.   
 
Figure 7.5 Protocol for iPSC differentiation to hepatocyte-like cells 
RMPI – Roswell Park Memorial medium, HGF – hepatocyte growth factor, 
KO/DMEM – Knock-out DMEM, NEAA – Non-essential amino acids, βME – 
βMercaptoethanol, IMDM – Iscove’s modified Dulbecco’s medium, OSM – 
Oncostatin M, ITS – Insulin/transferrin/selenium pre-mix. 
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7.5 Results 
7.5.1 Plasmid expansion 
After DNA purification a total yield of 1.4mg of plasmid with a 260/280 absorbance 
ratio of 1.99 was produced.  
 
7.5.2 Plasmid linearisation 
To increase the chances of a stable transfection and also produce a predictable break-
site in the plasmid (which would not disrupt the genes of interest) the plasmid was 
linearised. After incubation with PuvI restriction enzyme for 1 hour to linearise the 
plasmid (Figure 7.6A), equal concentrations of plasmid were electrophoresed on a 
0.8% agarose gel.  This demonstrated almost complete linearisation after digestion 
with a sharp band just above 12Kbp consistent with the plasmid size of 12.9Kbp 
(Figure 7.6B).  The circular plasmid band is less well defined likely due to a 
combination of super-coiling and nicks.  
 
Figure 7.6 pCAG2LMKOSimO plasmid map and gel demonstrating ligation 
A – plasmid map indicating single ligation site with PuvI enzyme. 
B - Electrophoresis of untreated and ligated plasmid.  Linearisation is almost 
complete with band at 12Kbp size.   
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7.5.3 Optimisation of electroporation 
Twenty-four hours after GFP plasmid electroporation, the cells were imaged under 
fluorescent microscopy (Figure 7.7).  A variation in transfection efficiency was noted 
between the different electroporation with programs U17 and W1 giving the most 
GFP positive cells. Both U17 and W1 were then selected to perform transfection 
with the pCAG2LMKOSimO plasmid containing the 4 Yamanaka factors. 
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Figure 7.7 Optimisation of electroporation with GFP plasmid into CPEK cells. 
CPEK cells imaged 24 hours after electroporation. Specific programmess are; A-S1, B-U12, C-W1, D-T20, E-T13. F – no 
electroporation control.  U12 and W1 appeared to give the best transfection efficiency. Experiments performed in triplicates. White bar 
represents 200µm. 
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7.5.4 G418 kill curve 
After 3 days, no viable cells were present at concentration of 800µg/ml and above.    
800µg/ml was then chosen as the effective concentration to select for transfected 
cells.  
7.5.5 CPEK can be successfully transfected with the 
pCAG2LMKOSimO plasmid 
Examination of the cells after electroporation with the pCAG2LMKOSimO plasmid 
and also GFP control plasmid demonstrated lower transfection efficiency compared 
to the GFP control. Figure 7.8 shows cells 24 hours after U17 program 
electroporation however this was identical to the W1 program.   
 
Figure 7.8 Transfection of CPEK with program U17 
A/B – CPEK 24 hours after transfection with GFP plasmid. C/D CPEK 24 hours 
after transfection with pCAG2LMKOSimO plasmid.  Both are demonstrating 
production of their respective fluorescent proteins GFP and mOrange. White bar 
represents 100µm. 
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Ten days after transfection, sparse dense colonies with a three dimensional structure 
were visible only in the cells which underwent U17.  These contained cells which 
contained orange/red fluorescence (Figure 7.9).  
 
 
Figure 7.9 CPEK transfected cells after 10 days culture on feeders 
Representative colonies 10 days after transfection. A&C – phase contrast images, 
B&D – Fluorescent microscopy.  White bar represents 200µm.  
 
G418 was added to the transfected cells at a concentration of 800µg/ml from day 10.  
Untransfected CPEKs were used as a control.  By day 20, dense colonies were still 
present and fluorescent in U17 (Figure 7.10A/B). Some colonies of cells were 
present in W1. No viable cells were present in the control CPEK wells demonstrating 
CPEK susceptibility to this concentration of G418 and resistance of the plasmid-
containing cells (Figure 7.10C).  
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Figure 7.10 CPEK 20 days after transfection and 10 days after G418 addition 
A/B – Transfected CPEK phase contrast and fluorescent microscopy.  
C – untransfected CPEK after 10 days in G418, no viable cells present. White bar 
represents 200µm. 
 
7.5.6 Is there evidence of plasmid integration into the 
genome? 
This was performed at day 20. The presence of plasmid DNA was detected by PCR 
analysis in U17 cells and not W1 cells (Figure 7.11) 
 
Figure 7.11 Electrophoresis gel of products after PCR of genomic DNA from cells 
10 days after undergoing U17 and W1 transfection 
Plasmid was used as positive control (plasmid).  Presence of plasmid DNA in U17 
cells and not in W1 cells.  
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7.5.7 Colonies demonstrate alkaline phosphatase activity 
CPEK cells transfected using the U17 program (day 10) demonstrated strong alkaline 
phosphatase staining of the colonies whilst W1 transfected cells were uniformly 
negative.  Mouse embryonic stem cells, used as a positive control, were strongly 
positive.   
 
Figure 7.12 Alkaline phosphatase staining of CPEK and mouse embryonic stem 
cells 
A- U17 transfected CPEK demonstrating strongly positive colonies. B- W1 
transfected CPEK, alkaline phosphatase negative. C- Mouse embryonic stem cells 
(IOUD2) uniformly positive. White bar represents 10mm.  
 
Twenty individual colonies were picked from the U17 plate and transferred to one 
well each of a 96 well plate.  These were then cultured, expanded and passaged to a 
24 well then a 12 well plate.  6 clones were viable and passaged to this stage. 
Alkaline phosphatase staining was then repeated (Figure 7.13).  This demonstrated 
intense staining of the positive control and a lack of staining of untransfected CPEK 
as a negative control.  The 6 clones showed only very weak staining which occurred 
in the centre of the colonies.  
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Figure 7.13 Alkaline phosphatase staining on mouse embryonic stem cells and 
picked transfected CPEK clones.  
Alkaline phosphatase staining highly positive in mouse ESC (positive control) and 
negative in untransfected CPEKs (negative control).   
 
The clones were further expanded and transferred to 6 well plates.  Clones1-3 and 6 
reached this stage whilst clones 4 and 5 failed to continue expanding.  
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7.5.8 Nanog and Sox 2 primer efficiency 
Primer efficiency, dissociation curve and gel size was acceptable (Table 7.4).  










Sox2 F- ACAGCTACGCGCACATGA  
R- GGTAGCCCAGCTGCTCCT 
69 95.5 59.7/61.09 √ √ 
Nanog F- CCTGCATCCTTGCCAATGTC 
R- TCCGGGCTGTCCTGAGTAAG 
98 99.6 59.54/60.9 √ √ 
Table 7.4 Sox2 and Nanog primer sequence and characteristics 
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7.5.9  Picked colonies do not exhibit Nanog and Sox2 
expression or have genomic plasmid integration 
Real time PCR was performed to assess Nanog and total Sox2 expression compared 
to untransfected CPEK cells (Figure 7.14). 
No difference in Sox2 (plasmid or endogenously expressed) or endogenous Nanog 
expression was noted in the remaining clones. Furthermore, no evidence of plasmid 
integration was detected in the genomic DNA of the remaining clones. Examination 
of the clones under fluorescent microscopy could not detect any orange fluorescence 















Figure 7.14 Fold change of relative gene expression compared to untransfected 
CPEK cells and plasmid integration in picked colonies.  
A - Nanog and Sox2 gene expression normalized to two reference genes (B2MG, 




As alkaline phosphatase activity and plasmid integration appeared to have been lost, 
induced pluripotent stem cells derived using lentiviral transfection with a 4 factor 
plasmid, produced and characterised by Alison Thompson and Ruchi Sharma in the 
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group were used for the hepatocyte differentiation experiments.  Cre excision of the 
transcription factors had not been performed.  
 
7.5.10 Canine iPSCs can be differentiated into 
hepatocyte-like cells  
7.5.10.1 There is morphologic evidence of hepatocyte-like cells 
After dissociation from feeder cells and plating onto Matrigel, all three cell types 
assumed a mono-layer formation (Figure 7.15 B, F, and J).  Cell attachment on the 
feeders was weak and this continued on Matrigel, leading to cell loss during media 
change. At the final day of maturation, the Ad-MSC iPSC had assumed compact 
round cell morphology, with BM-MSC iPSC exhibiting morphology most consistent 
with a hepatoblast, namely epithelioid polygonal cells with a moderate cytoplasm to 
nucleus ratio and obvious demarcations between cells (Figure 7.16).  The CEF iPSC 
morphology appeared midway between the other two cell types. 
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Figure 7.15 Morphology of iPSC to hepatocyte differentiation 
Time points from left to right – Colonies on SNL feeder cells prior to differentiation, 24 hours after dissociation and plating on Matrigel, 
Day 3 of differentiation, Day 10 – final time point.  A-D Ad-MSC iPSC, E-H BM-MSC iPSC, I-L CEF iPSC. White bar represents 
50µm. 
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Figure 7.16 Higher magnification of iPSC to hepatocyte differentiated cell morphology at day 10 
A- Ad-MSC iPSC, B –BM-MSC iPSC, C-  CEF iPSC. White scale bar represents 50µm.
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7.5.10.2 All cells exhibit increased hepatocyte gene expression 
after differentiation 
An increase in cytochrome gene expression was noted in all three cell types after 
differentiation (Figure 7.17). Increases were also noted in albumin, keratin 18, 
glycogen synthase, LDL receptor, transthyretin and α1 anti-trypsin. αfoetal protein 
was increased in CEF and Ad-MSC4f cells. When analysed for significance, a broad 
range of genes were significantly increased by the differentiation protocol in all cell 
types (Table 7.5).  
 
 




Figure 7.17 qPCR analysis of iPSC to hepatocyte differentiation 
K7 – Keratin 7, K18 – Keratin 18, GlyS – Glycogen synthase. 
 
 




Figure 7.18 PCR analysis of iPSC to hepatocyte differentiation 
LDL – Low density lipoprotein receptor, AFP – α Foetal protein, TTR – transthyretin, 
a1AT – α1 anti-trypsin 
Chapter 7: Production of canine iPSC and hepatocyte differentiation 
 248 
Cell Type Gene p value 
Ad-MSC iPSC albumin 0.019 
 Keratin 18 0.028 
 α1AT  0.019 
 Glycogen synthase 0.019 
 Low density lipoprotein 
receptor 
0.019 
BM-MSC iPSC   
 Cyp3A12 0.003 
 Cyp3A26 0.05 
 Cyp2D15 0.011 
 Albumin 0.036 
 Keratin 18 <0.0001 
 TTR 0.036 
 Glycogen synthase <0.0001 
 Low density lipoprotein 
receptor 
0.036 
CEF iPSC   
 Cyp1A2 0.024 
 Cyp2B11 0.034 
 Cyp2D15 0.034 
 Albumin 0.013 
 Keratin 18 <0.0001 
 α1AT 0.013 
 Glycogen synthase 0.037 
 Low density lipoprotein 
receptor 
0.037 
Table 7.5 Significant gene increases after hepatocyte differentiation 
 
7.5.10.3 Cells only demonstrate non-specific PAS staining 
In the undifferentiated cells, both diastase and non-diastase cells demonstrated the 
same level of mild staining, indicating that this was non-specific (Figure 7.19).   On 
staining the differentiated cells, cell loss during the staining made examination of 
cells difficult; however, no obvious difference in staining intensity was noted 
between diastase treated/untreated cells. 
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Figure 7.19 Periodic acid Schiff staining of iPSC before and after hepatocyte differentiation 
Ad-MSC iPSC day 0, diastase pretreatment (A), no diastase (B), final time point diastase pretreatment (C), no diastase (D). BM-MSC 
iPSC day 0, diastase pretreatment (E), no diastase (F), final time point diastase pretreatment (G), no diastase (H). CEF iPSC day 0, 
diastase pretreatment (I), no diastase (J), final time point diastase pretreatment (K), no diastase (L). All images x200. 
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7.5.10.4 Cells do not demonstrate CYP activity 
Cytochrome P450 activity was low at all-time points and no significant difference 
was noted after phenobarbital incubation (Figure 7.20).  The counts detected are 
likely to be background.  Negative counts are due to values being below blank 
measurements.  
 
Figure 7.20 CYP activity of iPSC before and after hepatocyte differentiation. 
Basal activity was measured at time point 0 and day 10 (0 & final) as well as after 







Chapter 7: Production of canine iPSC and hepatocyte differentiation 
 251 
7.6 Discussion 
7.6.1 The polycistronic vector was successfully transfected 
into CPEK cells 
The plasmid was successfully expanded in competent E.coli cells, plasmid-
containing cells cryopreserved, and a significant quantity was purified for subsequent 
use.  Using the PuvI restriction endonuclease the plasmid was successfully efficiently 
ligated. 
Using the control GFP plasmid, electroporation of the CPEK cells could be reliably 
performed with viable cells subsequently expressing GFP protein as demonstrated by 
fluorescence. The efficiency of transfection appeared lower using the 4 factor 
plasmid containing mOrange compared to the GFP control.  In part, this may be due 
to the fact that plasmid quantification for transfection was based on weight rather 
than copy number.  As the GFP control plasmid was approximately one quarter the 
size of the experimental plasmid (3468bp and 12939bp respectively), this would 
have meant that the transfection containing the experimental plasmid would contain a 
quarter of the amount of plasmid compared to the control.  It has also been 
demonstrated plasmid size is inversely correlated with transfection efficiency (Yin et 
al., 2005).  Finally, the experimental plasmid was linearised and control plasmid was 
not.  Linearisation has been shown to reduce transfection efficiency, however it was 
chosen for the advantage of ensuring the integrity of the genes to be delivered 
(Stuchbury and Munch, 2010). 
Successful plasmid transfection and protein expression is evident in the U17 cells. 
Fluorescent cells were present 24 hours after transfection, consistent with mOrange 
expression and these colonies were resistant to G418 addition.  PCR analysis at day 
20 confirmed the presence of plasmid DNA in the U17 cells.  Considering the cells 
which underwent W1 transfection, an equal number were seen to be fluorescent 24 
hours after transfection however this was not sustained.  It is possible that cells 
successfully transfected using W1 were either compromised by a combination of the 
program and plasmid insertion, out-competed by untransfected cells or transient 
transfection lost at an early stage.  PCR analysis at day 20 failed to detect the plasmid 
in remaining W1 cells.  
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7.6.2 The transfected cells did show signs of pluripotency 
Consistent with the above findings, the morphology of colonies produced after U17 
transfection is similar to that described for mouse iPSC, namely 3-dimensional 
domed colonies (Robinton and Daley, 2012).  These colonies also demonstrated 
strong alkaline phosphatase staining of similar intensity to the positive control of 
mouse embryonic stem cells. Conversely, untransfected CPEK and remaining W1 
cells showed no alkaline phosphatase staining.  
After colony picking from U17 and expansion, the remaining colonies changed 
morphology, becoming flattened, more consistent with human iPSC (Robinton and 
Daley, 2012).  Alkaline phosphatase staining was much weaker with the majority of 
cells appearing negative. End point PCR also failed to detect the presence of plasmid 
DNA in the expanded picked colonies.  Real time PCR demonstrated no upregulation 
of Sox-2 gene expression, either exogenous or endogenous, compared to 
untransfected CPEKs, confirming the lack of expressed expression factors or 
conversion to a pluripotent state.  Finally, no up regulation of Nanog, a key 
expression factor which would produce fully re-programmed cells, was detected in 
the remaining clones (Silva et al., 2009). 
Therefore from the data, although a successful transfection was documented, the 
plasmid appeared to have been lost between expansion of the initial transfection and 
expansion of selected colonies. Transformation of cells to a pluripotent state by 
reprogramming is estimated to take between 10-14 days and partial reprogramming 
may occur (Rodolfa, 2012).  It is of note that strong alkaline phosphatase staining, a 
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Possible explanations for this loss are: 
 Plasmid did not integrate into genomic DNA  
Rather than a stable transfection being achieved, a transient transfection was present 
where transcription occurred temporarily until the plasmid was lost/degraded.  
Although PCR of genomic DNA demonstrated the presence of the plasmid, DNA 
extraction would also have isolated plasmid DNA therefore this did not confirm a 
stable transfection.    During colony picking it is possible that only transiently 
transfected cells were picked.  Transient transfection may have been enough to 
initiate the process of pluripotency, as demonstrated by the change in morphology 
and alkaline phosphatase activity.  As the plasmid was lost this may cause the cells to 
revert to a differentiated state as evinced by the subsequent change in morphology 
and loss of alkaline phosphatase staining. 
 
 Integration was achieved then silenced/lost 
It is possible that the exogenous genes were silenced by methylation or insertion into 
inactive heterochromatin (Adamson et al., 2011). This is less likely as a positive 
result would still be expected using genomic DNA PCR analysis.  
 
 Selection pressure was insufficient to kill untransfected cells 
The kill curve was performed on untransfected CPEKs grown on tissue culture 
plastic whilst selection was on CPEK’s on SNL feeder cells which also contain the 
neomycin resistant gene. It is possible that this changed the susceptibility of the cells 
to G418, making CPEKs more resistant. An additional possibility is that the presence 
of the plasmid in transfected cells might have had an inhibitor effect on them 
compared to untransfected cells. As a result, non-transfected cells may have been 
picked.    
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7.6.3 Options for improving the outcome on subsequent 
experiments  
 Increasing plasmid copy number at transfection 
 Performing  a G418 kill curve of CPEKs on SNL feeder cells 
 Using G418 selection for a longer time period and/or earlier after transfection 
 For monitoring, other markers of early pluripotency could be assessed such as 
SEA-1, could be assessed during expansion (Stadtfeld et al., 2008a). 
 
7.6.4 Canine iPSCs can be differentiated towards 
hepatocyte-like cells 
During differentiation, the morphology of all three cell lines changed towards a 
monolayer with defined cell-cell boundaries.  Of the three lines, the BM-MSC iPSC 
exhibited the greatest transition to hepatocyte morphology with polygonal rather than 
rounded cells.  The cytoplasm to nucleus ratio was much less than expected in 
mature primary hepatocytes.  This change to morphology consistent with hepatocytes 
was mirrored in gene expression. At present no proof of function of these cells was 
found from glycogen storage or CYP activity.  The lack of glycogen staining was 
difficult to assess due to cell loss during culture and subsequent staining, however no 
convincing evidence of glycogen storage was detected.  This was despite significant 
upregulation of glycogen synthase gene expression after differentiation in all cell 
lines.  Similarly, no cytochrome functional activity was detected, although a 
significant increase in Cyp3A12 and 3A26 (the specific enzymes required for this 
luciferase assay) was only noted in the Ad-MSC iPSC.  Cell loss and resultant low 
cell density made albumin and urea measurement in the supernatant impossible. 
 
The iPSC used were still expressing the transfected pluripotency genes Oct4, Sox2, 
Klf4 and C-Myc and would thus be class II iPSC (Ruchi Sharma, Personal 
Communication 2014).  As pluripotency genes were delivered by a lentivirus, the 
exogenous genes which integrate are less likely to be naturally silenced than by 
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retroviral delivery (Stadtfeld and Hochedlinger, 2010).  The continued expression of 
these pluripotency genes may pose a block to differentiation.  Despite this, 
convincing phenotypic change towards hepatocytes was achieved in all three cell 
lines. 
 
7.6.5 Strategies for improving differentiation capacity 
Although it can be stated a hepatocyte-like phenotype was achieved, a key goal was 
to produce functional hepatocyte-like cells, specifically with cytochrome P450 
activity. Using this protocol, although CYP gene expression increased, no 
cytochrome activity was detected.   This experiment was a promising start and there 
are many avenues that can be explored to improve phenotype and function. 
7.6.5.1 Removal of transgene transcription factors 
As continued expression of transgenes can reduce the differentiation capacity of the 
iPSC, removal of the transgenes using Cre-recombinase would likely enhance the 
differentiation capacity.  
7.6.5.2 Alternative protocols 
The protocol chosen for hepatocyte-directed differentiation is described as a “rapid 
protocol” and used human induced pluripotent stem cells (Chen et al., 2012b). The 
resultant cells were demonstrated to be functional in vitro by positive PAS staining, 
LDL uptake, cytochrome activity and urea secretion.   There are a multitude of 
protocols described for generation of hepatocyte-like cells, with the majority 
describing a longer duration than the Chen study e.g. Roelandt et al. (2013) 25 days, 
Duan et al. (2010) 19-31 days, Roelandt et al. (2013) 28 days.  Therefore utilizing a 
longer protocol may allow development of a more mature hepatic phenotype 
including CYP activity and glycogen storage.  
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7.6.5.3 Culture substrates 
These include 3D culture system with collagen matrix and alginate scaffolds which 
significantly improved function and longevity compared to 2D culture (Gieseck Iii et 
al., 2014; Ramasamy et al., 2013).   Also synthetic polymers have been developed 
which improve hepatic phenotype of differentiated pluripotent stem cells (Hay et al., 
2011).  
 
7.6.5.4 Co-culture systems 
Javed et al. (2014) recently described co-culture of iPSC embroid bodies co-cultured 
with hepatic stellate cells whilst Nagamoto et al. (2012) utilized Swiss 3T cells (a 
fibroblast cell line).  It is thought that these cells secrete additional growth factors 
which enhance hepatic maturation. 
More complex 3D co-culture systems combining iPSC-derived hepatocyte-like cells, 
mesenchymal stem cells and endothelial cells have been successful in forming an 
“organ bud” , demonstrating hepatic functions, which then vascularized in 
immunodeficient mice (Takebe et al., 2013; Takebe et al., 2014). 
 
At a more basic level, the iPSC lines and especially BM-MSC and CEF-derived lines 
were very poorly adherent in culture and as a result, many cells were lost during 
differentiation, limiting especially the tests of function. Methods of maintaining cell 
numbers such as trapping cells in a Matrigel overlay could be investigated. A high 
confluence has been reported to improve differentiation and therefore simply 
maintaining cell numbers may improve differentiation (Cai et al., 2012). 
 
The Ad-MSC iPSC and BM-MSC iPSC were originally derived from mesenchymal 
stem cells which failed to transdifferentiate to hepatocyte-like cells from their 
mesenchymal state.  This demonstrates that re-programming with Oct4, Sox2, Klf4 
and C-Myc increased the differentiation capacity of these cells.   
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7.7 Summary 
 A polycistronic vector containing the 4 Yamanaka factors could be 
successfully transfected into CPEK. 
  These cells demonstrated early markers of pluripotency namely consistent 
morphology and alkaline phosphatase activity.  
 During single colony expansion alkaline phosphatase activity was lost.  
 Three lines of canine iPSC were successfully differentiated towards a 
hepatocyte-like phenotype based on morphology and gene expression.     
 No hepatocyte function has been demonstrated at present.    
 This is the first demonstration of production of canine hepatocyte-like cells 
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Chapter 8: Conclusions and future perspectives 
 
8.1 Introduction 
The aim of this thesis was to produce an in vitro source of functional hepatocytes 
from stem cell sources. The fact that primary hepatocyte cultures do not expand in 
vitro and lose function rapidly, combined with poor recovery after cryopreservation, 
means that a constant supply of hepatic tissue from research animals is required for 
this resource. Differentiation of stem cells to hepatocytes would provide potentially 
an inexhaustible supply of functional hepatocytes.  This resource would have a major 
impact, allowing the replacement or reduction of animals used in research, a key 
objective in the science community (http://www.nc3rs.org.uk/). 
8.1.1 Primary canine hepatocyte cultures 
To achieve this aim, what would constitute a canine hepatocyte in vitro had to be 
defined and a panel of tests developed. The question as to what would be adequate 
demonstration of hepatocyte-like cell has been discussed in the literature (Hengstler 
et al., 2005; Sancho-Bru et al., 2009; Zhang et al., 2013). No single test is sufficient 
and both gene expression and functional assays are recommended.  In particular, and 
crucially for drug metabolism studies, demonstration of cytochrome P450 activity is 
important. To validate potential tests, in vitro canine primary hepatocyte cultures 
were produced using hepatic tissue from recently euthanased dogs.  With these, a 
panel of primers to assess gene expression were developed along with tests of 
functionality; albumin secretion, glycogen storage and cytochrome P450 activity.   
To further characterise the differentiation pathway of stem cells to hepatocyte-like 
cells, the ability to assess gene expression at the definitive endoderm stage would be 
useful, for example Sox17 (Sancho-Bru et al., 2009).  One hurdle was the lack of 
canine cDNA from definitive endoderm and hepatic progenitor cells with which to 
validate primer efficiency and specificity.  Adult hepatic tissue was used; however, 
only αfoetal protein and keratin 7 expression was present in sufficient quantity to 
allow primer validation. Material from foetal endoderm and hepatic tissue would 
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allow primer optimisation so that this crucial stage could be assessed during 
differentiation.  
 
One test which is widely described in stem cell to hepatocyte research was found to 
be unreliable, at least in canine primary hepatocyte cultures.  The in vitro 
indocyanine green (ICG) uptake and subsequent excretion test, which appears to 
have arisen in the field of stem cell to hepatocyte research rather than from primary 
hepatocyte cultures, was assessed.  The majority of canine hepatocytes failed to 
demonstrate ICG uptake and those that did were found to be dead. These cells also 
subsequently appeared to lose staining intensity presumably by diffusion.  Therefore 
this test was not thought to be specific for canine hepatocyte function and not 
included in the final panel of tests.   It is unknown if this represents a species-specific 
idiosyncrasy or is a fundamental problem with this in vitro test.  Previous papers 
which show images of ICG uptake and subsequent excretion range from convincing 
demonstrations with primary hepatocytes as a positive control (Takayama et al., 
2012), to images which may be ICG staining of dead cells and debris (Zamule et al., 
2011). The fact that ICG has been demonstrated to be cytotoxic in its own right 
further complicates this finding (Balaiya et al., 2011; Kawahara et al., 2007).  
Evaluation of ICG uptake in primary hepatocyte cultures of other species, especially 
human and mouse, would be useful to assess if ICG uptake is truly a valid test in 
other species.  
 
Another test which is commonly employed in differentiation of stem cell to 
hepatocyte-like cells is low density lipoprotein uptake.  As stated in chapter 3, LDL 
and acetylated LDL appear to be used interchangeably despite these compounds 
being endocytosed via different receptors. Unequivocally canine primary hepatocytes 
took up native LDL rather than acetylated LDL.  This appeared to be a useful 
functional test of hepatocyte phenotype until undifferentiated adipose and bone 
marrow mesenchymal stem cells were also demonstrated to endocytose LDL. The 
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presence of the LDL receptor on primary hepatocytes as well as Ad-MSC and BM-
MSC was confirmed by gene expression and also immunocytochemistry.  
Commercial BM-MSC from the mouse and human were purchased and also 
demonstrated to endocytose LDL and express the LDL receptor.  Previous 
researchers have shown LDL receptor expression on human BM-MSC as well as a 
body of evidence of LDL receptor expression on fibroblasts.  Therefore LDL uptake 
is not specific for hepatocyte function and invalid for mesenchymal to hepatocyte 
transdifferentiation (Drevon et al., 1981; Gross and Webb, 1986; Haniffa et al., 2009; 
Liesveld et al., 1989; Quaschning et al., 1997; Sasaki and Cottam, 1982).    
 
At present only one method of cytochrome P450 activity has been validated namely 
the Promega Pro-Glo PFBE-Luciferase assay.  This is catalysed by human and 
murine Cyp3A4. The isoenzymes in the dog are Cyp3A12 and 3A26.  It is 
anticipated that the assay would measure enzymatic activity of these specific 
isoenzymes however this in unknown as differences between species in substrate 
specificity and affinity are recognised (Martinez et al., 2013).   Additionally, relative 
gene expression of Cyp3A12 and Cyp3A24 is much lower in the canine liver than 
Cyp3A4 is in the human liver (Martinez et al., 2013).  Therefore further tests to 
expand the range of Cyp activity would be useful.  This could include measurement 
of drug metabolites by high performance liquid chromatography, or investigating 
other compounds which produce fluorescence after Cyp metabolism e.g. production 
of resorufin from ethoxy-, methoxy-, pentoxy- and benzyloxyresorufin which can 
then be measured using a standard plate reader (Sakai et al., 2010; Walsky and 
Obach, 2004). 
Using the validated tests, the rapid decline in primary hepatocyte gene expression 
and function in vitro was noted.  Culture of hepatocytes with Matrigel overlay 
improved total cell number viability but not gene expression or function.  This rapid 
decline in function is well documented in other species, such that tests of hepatocyte 
function such as drug metabolism are recommended only in the initial 72 hours.  
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One area of further study would be optimising culture conditions to maintain primary 
hepatocyte cultures for longer. Despite primary hepatocyte cultures having been 
described for over 40 years, optimisation of culture systems has received little 
attention until recently.  This is likely to be a combination of increased emphasis on 
reducing the number of animals used in research and also the development of 
bioartifical liver devices (BAL) which utilise primary hepatocytes in large numbers 
to provide bridging support for human patients with acute liver disease and awaiting 
transplant (Struecker et al., 2013).  Improving the lifespan of the primary hepatocytes 
in this situation vastly reduces the cost of these devices (Shulman and Nahmias, 
2013). It would be anticipated that optimised conditions for canine primary 
hepatocytes would also be likely to improve function of stem cell derived 
hepatocyte-like cells.  Strategies to optimise primary hepatocyte culture can be 
broadly divided into three categories; media formulation, substrate/matric and co-
cultures. 
 
8.1.2 Media formulation 
Different culture media has been demonstrated to have a significant impact on 
primary hepatocyte function (Nelson et al., 2013).   This would be a useful initial 




8.1.3.1 Two- dimensional cultures 
Although collagen type I is most commonly employed in primary hepatocyte 
cultures, other substrates have been recommended. Matrigel overlay only improved 
viability and not function in this study, however it is reported to enhance gene 
expression in human hepatocytes (Page et al., 2007).  Equally, collagen sandwich 
overlay has been shown to improve function in rat hepatocytes (Dunn et al., 1992; 
Tuschl et al., 2009).  Conversely, Nelson et al. (2013) demonstrated that matrix-free 
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culture of porcine hepatocytes maintained good morphology and function, therefore 
optimum conditions cannot necessarily be predicted between species.  Therefore 
assessing different matrix substrates would help define optimum conditions for 
canine hepatocytes.  
 
8.1.3.2 Three dimensional cultures 
The above culture conditions would continue to utilise 2D culture techniques.  As 
discussed in Chapter 3, these conditions are inherently different from in vivo 
hepatocyte conditions where cell to cell contacts are three dimensional and a 
heterogeneous cell population is in intimate contact with the hepatocytes.   
Hepatocytes depend on cell attachment to maintain function. Various techniques 
have been described based on artificial and natural biological matrixes (Godoy et al., 
2013). There are three main 3D culture techniques; hydrogels, synthetic scaffolds 
and hepatospheres.  These all have inherent advantages and disadvantages but are an 
improvement on 2D culture systems. Commercially available polystyrene scaffold 
“Alvetex ™” (Reinnervate, Co Durham) supports 3D culture of primary hepatocytes 
however, polymers could be screened to assess if canine hepatocytes retain function 
on a specific substrate (Hay et al., 2011).  
 
8.1.3.3 Co-culture systems 
As the liver comprises a heterogeneous cell network, co-culture systems have been 
reported which used various cell types. This could be easily investigated with 
expertise and ability to culture the second cell type available within the research 
group. Co-culture with mesenchymal stem cells has been demonstrated to improve 
hepatocyte function and this would utilise the cell isolated in Chapter 5  (Fitzpatrick 
et al., 2013; Yang et al., 2013).  Endothelial cell co-culture prolongs rat hepatocyte 
function (Kang et al., 2013; Kim et al., 2012).  Canine endothelial cells are routinely 
isolated from vascular endothelia, readily cryopreserved and are available for co-
culture.  
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Co-cultures and 3D systems can be combined into more complex systems such as has 
been described by Takebe et al. (2013).  In this study, iPSC-derived hepatocytes, 
endothelial cells and mesenchymal stem cells were co-cultured.  This mix of cells, 
despite being plated in 2D, formed a 3D “liver bud” which then vascularised and 
became functional when implanted into NOD/SCID mice. Ultimately the aim would 
be to perform this using a canine stem-cell source of hepatocyte-like cells; however, 
optimising and demonstrating proof-of-concept using primary hepatocytes would be 
a useful exercise.   
 
8.1.4 Hepatic progenitor cells 
Cells morphologically consistent with hepatic stem cells and hepatoblasts were 
successfully isolated. Using MACS for CD133 produced colonies which expanded 
on initial plating.  The intermittent availability of primary tissue along with difficulty 
in passaging cells meant that optimum conditions for expansion were not completely 
defined.  Despite this, from the experiments, it appears that these cells require 
mechanical passaging, co-culture and laminin substrate.  This is similar to what has 
been described for human HpSCs.  One key hurdle is the low number of HPC in 
healthy tissue.  Isolation of HPC in other species often starts with induction of liver 
injury to stimulate proliferation of HPC.  This would only be possible using 
experimental animals.  Reports that mature hepatocytes de-differentiate into hepatic 
progenitor cells are intriguing and could be the source of the HPC colonies detected 
in this case (Chen et al., 2012; Krause et al., 2013).  Longer term culture of mature 
canine primary hepatocytes would assess if these could yield a population of HPC 
and therefore circumvent the problem of low density in hepatic tissue.  This could 
potentially allow a larger quantity to optimize culture conditions.  
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8.1.5 Canine mesenchymal stem cells 
Canine adipose-derived and bone marrow-derived mesenchymal stem cells could be 
repeatedly isolated and demonstration of their capacity to differentiate into 
mesenchymal tissues achieved.  Although adult Ad-MSC and BM-MSCs from a 
variety of species have been successfully differentiated towards hepatocyte-like cells, 
this was not achieved.  The one other report describing differentiation of canine 
MSCs to hepatocyte-like cells used both amniotic MSC and BM-MSC (Choi et al., 
2013).  Expression of pluripotency genes Oct4 and Sox2 was only detected in the 
amniotic cells and Nanog expression was much higher in the amniotic cells.  
Characterisation of the subsequent cells was limited and based on gene expression. 
Only α1-AT was expressed by the differentiated BM-MSC, which was also seen 
using the day 50 protocol in the current study.  The amniotic MSC’s expressed α1-
AT, albumin and tyrosine aminotransferase.  It is thought that amniotic mesenchymal 
stem cells have greater pluripotency which is backed up by the increased expression 
of pluripotency genes compared to the BM-MSC.   
Methods of improving the pluripotent potential of the MSC were used, namely DNA 
demethylation using 5AZA and increasing histone acetylation using valproic acid.  
These demonstrated no advantage.  The efficacy of these compounds in achieving the 
desired end result should be assessed.  Methylation status before and after 5AZA 
treatment may be assessed via PCR (Hernandez et al., 2013).  Similarly, the effect of 
valproic acid on histone deacetylase I expression could be evaluated using 
immunocytochemistry (Kurihara et al., 2014). 
If canine amniotic mesenchymal stem cells became available, comparing these to the 
Ad-MSC and BM-MSCs would be useful to assess if they had increased capacity to 
differentiate towards hepatocytes.    
8.1.6 Canine iPSC to hepatocyte-like cells 
 Although the iPSC used for differentiation towards hepatocyte-like cells were not 
fully reprogrammed i.e. the continued expression of transgenes, an increase in 
hepatocyte gene expression was seen in all three cell lines.  Morphology of the cell 
lines was variable, with the BM-MSC iPSC achieving the morphology of small 
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hepatocytes. The large amount of cell loss due to poor adherence prevented 
functional testing apart from cytochrome P450 activity therefore subsequent 
experiments will assess methods of reducing cell loss.  Alternative differentiation 
protocols, perhaps involving a longer time scale would also be assessed as these may 
result in an improved hepatocyte phenotype. When fully reprogrammed canine iPSC 
become available it is likely that these will have improved differentiation capacity 
due to silencing of the pluripotent transgenes.  
 
Ultimately, if canine functional hepatocyte-like cells are derived from stem cells 
sources, assessment of the ability of these cells to produce canine albumin in 
NOD/SCID mice or rescue animal models of liver dysfunction would be the next 
step in demonstrating a hepatocyte-like phenotype. 
 
8.2 Summary 
The work in this thesis has generated a primary hepatocyte culture system and 
methods of assessing hepatocyte phenotype in vitro that can be used to optimise the 
function and lifespan of canine primary hepatocytes in vitro. In addition, the isolation 
and characterisation of canine mesenchymal stem cells opens up the option of co-
culture systems.  Results of this would be a useful basis for maintaining the 
hepatocyte phenotype in hepatocyte-like cells derived from stem cell sources. From 
the stem cell sources investigated the class I canine iPSC displayed gene expression 
compatible with differentiation towards hepatocytes.  Additional research to improve 







Appendix 1 Digestion/Perfusion buffers 
Chelation Buffer 
490ml Earle’s Balanced Salt Solution without Calcium or Magnesium (Invitrogen, 
UK) 
10ml 25mM EGTA, pH 7.4 (Sigma-Aldrich, UK) 
 
Collagenase Buffer  
100ml Earle’s Balanced Salt Solution without Calcium or Magnesium (Invitrogen, 
UK) 
200µL 1M Calcium chloride 













Appendix 2: Hepatocyte isolations 
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Appendix 3: Kubota’s medium 
500mls RPMI (Invitrogen,UK) 
0.5g Bovine serum albumin (Sigma-Aldrich, UK) 
270mg Niacinamide (Sigma-Aldrich, UK) 
2.5mg Insulin (Gibco, UK) 
5mg Transferrin (Sigma-Aldrich, UK) 
L-Glutamine (Invitrogen,UK) 
100 U/mL penicillin G (Invitrogen, UK) 
100 μg/mL streptomycin (Invitrogen, UK) 
18µg Hydrocortisone (Invitrogen,UK) 
0.1mM β Mercaptoethanol (Gibco) 
0.001µM Sodium selenite (Sigma-Aldrich, UK) 
0.001µM  Zinc Sulphate hepahydrate (Sigma-Aldrich, UK) 
5mg HDL (Sigma-Aldrich, UK) 
 





Linoleic acid salt 
Linoleic acid (free)  
Add 38µl to 500ml  media 
 
 











Appendix 4: Hepatic progenitor cell isolations 












very few adherent cells, 
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Sparse cells, less debris, 
no expansion 
DM251111 Collie X MN 50 Percoll/collagen Less 
debris 
Sparse cells, no 
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D13112 SBT ME 48 Percoll/collagen Little 
debris 
Sparse cells, small 
clusters, no expansion 
 
D 18112a Rottweiler 
X 
ME 36 Ficoll/collagen  
-- 
 No viable cells 
D18112b Mastiff ME 24 Ficoll/collagen -- No viable cells 
D8212 Lab X ME 36 Ficoll/collagen 1.2 x10
 5
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